var title_f12_6_12384="Rash in erythema infectiosum PI";
var content_f12_6_12384=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F83122&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F83122&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rash in erythema infectiosum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 383px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Children with erythema infectiosum can get a rash on the chest, back, arms, and legs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lee T Nesbitt, Jr. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_6_12384=[""].join("\n");
var outline_f12_6_12384=null;
var title_f12_6_12385="Contact derm vulva2";
var content_f12_6_12385=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F80139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F80139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Contact dermatitis vulva",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_6_12385=[""].join("\n");
var outline_f12_6_12385=null;
var title_f12_6_12386="Skin lesions of disseminated fusariosis";
var content_f12_6_12386=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F74279&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F74279&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Skin lesions of disseminated fusariosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 272px; height: 450px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Skin lesions of disseminated fusariosis diagnosed in a patient after allogeneic hematopoietic stem cell transplantation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Steinbach WJ, Marr KA. Mold infections after hematopoeitic stem cell transplantation. In: Transplant Infections, 3rd Ed, Bowden RA, Ljungman P, Snydman DR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_6_12386=[""].join("\n");
var outline_f12_6_12386=null;
var title_f12_6_12387="Inflammatory breast ca Light";
var content_f12_6_12387=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F60801&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F60801&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Inflammatory carcinoma of the breast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 226px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The skin of the breast with an inflammatory carcinoma shows dermal lymphatic invasion by carcinoma cells (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stuart Schnitt, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_6_12387=[""].join("\n");
var outline_f12_6_12387=null;
var title_f12_6_12388="Autonomic nerve scleroderma EM";
var content_f12_6_12388=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F54076&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F54076&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Autonomic nerve in scleroderma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 328px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron micrograph of an autonomic nerve in the intestine from a patient with scleroderma. The two main changes are axonal degeneration (up arrow) and collagenous cuffing of the nerve (down arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD, FRCP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_6_12388=[""].join("\n");
var outline_f12_6_12388=null;
var title_f12_6_12389="Circumscribed morphea - hyperpigmented plaque";
var content_f12_6_12389=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F63984&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F63984&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Circumscribed morphea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A well-defined, sclerotic plaque with central hyperpigmentation is present in this patient with circumscribed morphea.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_6_12389=[""].join("\n");
var outline_f12_6_12389=null;
var title_f12_6_12390="Psoriatic juvenile idiopathic arthritis: Management and prognosis";
var content_f12_6_12390=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Psoriatic juvenile idiopathic arthritis: Management and prognosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/6/12390/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/6/12390/contributors\">",
"     Peter A Nigrovic, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/6/12390/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/6/12390/contributors\">",
"     Robert Sundel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/6/12390/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/6/12390/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/6/12390/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H22628149\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psoriatic juvenile idiopathic arthritis (psJIA), or alternately juvenile psoriatic arthritis (JPsA), is a condition that can range widely in presentation and severity. Frank cutaneous psoriasis is not always evident, and the extent of articular involvement may vary from mild enthesitis (inflammation of sites at which ligaments, tendons, and other fibrous structures insert into bone) to polyarticular involvement of multiple axial (spine, sacroiliac joints) and peripheral joints.",
"   </p>",
"   <p>",
"    The treatment and prognosis of psJIA are discussed here. The epidemiology, pathogenesis, clinical manifestations, and diagnosis of psJIA are discussed separately, as is psoriatic arthritis in adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/40/40584?source=see_link\">",
"     \"Psoriatic juvenile idiopathic arthritis: Pathogenesis, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30488?source=see_link\">",
"     \"Clinical manifestations and diagnosis of psoriatic arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/18/40234?source=see_link\">",
"     \"Treatment of psoriatic arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23608?source=see_link\">",
"     \"Pathogenesis of psoriatic arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7137357\">",
"    <span class=\"h1\">",
"     MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory tests and imaging studies are of limited value in the management of psJIA. As in other subtypes of JIA, destructive arthritis may continue in the face of normal laboratory studies. Similarly, as with JIA generally, the role of conventional radiography in the day to day management of arthritis also is small, since bony changes take months or years to become evident. Treatment should not be withheld because radiologic changes are not yet evident. Rather, careful clinical monitoring of the physical exam remains of paramount importance in following children with psoriatic arthritis. Monitoring for uveitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/40/40584?source=see_link&amp;anchor=H30434959#H30434959\">",
"     \"Psoriatic juvenile idiopathic arthritis: Pathogenesis, clinical manifestations, and diagnosis\", section on 'Laboratory findings'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/40/40584?source=see_link&amp;anchor=H30434967#H30434967\">",
"     \"Psoriatic juvenile idiopathic arthritis: Pathogenesis, clinical manifestations, and diagnosis\", section on 'Radiologic studies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24056?source=see_link&amp;anchor=H7#H7\">",
"     \"Pauciarticular onset juvenile idiopathic arthritis\", section on 'Uveitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22628165\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment recommendations for psJIA are derived from trials in other JIA subtypes and from adult psoriatic arthritis, since no randomized controlled trials (RCTs) have been conducted specifically in psJIA [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12390/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Management should be conducted in consultation with a pediatric rheumatologist and pediatric ophthalmologist whenever possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22628173\">",
"    <span class=\"h2\">",
"     Peripheral arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment priority in psJIA, as in other types of JIA, is to extinguish synovitis in order to avoid damage to cartilage and bone. This imperative is particularly critical for the growing skeleton, where injury to growth plates and growth centers can cause permanent derangement of bone shape and length [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12390/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Absence of pain and lack of functional impairment are imperfect guides to successful therapy, since children may adapt remarkably well to ongoing arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12390/abstract/8\">",
"     8",
"    </a>",
"    ]. Such children may still go on to experience substantial joint injury, developing functional impairment later in childhood or as young adults [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12390/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The basic treatment algorithm of psJIA is similar to that employed in other subtypes of JIA, with a few exceptions noted (",
"    <a class=\"graphic graphic_table graphicRef64063 \" href=\"UTD.htm?22/38/23149\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12390/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonsteroidal antiinflammatory drugs (NSAIDs) are often employed initially, but typically do not induce remission and are",
"      <strong>",
"       inappropriate",
"      </strong>",
"      as monotherapy for synovitis that persists beyond two months of treatment.",
"     </li>",
"     <li>",
"      Individual large joints and dactylitic digits can be treated effectively with glucocorticoid injection.",
"     </li>",
"     <li>",
"      Disease modifying antirheumatic drugs (DMARDs) are indicated in patients with involvement of multiple joints. The most commonly used DMARD is",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/32/13833?source=see_link\">",
"       methotrexate",
"      </a>",
"      . Methotrexate is associated with a higher risk of hepatotoxicity in adults with psoriatic arthritis than in those with rheumatoid arthritis, but methotrexate is typically well tolerated in children with psJIA [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12390/abstract/10\">",
"       10",
"      </a>",
"      ].",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/43/21173?source=see_link\">",
"       Sulfasalazine",
"      </a>",
"      is an alternative, especially for lower extremity large joint arthritis.",
"     </li>",
"     <li>",
"      Failure to achieve remission is addressed by substitution or addition of a second oral DMARD, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      , or more commonly by institution of antitumor necrosis factor (TNF) therapy with any of the available agents. TNF blockade is particularly useful when there is axial disease, since no other treatment is effective for inflammation of the spine and sacroiliac joints.",
"     </li>",
"     <li>",
"      Anti-TNF agents are also effective for dactylitis and enthesitis.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/6/44132?source=see_link\">",
"       Abatacept",
"      </a>",
"      , a T cell costimulatory blocker, is effective for psoriatic arthritis in some adults and is effective and well tolerated in polyarticular-course JIA [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12390/abstract/2,11\">",
"       2,11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some rheumatologists believe that psoriatic arthritis is less responsive to systemic glucocorticoids than other types of arthritis, but this observation has yet to be rigorously tested. In addition, systemic glucocorticoids can provoke a flare of cutaneous psoriasis when tapered [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12390/abstract/12\">",
"       12",
"      </a>",
"      ]. Some data also suggest a risk for worsening psoriasis with antimalarials such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/0/40965?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12390/abstract/13\">",
"       13",
"      </a>",
"      ]. These agents are therefore avoided when possible, although low to moderate dose systemic glucocorticoids are sometimes employed as short-term &ldquo;bridge&rdquo; therapy while awaiting the effect of slower-acting DMARDs in highly symptomatic patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22628181\">",
"    <span class=\"h2\">",
"     Spondylitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of psoriatic spondylitis is based primarily upon experience with ankylosing spondylitis (AS) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12390/abstract/12\">",
"     12",
"    </a>",
"    ]. Axial disease in psJIA tends to run a milder course than AS, but treatment should be initiated in patients who experience axial symptoms or show limitation of spinal mobility. Continuous treatment with NSAIDs results in measurable radiographic improvement, but the effect is small [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12390/abstract/14\">",
"     14",
"    </a>",
"    ]. Standard DMARDs, including",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/43/21173?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/32/13833?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    , are of minimal benefit. Anti-TNF therapy is highly effective for axial disease as assessed both by symptoms and by magnetic resonance imaging (MRI) evidence of inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12390/abstract/12\">",
"     12",
"    </a>",
"    ]. However, studies in adults have so far failed to show a corresponding reduction in radiographic progression, although this area remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12390/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8696?source=see_link\">",
"     \"Spondyloarthropathy in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35194?source=see_link\">",
"     \"Assessment and treatment of ankylosing spondylitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/23/17782?source=see_link\">",
"     \"General guidelines for use of anti-tumor necrosis factor alpha agents in ankylosing spondylitis and axial spondyloarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22628189\">",
"    <span class=\"h2\">",
"     Uveitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for uveitis in psJIA is similar to that in other subtypes of JIA. Chronic anterior uveitis is treated initially with topical corticosteroids, usually together with oral or subcutaneous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/32/13833?source=see_link\">",
"     methotrexate",
"    </a>",
"    . Resistant disease often responds to a TNF antagonist such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/51/21303?source=see_link\">",
"     infliximab",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/6/44132?source=see_link\">",
"     abatacept",
"    </a>",
"    (but not",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/1/32790?source=see_link\">",
"     etanercept",
"    </a>",
"    ). Third line agents include",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/50/12072?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . Acute anterior uveitis, associated with a spondyloarthropathic presentation, is less frequently sight-threatening and typically responds to topical or oral corticosteroids. These options are discussed separately in the relevant topics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24056?source=see_link&amp;anchor=H7#H7\">",
"     \"Pauciarticular onset juvenile idiopathic arthritis\", section on 'Uveitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/48/17162?source=see_link&amp;anchor=H24#H24\">",
"     \"Polyarticular onset juvenile idiopathic arthritis: Management\", section on 'Uveitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/10/10407?source=see_link\">",
"     \"Uveitis: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22628197\">",
"    <span class=\"h2\">",
"     Cutaneous disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous manifestations of pediatric psoriasis are phenotypically similar to skin involvement in adults regardless of whether there is concomitant arthritis. The only exception is a higher prevalence of nail changes in psJIA [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12390/abstract/17\">",
"     17",
"    </a>",
"    ]. Conventional psoriasis treatment is appropriate for skin disease associated with psJIA, although frequently articular manifestations drive early use of systemic agents that are highly effective for skin disease, including",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/32/13833?source=see_link\">",
"     methotrexate",
"    </a>",
"    and TNF blockers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/40/40584?source=see_link&amp;anchor=H7137789#H7137789\">",
"     \"Psoriatic juvenile idiopathic arthritis: Pathogenesis, clinical manifestations, and diagnosis\", section on 'Skin and nail disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40042?source=see_link\">",
"     \"Treatment of psoriasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22628205\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term outcome of children with psJIA is not well defined. Clinical remission (on medication) is achieved in the majority of patients in both older and younger subgroups [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12390/abstract/18\">",
"     18",
"    </a>",
"    ]. Among patients with psJIA followed for at least five years, persistently active disease was found in 70 percent and physical activity limitations in one-third in one series published in 1996 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12390/abstract/19\">",
"     19",
"    </a>",
"    ]. Improvement over these historical outcomes is expected with appropriate therapy using the expanding repertoire of agents. In another series, patients with psJIA followed for at least 15 years demonstrated worse functional outcomes than patients with oligo- or polyarticular JIA, and 33 percent still required DMARD therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12390/abstract/20\">",
"     20",
"    </a>",
"    ]. Poor outcomes and long-term disability were seen principally in patients who experienced a long delay in diagnosis or in whom effective therapy was not instituted, often through clinician or family reluctance to take the steps necessary to induce remission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/6/7267?source=see_link\">",
"       \"Patient information: Psoriatic arthritis in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22628213\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Psoriatic juvenile idiopathic arthritis (psJIA), or alternately juvenile psoriatic arthritis (JPsA), is a relatively common subtype of JIA, but its clinical presentation can be highly variable. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/40/40584?source=see_link\">",
"       \"Psoriatic juvenile idiopathic arthritis: Pathogenesis, clinical manifestations, and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35717?source=see_link\">",
"       \"Classification of juvenile arthritis (JRA/JIA)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Laboratory tests and radiologic studies are of limited value in the management of psJIA. (See",
"      <a class=\"local\" href=\"#H7137357\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment priority in psJIA, as in other types of JIA, is to extinguish all clinical, laboratory, and radiographic manifestations of synovitis in order to avoid damage to cartilage and bone. (See",
"      <a class=\"local\" href=\"#H22628165\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The basic treatment algorithm of psJIA is similar to that employed in other subtypes of JIA, with a few exceptions (",
"      <a class=\"graphic graphic_table graphicRef64063 \" href=\"UTD.htm?22/38/23149\">",
"       table 1",
"      </a>",
"      ). Nonsteroidal antiinflammatory drugs (NSAIDs) are often employed initially, but typically do not induce remission. Arthritis in individual large joints, as well as dactylitic digits, may be treated with glucocorticoid injections. Disease modifying antirheumatic drugs (DMARDs) are indicated in patients with involvement of multiple joints or who fail to achieve remission with intraarticular glucocorticoids. Failure to achieve remission is addressed by addition of a second DMARD or more commonly by institution of antitumor necrosis factor (TNF) therapy. Systemic glucocorticoids are employed less commonly, and antimalarial agents are generally avoided due to a risk of worsening the psoriasic rash. (See",
"      <a class=\"local\" href=\"#H22628173\">",
"       'Peripheral arthritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Axial disease in psJIA is phenotypically similar to ankylosing spondylitis, but tends to run a milder course. However, treatment should be initiated in patients with psJIA who experience axial symptoms or show limitation of spinal mobility. Anti-TNF agents are generally the most effective, while NSAIDs can provide relief to some patients. Other DMARDs are minimally effective. (See",
"      <a class=\"local\" href=\"#H22628181\">",
"       'Spondylitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Monitoring for and treatment of uveitis in psJIA are similar to that in other subtypes of JIA. (See",
"      <a class=\"local\" href=\"#H22628189\">",
"       'Uveitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Conventional psoriasis treatment is appropriate for skin disease associated with psJIA. Frequently this is not an issue, since articular manifestations may drive early use of systemic agents that are highly effective for skin disease, including",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/32/13833?source=see_link\">",
"       methotrexate",
"      </a>",
"      and TNF blockers. (See",
"      <a class=\"local\" href=\"#H22628197\">",
"       'Cutaneous disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Poor outcomes and long-term disability are seen principally in patients who had a long delay in diagnosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      in whom effective therapy was not instituted, often through clinician or family reluctance to take the steps necessary to induce remission. (See",
"      <a class=\"local\" href=\"#H22628205\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12390/abstract/1\">",
"      Ruperto N, Lovell DJ, Cuttica R, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007; 56:3096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12390/abstract/2\">",
"      Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008; 372:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12390/abstract/3\">",
"      Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008; 359:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12390/abstract/4\">",
"      Hashkes PJ, Laxer RM. Medical treatment of juvenile idiopathic arthritis. JAMA 2005; 294:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12390/abstract/5\">",
"      Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 2011; 63:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12390/abstract/6\">",
"      Simon S, Whiffen J, Shapiro F. Leg-length discrepancies in monoarticular and pauciarticular juvenile rheumatoid arthritis. J Bone Joint Surg Am 1981; 63:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12390/abstract/7\">",
"      ANSELL BM, BYWATERS EG. Growth in Still's disease. Ann Rheum Dis 1956; 15:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12390/abstract/8\">",
"      McGhee JL, Burks FN, Sheckels JL, Jarvis JN. Identifying children with chronic arthritis based on chief complaints: absence of predictive value for musculoskeletal pain as an indicator of rheumatic disease in children. Pediatrics 2002; 110:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12390/abstract/9\">",
"      Nigrovic PA, White PH. Care of the adult with juvenile rheumatoid arthritis. Arthritis Rheum 2006; 55:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12390/abstract/10\">",
"      Soriano ER, McHugh NJ. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol 2006; 33:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12390/abstract/11\">",
"      Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 2011; 63:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12390/abstract/12\">",
"      Nash P. Therapies for axial disease in psoriatic arthritis. A systematic review. J Rheumatol 2006; 33:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12390/abstract/13\">",
"      Gladman DD, Blake R, Brubacher B, Farewell VT. Chloroquine therapy in psoriatic arthritis. J Rheumatol 1992; 19:1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12390/abstract/14\">",
"      Wanders A, Heijde Dv, Landew&eacute; R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005; 52:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12390/abstract/15\">",
"      Sieper J, Appel H, Braun J, Rudwaleit M. Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes. Arthritis Rheum 2008; 58:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12390/abstract/16\">",
"      van der Heijde D, Landew&eacute; R, Baraliakos X, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008; 58:3063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12390/abstract/17\">",
"      Morris A, Rogers M, Fischer G, Williams K. Childhood psoriasis: a clinical review of 1262 cases. Pediatr Dermatol 2001; 18:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12390/abstract/18\">",
"      Stoll ML, Zurakowski D, Nigrovic LE, et al. Patients with juvenile psoriatic arthritis comprise two distinct populations. Arthritis Rheum 2006; 54:3564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12390/abstract/19\">",
"      Roberton DM, Cabral DA, Malleson PN, Petty RE. Juvenile psoriatic arthritis: followup and evaluation of diagnostic criteria. J Rheumatol 1996; 23:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12390/abstract/20\">",
"      Flat&oslash; B, Lien G, Smerdel-Ramoya A, Vinje O. Juvenile psoriatic arthritis: longterm outcome and differentiation from other subtypes of juvenile idiopathic arthritis. J Rheumatol 2009; 36:642.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16366 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-197.136.42.3-BC8603A877-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_6_12390=[""].join("\n");
var outline_f12_6_12390=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22628213\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22628149\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7137357\">",
"      MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22628165\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22628173\">",
"      Peripheral arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22628181\">",
"      Spondylitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22628189\">",
"      Uveitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22628197\">",
"      Cutaneous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22628205\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22628213\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/16366\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/16366|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/38/23149\" title=\"table 1\">",
"      Therapeutic options in psoriatic juvenile idiopathic arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35194?source=related_link\">",
"      Assessment and treatment of ankylosing spondylitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35717?source=related_link\">",
"      Classification of juvenile arthritis (JRA/JIA)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30488?source=related_link\">",
"      Clinical manifestations and diagnosis of psoriatic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/23/17782?source=related_link\">",
"      General guidelines for use of anti-tumor necrosis factor alpha agents in ankylosing spondylitis and axial spondyloarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23608?source=related_link\">",
"      Pathogenesis of psoriatic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/6/7267?source=related_link\">",
"      Patient information: Psoriatic arthritis in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24056?source=related_link\">",
"      Pauciarticular onset juvenile idiopathic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/48/17162?source=related_link\">",
"      Polyarticular onset juvenile idiopathic arthritis: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/40/40584?source=related_link\">",
"      Psoriatic juvenile idiopathic arthritis: Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8696?source=related_link\">",
"      Spondyloarthropathy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40042?source=related_link\">",
"      Treatment of psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/18/40234?source=related_link\">",
"      Treatment of psoriatic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/10/10407?source=related_link\">",
"      Uveitis: Treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_6_12391="Li-Fraumeni syndrome";
var content_f12_6_12391=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Li-Fraumeni syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/6/12391/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/6/12391/contributors\">",
"     D Gareth Evans, MD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/6/12391/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/6/12391/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/6/12391/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/6/12391/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/6/12391/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H639664550\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Li-Fraumeni syndrome (OMIM#151623) is an inherited disorder that is manifested by a wide range of malignancies that appear at an unusually early age [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12391/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Li-Fraumeni syndrome is also known as the Sarcoma, Breast, Leukemia, and Adrenal Gland (SBLA) cancer syndrome. This cancer predisposition syndrome is inherited as an autosomal dominant disorder and is associated with abnormalities in the tumor protein p53 gene (",
"    <em>",
"     TP53",
"    </em>",
"    ).",
"   </p>",
"   <p>",
"    The molecular pathogenesis, clinical manifestations, diagnosis, management, and implications for genetic counseling of patients with Li-Fraumeni syndrome and their families are reviewed here. The treatment of specific malignancies is discussed in detail elsewhere, as noted below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H639664557\">",
"    <span class=\"h1\">",
"     MOLECULAR PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only gene that has been definitively associated with Li-Fraumeni syndrome is",
"    <em>",
"     TP53",
"    </em>",
"    , which is located on chromosome 17p13.1 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12391/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"    <em>",
"     TP53",
"    </em>",
"    is a tumor suppressor gene that has a major role in determining the fate of cells that contain damaged DNA. The gene product, tumor protein p53, can delay cell cycle progression, permitting an opportunity for DNA repair or initiation of programmed cell death (apoptosis). In the absence of the normal activated p53 protein, cells containing damaged DNA can survive and proliferate, which contributes to malignant transformation.",
"   </p>",
"   <p>",
"    A variety of molecular techniques have been used to detect mutations in the",
"    <em>",
"     TP53",
"    </em>",
"    gene, including sequence analysis of all or part of the gene, and techniques for detecting gene deletion or duplication. Over 300 distinct germline mutations of",
"    <em>",
"     TP53",
"    </em>",
"    have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12391/abstract/4\">",
"     4",
"    </a>",
"    ]. Missense mutations comprise the majority of these; most occur in exons 5-8, which are the DNA-binding region of the gene.",
"   </p>",
"   <p>",
"    Li-Fraumeni syndrome is an autosomal dominant disease, in which affected individuals have inherited one abnormal copy of the",
"    <em>",
"     TP53",
"    </em>",
"    gene. In tumors from these patients, the second allele of",
"    <em>",
"     TP53",
"    </em>",
"    is either somatically mutated or deleted, leaving cells with no functional gene product.",
"   </p>",
"   <p>",
"    Not all patients with Li-Fraumeni syndrome diagnosed based upon clinical criteria have a detectable mutation or abnormality in",
"    <em>",
"     TP53",
"    </em>",
"    . The absence of a detectable mutation may be due to novel mutations that have not previously been described or to an abnormality of the gene promoter that leads to defective protein expression. Alternatively, such individuals may not have a germline abnormality of",
"    <em>",
"     TP53",
"    </em>",
"    , may have a mutation in an as yet unidentified gene, or may represent cases where the malignancy has occurred by chance. (See",
"    <a class=\"local\" href=\"#H639664593\">",
"     'Diagnostic criteria'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H639664564\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H639664664\">",
"    <span class=\"h2\">",
"     Spectrum of malignancies and age at onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Li-Fraumeni syndrome was originally described in 1969, based upon the identification of second soft tissue sarcomas in five families with index cases of rhabdomyosarcoma",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12391/abstract/5\">",
"     5",
"    </a>",
"    ]",
"    <strong>",
"     .",
"    </strong>",
"    These observations were subsequently extended to 24 kindreds in which 151 individuals developed cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12391/abstract/6\">",
"     6",
"    </a>",
"    ]. These patients were characterized by a variety of bone and soft tissue sarcomas and breast cancer, approximately 80 percent of which occurred prior to 45 years of age. Other tumors that occurred disproportionately in this series included brain tumors, leukemia, and adrenocortical carcinoma, and there were six patients with cancer that was linked to antecedent radiation therapy. Other reports have confirmed the importance of early age at onset in patients with Li-Fraumeni syndrome, as well as the wide range of cancers that are seen [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12391/abstract/1-3,7\">",
"     1-3,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations of this syndrome are illustrated by a series of 525 patients who were referred for sequencing of their germline DNA in the",
"    <em>",
"     TP53",
"    </em>",
"    gene based upon a clinical suspicion of Li-Fraumeni syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12391/abstract/7\">",
"     7",
"    </a>",
"    ]. Results of mutation testing were correlated with family history and clinical histories. In this series, 91 patients (17 percent) were ultimately found to have a",
"    <em>",
"     TP53",
"    </em>",
"    mutation. Although this series is subject to ascertainment bias, it does offer some insights into the clinical manifestations of Li-Fraumeni syndrome:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In all cases where a",
"      <em>",
"       TP53",
"      </em>",
"      mutation was identified, either the proband or a family member had a history of one of four &ldquo;core&rdquo; malignancies (breast cancer, sarcoma, adrenocortical carcinoma, brain tumor) prior to age 50 years. A total of 141 cancers were diagnosed in the 82 patients with mutations where clinical information was available.",
"     </li>",
"     <li>",
"      Breast cancer was present in 44 of the patients with germline mutations and occurred exclusively in women. Sarcoma, adrenocortical carcinoma, and brain tumors were present in 38, 14, and 13 cases, respectively. In patients with adrenocortical carcinoma or choroid plexus carcinoma there was a particularly strong association with",
"      <em>",
"       TP53",
"      </em>",
"      mutations.",
"     </li>",
"     <li>",
"      The average age at cancer diagnosis was not significantly different in males and females with germline",
"      <em>",
"       TP53",
"      </em>",
"      mutations (21 and 28 years, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A wide variety of other malignancies have been reported in smaller numbers of patients in other series [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12391/abstract/1\">",
"     1",
"    </a>",
"    ]. These have included melanoma, gastric cancer, lymphoma, Wilms tumor, and colorectal carcinoma. As with the more common malignancies associated with Li-Fraumeni syndrome, these have also occurred at a much earlier age.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H525774358\">",
"    <span class=\"h2\">",
"     Multiple cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with an abnormality of",
"    <em>",
"     TP53",
"    </em>",
"    who develop cancer are at a markedly increased risk of developing a second malignancy. This was illustrated by a series of 200 Li-Fraumeni syndrome individuals from 24 kindreds who had been diagnosed with cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12391/abstract/8\">",
"     8",
"    </a>",
"    ]. In this group, 30 (15 percent) developed a second malignancy, and smaller numbers developed a third or fourth cancer. The cumulative probability of developing a second malignancy 30 years after the diagnosis of the initial cancer was 57 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H525774378\">",
"    <span class=\"h2\">",
"     Radiation-induced cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several case reports have suggested that radiation-induced cancers are more common than in patients without Li-Fraumeni syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12391/abstract/9,10\">",
"     9,10",
"    </a>",
"    ], and preclinical studies have provided additional evidence in support of this relationship [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12391/abstract/11\">",
"     11",
"    </a>",
"    ]. Thus, radiation therapy is generally avoided as a component in the management of these patients whenever possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H639664572\">",
"    <span class=\"h2\">",
"     Lifetime risk of cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a high penetrance of the mutated",
"    <em>",
"     TP53",
"    </em>",
"    gene. For women, the lifetime risk of cancer approaches 100 percent, and has been estimated to be about 90 percent by age 60 years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12391/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. This risk may be lower in men compared to women, with an estimated lifetime risk of developing cancer of 73 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12391/abstract/14\">",
"     14",
"    </a>",
"    ]. These risks, nonetheless, reflect mutations predominantly in the core binding domain of",
"    <em>",
"     TP53",
"    </em>",
"    , whereas mutations outside these regions may have somewhat lower risks [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12391/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H639664579\">",
"    <span class=\"h2\">",
"     Specific malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once cancers develop, their behavior is generally similar to that in patients without Li-Fraumeni syndrome, other than the earlier age of onset. However, the susceptibility to second and subsequent primary tumors and the implications for other family members are important factors in patient management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H639664672\">",
"    <span class=\"h3\">",
"     Sarcomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost all types of soft tissue and bone sarcomas are seen in families with Li-Fraumeni syndrome, with the exception of Ewing sarcoma. Although these tumors can occur in adults with Li-Fraumeni syndrome, the median age at onset is approximately 15 years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12391/abstract/18\">",
"     18",
"    </a>",
"    ]. In an analysis of 531 families or individuals with germline",
"    <em>",
"     TP53",
"    </em>",
"    mutations, sarcomas accounted for approximately 25 percent of tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12391/abstract/19\">",
"     19",
"    </a>",
"    ]. At all ages, osteosarcomas were more common in those with germline mutations compared with those developing sporadic sarcomas; rhabdomyosarcomas were particularly common in those less than five years of age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20842?source=see_link\">",
"     \"Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31418?source=see_link&amp;anchor=H12227065#H12227065\">",
"     \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H639664682\">",
"    <span class=\"h3\">",
"     Breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with Li-Fraumeni syndrome are at markedly increased risk of developing premenopausal breast cancer. In one series, the median age at diagnosis was 33 years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12391/abstract/18\">",
"     18",
"    </a>",
"    ]; in another report approximately one-third occurred prior age 30 years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12391/abstract/20\">",
"     20",
"    </a>",
"    ]. In a population based series of breast cancer &lt;31 years of age, 6 of 115 patients (5 percent) had",
"    <em>",
"     TP53",
"    </em>",
"    mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12391/abstract/16\">",
"     16",
"    </a>",
"    ]. Breast cancer in men has not been a part of the Li-Fraumeni syndrome. For women with breast cancer, mastectomy rather than lumpectomy plus radiation therapy is generally recommended because of the risks of a second breast primary or a radiation-induced second cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19177?source=see_link\">",
"     \"Overview of the treatment of newly diagnosed, non-metastatic breast cancer\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H525774378\">",
"     'Radiation-induced cancers'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Breast cancer that arises in women with a",
"    <em>",
"     TP53",
"    </em>",
"    germline mutation appears to be significantly more likely to have amplification of the human epidermal growth factor receptor (HER2) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12391/abstract/15\">",
"     15",
"    </a>",
"    ]. In a series of 12 cancers in nine young women, 10 were positive for HER2 (83 percent), whereas only 16 percent of a control group of 231 breast cancers in young women without the",
"    <em>",
"     TP53",
"    </em>",
"    mutation were positive for HER2. There was no difference in the frequency of estrogen and progesterone receptor positivity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H639664692\">",
"    <span class=\"h3\">",
"     Brain tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide range of brain tumors, including high-grade gliomas, have been reported in patients with Li-Fraumeni syndrome, occurring either in childhood or young adults [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12391/abstract/18\">",
"     18",
"    </a>",
"    ]. Of particular note, a high percentage of choroid plexus carcinomas are associated with germline mutations in",
"    <em>",
"     TP53",
"    </em>",
"    even in the absence of another cancer or a positive family history. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25657?source=see_link\">",
"     \"Clinical presentation and diagnosis of brain tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35946?source=see_link&amp;anchor=H18#H18\">",
"     \"Uncommon brain tumors\", section on 'Choroid plexus carcinomas'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H639664702\">",
"    <span class=\"h3\">",
"     Adrenocortical carcinomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenocortical carcinomas are more common in patients with Li-Fraumeni syndrome and are very frequently associated with germline mutations of",
"    <em>",
"     TP53",
"    </em>",
"    , both in children [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12391/abstract/18,21\">",
"     18,21",
"    </a>",
"    ] and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12391/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40762?source=see_link\">",
"     \"Treatment of adrenocortical carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12826?source=see_link\">",
"     \"Clinical presentation and evaluation of adrenocortical tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H639664586\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diversity of tumors and the potential chance occurrence of these cancers at an early age have made establishing the diagnosis of Li-Fraumeni syndrome (LFS) particularly difficult. Definitive diagnosis requires demonstration of a",
"    <em>",
"     TP53",
"    </em>",
"    mutation or",
"    <span class=\"nowrap\">",
"     exonic/multiexonic",
"    </span>",
"    rearrangement (deletion or duplication).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H639664593\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several different criteria have been proposed to determine which patients or families are candidates for molecular testing:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Classical Li-Fraumeni syndrome",
"      </strong>",
"      &ndash; The original descriptions of Li-Fraumeni syndrome served as the basis for a clinical diagnosis, which was defined as follows (",
"      <a class=\"graphic graphic_table graphicRef79296 \" href=\"UTD.htm?3/58/4011\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12391/abstract/3,6\">",
"       3,6",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A proband with a sarcoma diagnosed before age 45 years AND",
"     </li>",
"     <li>",
"      A first-degree relative with any cancer before age 45 years AND",
"     </li>",
"     <li>",
"      A first- or second-degree relative with any cancer before age 45 years or a sarcoma at any age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Chompret criteria",
"      </strong>",
"      &ndash; The Chompret criteria allow the spectrum of malignancies in the proband to include sarcoma, brain tumor, breast cancer, and adrenocortical carcinoma, but have a lower age cut-off than the classical Li-Fraumeni syndrome criteria (",
"      <a class=\"graphic graphic_table graphicRef58516 \" href=\"UTD.htm?31/14/31979\">",
"       table 2",
"      </a>",
"      ). The Chompret criteria recommend mutation testing for individuals with adrenocortical carcinoma and a negative family history [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12391/abstract/22,23\">",
"       22,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Li-Fraumeni-like syndrome",
"      </strong>",
"      &ndash; The Birch definition still requires three affected individuals in the family and the Eeles definition used slightly looser criteria to define the so-called Li-Fraumeni-like syndrome in patients who do not meet the classical Li-Fraumeni syndrome criteria [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12391/abstract/20,24\">",
"       20,24",
"      </a>",
"      ]. These Li-Fraumeni-like syndrome definitions are also based upon the occurrence of typical malignancy in both the proband and one or more relatives at a relatively early age [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12391/abstract/20,24\">",
"       20,24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The classical Li-Fraumeni syndrome criteria, Li-Fraumeni-like syndrome definitions, and the Chompret criteria were compared in a series of 525 cases, in which samples had been referred for germline analysis for",
"    <em>",
"     TP53",
"    </em>",
"    mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12391/abstract/7\">",
"     7",
"    </a>",
"    ]. Overall, mutations were identified in 91 of 525 cases (17 percent). The results of",
"    <em>",
"     TP53",
"    </em>",
"    analysis were combined with clinical and family history to estimate the relative reliability of these different approaches.",
"   </p>",
"   <p>",
"    Overall, the classic Li-Fraumeni syndrome criteria and the Chompret criteria were most useful [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12391/abstract/7\">",
"     7",
"    </a>",
"    ]. When these criteria were combined, these two approaches detected 71 of 75 families with",
"    <em>",
"     TP53",
"    </em>",
"    mutations (sensitivity 95 percent), with a specificity of 52 percent. The Birch and Eeles definitions of Li-Fraumeni-like syndrome each identified one additional case with a germline mutation, and in two families none of the criteria yielded a positive result. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H639664600\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis includes other inherited cancer syndromes in patients whose presentation suggests Li-Fraumeni syndrome:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H639664607\">",
"    <span class=\"h3\">",
"     BRCA1 and BRCA2 mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hereditary breast-ovarian cancer syndrome is characterized by mutations in BRCA1 or BRCA2. This syndrome is associated with a marked increase in the incidence of premenopausal breast cancer and ovarian cancer. Other malignancies seen in individuals with BRCA2 mutations include pancreatic cancer, melanoma, and prostate cancer.",
"   </p>",
"   <p>",
"    A germline mutation of",
"    <em>",
"     TP53",
"    </em>",
"    should be included in the differential diagnosis in young women with breast cancer who do not have a mutation in either BRCA1 or BRCA2. In a series of 161 women diagnosed with breast cancer before age 36 years and without a BRCA1 or BRCA2 mutation, sequencing the",
"    <em>",
"     TP53",
"    </em>",
"    gene revealed a characteristic, deleterious mutation in 12 women (7 percent) who did not have a family history suggestive of Li-Fraumeni syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12391/abstract/22\">",
"     22",
"    </a>",
"    ]. In 7 of the 12, there was either a family history or a history of other malignancy suggesting Li-Fraumeni syndrome. Among the 128 patients who had no other feature suggestive of Li-Fraumeni syndrome, there were five (3 percent) with a germline",
"    <em>",
"     TP53",
"    </em>",
"    mutation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H639664614\">",
"    <span class=\"h3\">",
"     Mismatch repair cancer syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of genes involved in the repair of DNA mismatch errors, including M1H1, MSH2, MSH6, PMS1, and PMS2. Inheritance of one abnormal allele causes hereditary nonpolyposis colorectal carcinoma (Lynch syndrome). Individuals who inherit two mutated alleles in the same mismatch repair gene have the mismatch repair (MMR) cancer syndrome, which is also known as the Turcot syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=see_link\">",
"     \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with mismatch repair deficiency syndrome are at risk for the development of leukemia, brain tumors, and intestinal cancer. Clinically, this can overlap with the spectrum seen in Li-Fraumeni syndrome, and in previously undiagnosed kindreds patients or families genetic testing may be required to distinguish these syndromes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H639664621\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with Li-Fraumeni syndrome or suspected Li-Fraumeni syndrome, key issues include who to test for mutations in",
"    <em>",
"     TP53",
"    </em>",
"    , surveillance strategy for patients who have already had one or more Li-Fraumeni-associated cancers or who are known carriers of a mutation in",
"    <em>",
"     TP53",
"    </em>",
"    , and the optimal approach to the genetic counseling and testing of other family members.",
"    <strong>",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H639664628\">",
"    <span class=\"h2\">",
"     Who to test for TP53 mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing for deleterious mutations in",
"    <em>",
"     TP53",
"    </em>",
"    can provide important information for both the tested individual and for other members of the family. The decision of whether or not to proceed with genetic testing requires careful assessment of multiple factors.",
"   </p>",
"   <p>",
"    Situations where genetic counseling and TP53 mutation testing should be considered can be divided into several categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Individuals at high risk for Li-Fraumeni syndrome based upon their clinical features (See",
"      <a class=\"local\" href=\"#H639664593\">",
"       'Diagnostic criteria'",
"      </a>",
"      above.):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      People who satisfy either classical criteria for Li-Fraumeni syndrome (",
"      <a class=\"graphic graphic_table graphicRef79296 \" href=\"UTD.htm?3/58/4011\">",
"       table 1",
"      </a>",
"      ), the Chompret criteria (",
"      <a class=\"graphic graphic_table graphicRef58516 \" href=\"UTD.htm?31/14/31979\">",
"       table 2",
"      </a>",
"      ), or who have other combinations of cancer and family history that put them at risk for Li-Fraumeni syndrome or Li-Fraumeni-like syndrome, but in whom there is no known mutation in the family. In this setting, a more extensive laboratory evaluation for mutation is required. Negative results do",
"      <strong>",
"       not",
"      </strong>",
"      rule out a diagnosis of Li-Fraumeni syndrome, and these individuals may still need to be managed as if they had Li-Fraumeni syndrome. (See",
"      <a class=\"local\" href=\"#H639664593\">",
"       'Diagnostic criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with early onset breast cancer (less than age 30 years) and without a detectable BRCA1 or BRCA2 mutation. The index of suspicion for Li-Fraumeni syndrome is increased if there is a family history of sarcoma, brain tumor, or adrenocortical carcinoma. As with those who satisfy the classical criteria or the Chompret criteria for Li-Fraumeni syndrome, a negative result does not exclude Li-Fraumeni syndrome. Aggressive screening for cancer may be indicated for those without a detectable mutation and those who choose not to undergo mutation testing. (See",
"      <a class=\"local\" href=\"#H639664664\">",
"       'Spectrum of malignancies and age at onset'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=see_link\">",
"       \"Genetic testing for hereditary breast and ovarian cancer syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Individuals with adrenocortical carcinoma regardless of age or family history.",
"     </li>",
"     <li>",
"      Individuals with choroid plexus carcinoma regardless of age or family history.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Predispositional testing may be considered for individuals from a family with a known TP53 mutation. In this setting, testing can be restricted to testing for the known mutation. A negative test in this setting effectively rules out Li-Fraumeni syndrome. Those who choose not to undergo testing should be managed as if they harbor the TP53 mutation.",
"     </li>",
"     <li>",
"      Prenatal testing may be considered for at-risk pregnancies in situations where a specific TP53 mutation has been identified.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Predisposition testing is controversial for a number of reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12391/abstract/1\">",
"     1",
"    </a>",
"    ]. Key factors to consider in deciding whether or not to conduct testing include the genetic heterogeneity associated with cancer predisposition, the fact that genetic testing only detects approximately 70 percent of individuals with Li-Fraumeni syndrome, and the psychosocial impact of a positive test. Furthermore there is no evidence that knowledge of the TP53 mutation status can alter the natural history of Li-Fraumeni syndrome-associated cancers. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H639664635\">",
"    <span class=\"h2\">",
"     Cancer management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of the various cancers is generally the same as that in patients without Li-Fraumeni syndrome. However, for women with breast cancer, mastectomy rather than lumpectomy followed by radiation therapy is generally preferred because of the risks of second breast cancers or radiation-induced neoplasms [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12391/abstract/8,9,25\">",
"     8,9,25",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H639664682\">",
"     'Breast cancer'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H525774378\">",
"     'Radiation-induced cancers'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H639664642\">",
"    <span class=\"h2\">",
"     Cancer surveillance strategy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A heightened level of surveillance for cancer is required for individuals who are considered at risk, based upon a history of a Li-Fraumeni syndrome malignancy, the presence of a known TP53 mutation, or the presence of increased risk in a family with Li-Fraumeni syndrome but without an identifiable mutation or that has not undergone mutation testing [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12391/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no clinical trials that define the optimal screening strategy in such patients, nor is their evidence that screening alters the outcome in these patients. The National Comprehensive Cancer Network (NCCN) has defined guidelines that are useful in attempting to diagnosis cancer early in patients with Li-Fraumeni syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12391/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      General measures included an annual physical examination including careful skin and neurologic examinations. Patients should be counseled to seek medical attention for evaluation of any unexplained symptoms.",
"     </li>",
"     <li>",
"      Breast cancer &ndash; Modalities available for breast cancer detection or prevention include monthly breast self examination, clinical examination by a health care provider twice a year, and annual imaging (mammography or MRI). In general, noninvasive screening should begin around age 18 to 20 years, and diagnostic imaging should begin at age 20 to 25 years. Prophylactic mastectomy may also be an option for some women.",
"     </li>",
"     <li>",
"      Colorectal cancer risk &ndash; Initiation of screening at an early age (25 years) and increased frequency of screening (every two to five years) has been advocated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A prospective observational study has demonstrated that an intensive screening program including whole body MRI imaging can detect tumors early [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12391/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H639665000\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Li-Fraumeni syndrome (LFS) is a cancer predisposition syndrome associated with germline abnormalities of the TP53 gene. Li-Fraumeni syndrome is manifested by a tendency to develop various malignancies at an unusual age, including breast cancer, sarcomas, brain tumors, and adrenocortical carcinomas. (See",
"    <a class=\"local\" href=\"#H639664557\">",
"     'Molecular pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Definitive diagnosis is based upon the identification of a germline",
"      <em>",
"       TP53",
"      </em>",
"      mutation. The classical, Birch and Chompret criteria have been proposed to identify individuals who are candidates for molecular screening (",
"      <a class=\"graphic graphic_table graphicRef79296 \" href=\"UTD.htm?3/58/4011\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef58516 \" href=\"UTD.htm?31/14/31979\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H639664593\">",
"       'Diagnostic criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For individuals known to harbor a TP53 germline mutation, surveillance should include careful attention to overall health. Screening for breast cancer in women and colon cancer should begin at an early age. The use of annual whole body MRI may also be considered. (See",
"      <a class=\"local\" href=\"#H639664642\">",
"       'Cancer surveillance strategy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of malignancies that are diagnosed in Li-Fraumeni syndrome patients generally is the same as for other individuals. However, in women with breast cancer, mastectomy rather than lumpectomy plus radiation therapy is generally indicated because of the risk of second malignancies due to radiation induced tumors. (See",
"      <a class=\"local\" href=\"#H639664635\">",
"       'Cancer management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12391/abstract/1\">",
"      Malkin D. Li-fraumeni syndrome. Genes Cancer 2011; 2:475.",
"     </a>",
"    </li>",
"    <li>",
"     file://omim.org/entry/151623.",
"    </li>",
"    <li>",
"     Schneider K, Garber J. Li-Fraumeni syndrome. In: GeneReviews [Internet], Pagon RA, Bird TC, Dolan CR, Stephens K.  (Eds), University of Washington, Seattle 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12391/abstract/4\">",
"      Lindor NM, McMaster ML, Lindor CJ, et al. Concise handbook of familial cancer susceptibility syndromes - second edition. J Natl Cancer Inst Monogr 2008; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12391/abstract/5\">",
"      Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 1969; 71:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12391/abstract/6\">",
"      Li FP, Fraumeni JF Jr, Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988; 48:5358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12391/abstract/7\">",
"      Gonzalez KD, Noltner KA, Buzin CH, et al. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 2009; 27:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12391/abstract/8\">",
"      Hisada M, Garber JE, Fung CY, et al. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 1998; 90:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12391/abstract/9\">",
"      Limacher JM, Frebourg T, Natarajan-Ame S, Bergerat JP. Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int J Cancer 2001; 96:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12391/abstract/10\">",
"      Heymann S, Delaloge S, Rahal A, et al. Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiat Oncol 2010; 5:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12391/abstract/11\">",
"      Boyle JM, Spreadborough A, Greaves MJ, et al. The relationship between radiation-induced G(1)arrest and chromosome aberrations in Li-Fraumeni fibroblasts with or without germline TP53 mutations. Br J Cancer 2001; 85:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12391/abstract/12\">",
"      Chompret A, Brugi&egrave;res L, Ronsin M, et al. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer 2000; 82:1932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12391/abstract/13\">",
"      Lustbader ED, Williams WR, Bondy ML, et al. Segregation analysis of cancer in families of childhood soft-tissue-sarcoma patients. Am J Hum Genet 1992; 51:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12391/abstract/14\">",
"      Wu CC, Shete S, Amos CI, Strong LC. Joint effects of germ-line p53 mutation and sex on cancer risk in Li-Fraumeni syndrome. Cancer Res 2006; 66:8287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12391/abstract/15\">",
"      Wilson JR, Bateman AC, Hanson H, et al. A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations. J Med Genet 2010; 47:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12391/abstract/16\">",
"      Evans DG, Moran A, Hartley R, et al. Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status. Br J Cancer 2010; 102:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12391/abstract/17\">",
"      Varley JM, McGown G, Thorncroft M, et al. Are there low-penetrance TP53 Alleles? evidence from childhood adrenocortical tumors. Am J Hum Genet 1999; 65:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12391/abstract/18\">",
"      Olivier M, Goldgar DE, Sodha N, et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 2003; 63:6643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12391/abstract/19\">",
"      Ognjanovic S, Olivier M, Bergemann TL, Hainaut P. Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database. Cancer 2012; 118:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12391/abstract/20\">",
"      Birch JM, Hartley AL, Tricker KJ, et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 1994; 54:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12391/abstract/21\">",
"      Lib&eacute; R, Bertherat J. Molecular genetics of adrenocortical tumours, from familial to sporadic diseases. Eur J Endocrinol 2005; 153:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12391/abstract/22\">",
"      Tinat J, Bougeard G, Baert-Desurmont S, et al. 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol 2009; 27:e108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12391/abstract/23\">",
"      Chompret A, Abel A, Stoppa-Lyonnet D, et al. Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet 2001; 38:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12391/abstract/24\">",
"      Eeles RA. Germline mutations in the TP53 gene. Cancer Surv 1995; 25:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12391/abstract/25\">",
"      Cohen RJ, Curtis RE, Inskip PD, Fraumeni JF Jr. The risk of developing second cancers among survivors of childhood soft tissue sarcoma. Cancer 2005; 103:2391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12391/abstract/26\">",
"      Lammens CR, Aaronson NK, Wagner A, et al. Genetic testing in Li-Fraumeni syndrome: uptake and psychosocial consequences. J Clin Oncol 2010; 28:3008.",
"     </a>",
"    </li>",
"    <li>",
"     NCCN Clinical Practice Guidelines in Oncology.  file://www.nccn.org (Accessed on July 22, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12391/abstract/28\">",
"      Villani A, Tabori U, Schiffman J, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol 2011; 12:559.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14255 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-60.18.131.125-4DC6258CCE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_6_12391=[""].join("\n");
var outline_f12_6_12391=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H639665000\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H639664550\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H639664557\">",
"      MOLECULAR PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H639664564\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H639664664\">",
"      Spectrum of malignancies and age at onset",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H525774358\">",
"      Multiple cancers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H525774378\">",
"      Radiation-induced cancers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H639664572\">",
"      Lifetime risk of cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H639664579\">",
"      Specific malignancies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H639664672\">",
"      - Sarcomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H639664682\">",
"      - Breast cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H639664692\">",
"      - Brain tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H639664702\">",
"      - Adrenocortical carcinomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H639664586\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H639664593\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H639664600\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H639664607\">",
"      - BRCA1 and BRCA2 mutations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H639664614\">",
"      - Mismatch repair cancer syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H639664621\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H639664628\">",
"      Who to test for TP53 mutation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H639664635\">",
"      Cancer management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H639664642\">",
"      Cancer surveillance strategy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H639665000\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/14255\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/14255|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/58/4011\" title=\"table 1\">",
"      Classic Li-Fraumeni syndrome - Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/14/31979\" title=\"table 2\">",
"      Chompret diagn criteria Li-Fraumeni syndrome and TP53 testing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=related_link\">",
"      Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25657?source=related_link\">",
"      Clinical presentation and diagnosis of brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12826?source=related_link\">",
"      Clinical presentation and evaluation of adrenocortical tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31418?source=related_link\">",
"      Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=related_link\">",
"      Genetic testing for hereditary breast and ovarian cancer syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20842?source=related_link\">",
"      Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19177?source=related_link\">",
"      Overview of the treatment of newly diagnosed, non-metastatic breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40762?source=related_link\">",
"      Treatment of adrenocortical carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35946?source=related_link\">",
"      Uncommon brain tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_6_12392="Osgood-Schlatter disease (tibial tuberosity avulsion)";
var content_f12_6_12392=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Osgood-Schlatter disease (tibial tuberosity avulsion)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/6/12392/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/6/12392/contributors\">",
"     Andrew J Kienstra, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/6/12392/contributors\">",
"     Charles G Macias, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/6/12392/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/6/12392/contributors\">",
"     William Phillips, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/6/12392/contributors\">",
"     Jonathan I Singer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/6/12392/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/6/12392/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/6/12392/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osgood-Schlatter disease, also known as osteochondritis of the tibial tubercle, was first described in 1903 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It is a traction apophysitis of the proximal tibial tubercle at the insertion of the patellar tendon.",
"   </p>",
"   <p>",
"    The clinical features and management of Osgood-Schlatter disease will be discussed here. Causes of knee pain and the general approach to the diagnosis of knee pain in children and adolescents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28455?source=see_link\">",
"     \"Traumatic causes of acute knee pain and injury in the young athlete\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5273?source=see_link\">",
"     \"Approach to the young athlete with acute knee pain or injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29223?source=see_link\">",
"     \"Approach to the young athlete with chronic knee pain or injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osgood-Schlatter disease is characterized by pain and swelling at the tibial tubercle, the point of insertion of the patellar tendon (",
"    <a class=\"graphic graphic_figure graphicRef51102 \" href=\"UTD.htm?20/6/20578\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef50421 \" href=\"UTD.htm?5/17/5395\">",
"     picture 1",
"    </a>",
"    ). The patellar tendon arises from the inferior pole of the patella, a sesamoid bone within the quadriceps tendon. The quadriceps muscle is involved in knee extension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osgood-Schlatter disease generally occurs in children 9 to 14 years of age who have undergone a rapid growth spurt. It occurs in approximately 20 percent of adolescents who are active in sports compared with 5 percent of nonathletes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/3\">",
"     3",
"    </a>",
"    ]. It is bilateral in 25 to 50 percent of cases, although the involvement is typically asymmetric [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Osgood-Schlatter has traditionally occurred most commonly in boys. However, it is becoming more common in girls as their sports participation increases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/6\">",
"     6",
"    </a>",
"    ]. Osgood-Schlatter typically occurs one to two years earlier in girls than in boys, corresponding to the different timing of the pubertal growth spurt. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=see_link&amp;anchor=H5#H5\">",
"     \"Normal puberty\", section on 'Peak height velocity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osgood-Schlatter occurs most frequently in participants of sports that involve running, cutting, and jumping (eg, soccer, football, basketball, volleyball, gymnastics, figure skating, ballet) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. These activities place stress on the tibial tubercle through repetitive contraction of the quadriceps muscle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osgood-Schlatter disease is an overuse injury caused by repetitive strain and chronic avulsion of the secondary ossification center (apophysis) of the tibial tubercle [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/9-13\">",
"     9-13",
"    </a>",
"    ]. Chronic avulsion causes separation of the proximal patellar tendon insertion from the tibial tubercle, which results in elevation (",
"    <a class=\"graphic graphic_figure graphicRef73362 \" href=\"UTD.htm?15/50/16166\">",
"     figure 2",
"    </a>",
"    ). As callous is laid down during healing, the tubercle may become markedly pronounced. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Complications and sequelae'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other factors that may be related to the development of Osgood-Schlatter disease include a more proximal attachment of the patellar tendon [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/14\">",
"     14",
"    </a>",
"    ], attachment to a broader area of the tibia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/14\">",
"     14",
"    </a>",
"    ], a history of calcaneal apophysitis (Sever syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/3\">",
"     3",
"    </a>",
"    ], and a high-riding patella (patella alta) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/15\">",
"     15",
"    </a>",
"    ]. Patella alta requires increased force from the quadriceps for full extension, which may contribute to apophyseal stress [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/15\">",
"     15",
"    </a>",
"    ]. However, the temporal relationship between patella alta and Osgood-Schlatter has not been established, and it is possible that patella alta is the effect, rather than the cause, of Osgood-Schlatter [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osgood-Schlatter typically occurs in the 13 to 14-year-old boy or skeletally equivalent 11 to 12-year-old girl who has recently undergone a rapid growth spurt [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common presenting complaint is anterior knee pain that increases gradually over time, from a low-grade ache to pain that causes a limp",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    impairs activity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/18\">",
"     18",
"    </a>",
"    ]. Pain is exacerbated by direct trauma, kneeling, running, jumping, squatting, climbing stairs, or walking uphill, and is relieved by rest. Involvement usually is asymmetric, although both knees are involved in 25 to 50 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/3,4,9\">",
"     3,4,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of Osgood-Schlatter disease is made by clinical examination. Radiographs are not necessary unless the patient has atypical complaints (pain at night, pain that is unrelated to activity, acute onset of pain, associated systemic complaints) or pain that is not directly over the tibial tubercle. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Imaging'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H10\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A description of the complete knee examination for children and adolescents is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5273?source=see_link&amp;anchor=H11#H11\">",
"     \"Approach to the young athlete with acute knee pain or injury\", section on 'Physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The characteristic examination findings of Osgood-Schlatter disease include tenderness and soft tissue or bony prominence of the tibial tubercle [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/17\">",
"     17",
"    </a>",
"    ]. Pain may be reproduced by extending the knee against resistance, stressing the quadriceps, or squatting with the knee in full flexion [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/19\">",
"     19",
"    </a>",
"    ]. Straight-leg raising usually is painless. Pain that is more prominent in the patellar tendon than the bony prominence is suggestive of patellar tendinopathy (jumper's knee) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8726?source=see_link&amp;anchor=H8889733#H8889733\">",
"     \"Causes of chronic knee pain in the young athlete\", section on 'Tendonitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The hamstrings may be shortened and the quadriceps taut. Quadriceps flexibility is assessed by passively flexing the knee with the patient prone (ie, the Ely test) (",
"    <a class=\"graphic graphic_figure graphicRef64226 \" href=\"UTD.htm?23/17/23839\">",
"     figure 3",
"    </a>",
"    ). The range of motion of the knee is not affected, and the knee and patellofemoral joints are stable [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/19,21\">",
"     19,21",
"    </a>",
"    ]. The remainder of the knee examination is usually normal.",
"   </p>",
"   <p>",
"    Erythema and warmth of the tibial tubercle, which suggest an acute inflammatory process, require additional evaluation (eg, for osteomyelitis). However, these findings must be interpreted with caution in patients who have used an ace wrap or heating pad before presenting for evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Examination of patients with knee pain should include evaluation of range of motion of the hip to make sure that the knee pain is not related to referred pain from pathology in the hip (eg, due to slipped capital femoral epiphysis, Legg-Calv&eacute;-Perthes disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16729?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of hip pain in childhood\", section on 'Hip examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not necessary to obtain radiographs in patients with clinical findings characteristic of Osgood-Schlatter disease. Plain radiographs are obtained to exclude other conditions (eg, tibial apophyseal fracture, tumors, osteomyelitis) in patients who have atypical features. Computed tomography or magnetic resonance imaging is not indicated. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Atypical features include, but are not limited to [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Erythema or warmth in addition to pain at the tibial tubercle is suggestive of an inflammatory process, such as osteomyelitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20087?source=see_link\">",
"       \"Clinical features of hematogenous osteomyelitis in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute onset of pain (particularly after an injury) may indicate avulsion fracture of the tibial tubercle [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5957?source=see_link&amp;anchor=H16#H16\">",
"       \"Proximal tibial fractures in adults\", section on 'Tibial tubercle avulsions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pain at night, rest-related pain, mechanical symptoms (catching or locking), associated systemic complaints,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      tenderness that is not directly localized to the tibial tubercle may indicate tumor, infection, or osteochondritis dissecans. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/47/5882?source=see_link&amp;anchor=H13#H13\">",
"       \"Clinical assessment of the child with suspected cancer\", section on 'Bone and joint pain'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20087?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical features of hematogenous osteomyelitis in children\", section on 'General clinical features'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13913?source=see_link&amp;anchor=H2510199#H2510199\">",
"       \"Clinical manifestations and diagnosis of osteochondritis dissecans (OCD)\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The radiographic findings of Osgood-Schlatter disease are best depicted on the lateral radiograph. The findings are nonspecific and must be correlated with clinical findings to make the diagnosis. Soft tissue swelling anterior to the tibial tubercle may be the only abnormality (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65651 \" href=\"UTD.htm?41/15/42225\">",
"     image 1",
"    </a>",
"    ). Other signs may include [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/7,19\">",
"     7,19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Elevation of the tubercle away from the shaft",
"     </li>",
"     <li>",
"      Irregularity, fragmentation, or increased density of the tubercle",
"     </li>",
"     <li>",
"      A superficial ossicle in the patellar tendon",
"     </li>",
"     <li>",
"      Calcification within or thickening of the patellar tendon",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings may be difficult to distinguish from normal variation in the ossification of the tubercle. One or more ossicles may be present but may be normal variants [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/25\">",
"     25",
"    </a>",
"    ]. Changes in the surrounding soft tissues and the infrapatellar fat pad may be more reliable diagnostic features [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osgood-Schlatter is one in a spectrum of conditions that cause anterior knee pain in children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/19,27\">",
"     19,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28455?source=see_link\">",
"     \"Traumatic causes of acute knee pain and injury in the young athlete\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bone tumors (eg, Ewing sarcoma, osteogenic sarcoma, osteoid osteoma, osteoblastoma, eosinophilic granuloma, and enchondroma) and subacute osteomyelitis of the proximal tibial apophysis rarely cause anterior knee pain in children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. These conditions usually have associated features that are absent in patients with Osgood-Schlatter (eg, pain at night, rest-related pain, erythema",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    warmth over the tibial tubercle, fever and other systemic complaints). Patients who have such atypical features should undergo imaging as part of the initial evaluation. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Imaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Other conditions that cause anterior knee pain in children and adolescents include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stress fracture of the proximal tibia",
"     </li>",
"     <li>",
"      Quadriceps tendon avulsion",
"     </li>",
"     <li>",
"      Avulsion fracture of the tibial tubercle",
"     </li>",
"     <li>",
"      Peripatellar tendinopathy",
"     </li>",
"     <li>",
"      Sinding-Larsen-Johansson (traction apophysitis at the inferior pole of the patella that typically occurs in boys aged 9 to 11 years)",
"     </li>",
"     <li>",
"      Plica syndrome (inflammation of the synovial folds)",
"     </li>",
"     <li>",
"      Hoffa disease (impingement of the infrapatellar fat pad)",
"     </li>",
"     <li>",
"      Idiopathic anterior knee pain",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Tenderness over the tibial tubercle usually distinguishes Osgood-Schlatter from the above conditions, in which such tenderness is rarely present. The exception is avulsion fracture of the tibial tubercle, in which there is generally a history of acute injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/24\">",
"     24",
"    </a>",
"    ]. The evaluation of patients with anterior knee pain that is not localized to the tibial tubercle is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5273?source=see_link\">",
"     \"Approach to the young athlete with acute knee pain or injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29223?source=see_link\">",
"     \"Approach to the young athlete with chronic knee pain or injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of Osgood-Schlatter disease has not been studied in randomized controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/30\">",
"     30",
"    </a>",
"    ]. Observational studies suggest that most patients respond to nonsurgical treatment and that those with persistent symptoms may benefit from surgical therapy (eg, ossicle excision) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/3,4,9,31-33\">",
"     3,4,9,31-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A discussion of the treatment of knee injuries in the young athlete, including general treatment principles, is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4056?source=see_link\">",
"     \"Treatment of knee injuries in the young athlete\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Nonsurgical treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osgood-Schlatter disease usually is a benign and self-limited condition. Symptoms generally resolve once the growth plate is ossified. The usual course is 6 to 18 months, during which symptoms may wax and wane [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/23,34\">",
"     23,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Conservative measures are the mainstay of therapy. Conservative measures for Osgood-Schlatter disease include control of pain and swelling, continuation of activity, and physical therapy (to strengthen the quadriceps and improve quadriceps and hamstring flexibility). The efficacy of these measures for patients with Osgood-Schlatter has not been evaluated in randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/30\">",
"     30",
"    </a>",
"    ]. The recommendations below are based upon observational studies and clinical experience [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/3,4,9,31-33\">",
"     3,4,9,31-33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Pain control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measures to control pain and swelling may include the application of ice, administration of analgesics",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nonsteroidal (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65651 \" href=\"UTD.htm?41/15/42225\">",
"     image 1",
"    </a>",
"    )antiinflammatory drugs (NSAIDS) for a limited duration (eg, three to four days), and the wearing of a protective pad over the tibial tubercle.",
"   </p>",
"   <p>",
"    The application of ice to the involved area after participating in sports activity may be helpful in reducing pain and swelling [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/30\">",
"     30",
"    </a>",
"    ]. During periods of symptom exacerbation, ice should be applied for 20 to 30 minutes at a time at least twice per day. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4056?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of knee injuries in the young athlete\", section on 'RICE'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Analgesics (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ) or nonsteroidal antiinflammatory medications (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ) may help to control the pain.",
"   </p>",
"   <p>",
"    Patients with persistent pain that alters their ability to participate in sports for more than three months may benefit from injection of hyperosmolar dextrose (eg, 12.5 percent dextrose) by a sports medicine specialist or orthopedic surgeon. As an example, in a small blinded trial of 54 young athletes (mean age 13 years) with Osgood Schlatter disease and persistent pain despite three months of usual care (ie, local pain control, oral analgesics, and strengthening and stretching exercises with gradual sports reintroduction), injection of 12.5 percent dextrose mixed with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/57/37776?source=see_link\">",
"     lidocaine",
"    </a>",
"    was significantly associated with no symptoms during sports activities at three months and one year when compared to lidocaine injection or usual care [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/35\">",
"     35",
"    </a>",
"    ]. Although these results are encouraging, additional study is necessary to clarify any potential adverse events before this procedure can be routinely recommended.",
"   </p>",
"   <p>",
"    Glucocorticoid injections generally are not recommended because of case reports of complications, primarily related to subcutaneous atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Wearing a protective pad over the tibial tubercle (an Osgood-Schlatter pad, or a brace with a doughnut pad around the tibial tubercle) may prevent direct trauma to the tender tibial tubercle [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Activity continuation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete avoidance of sports activity is neither necessary nor recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/37\">",
"     37",
"    </a>",
"    ]. Inactivity can lead to deconditioning and increases the risk of recurrence or other injury after returning to sports participation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Osgood-Schlatter is one condition in which playing with pain is permitted (provided the pain is tolerated and resolves within 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/23\">",
"     23",
"    </a>",
"    ]). Activities that require prolonged squatting or kneeling may not be tolerated; for some athletes, a change in position may be necessary (eg, from catcher to outfielder in baseball) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/34,38\">",
"     34,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Crutches are rarely indicated, and knee immobilizers are contraindicated. Extended periods of casting worsen the ultimate outcome because they lead to atrophy of the quadriceps and hamstring muscles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Physical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once pain is adequately controlled, athletes with Osgood-Schlatter disease should participate in a rehabilitative program that includes stretching of the quadriceps and hamstring muscles and strengthening of the quadriceps muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/23\">",
"     23",
"    </a>",
"    ]. (For specific exercises, (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4056?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment of knee injuries in the young athlete\", section on 'Patellofemoral injuries'",
"    </a>",
"    )).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children and adolescents with Osgood-Schlatter disease and their parents should be educated regarding the anticipated disease course. They should understand that during the course of resolution, there may be unpredictable exacerbations of symptoms that resolve quickly with appropriate management [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/23,34\">",
"     23,34",
"    </a>",
"    ]. They should also understand that variable amounts of tibial tubercle prominence will persist after symptoms have resolved [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Complications and sequelae'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no specific follow-up schedule for patients with Osgood-Schlatter. Patients should follow-up with their primary care provider as regularly scheduled for health maintenance. They should make arrangements to be seen sooner if they have persistent or worsening pain or develop atypical features (a new or different type of pain, pain at night, pain that is unrelated to activity, or associated systemic complaints).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Surgical treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical management is reserved for patients who fail to respond to conservative measures; it is generally undertaken after closure of the proximal tibial growth plate [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/33\">",
"     33",
"    </a>",
"    ]. Specific procedures have not been evaluated in randomized trials. In case series, ossicle resection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    excision of the tibial tuberosity have been beneficial in reducing symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/9,33,39-42\">",
"     9,33,39-42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osgood-Schlatter disease typically subsides with the closure of the proximal tibial growth plate at skeletal maturity (usually between 14 and 18 years of age). Pain that persists after the closure of the growth plate may be related to a residual ossicle [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The natural history of Osgood-Schlatter was evaluated in a retrospective review of 50 patients (69 knees) for whom no treatments or activity restrictions were recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/4\">",
"     4",
"    </a>",
"    ]. After an average of nine years, 24 percent of patients reported some limitation in activities, and 60 percent had discomfort with kneeling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     COMPLICATIONS AND SEQUELAE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications and sequelae of Osgood-Schlatter disease may include persistent prominence of the tibial tubercle, persistent pain, and rarely, genu recurvatum (back knee, hyperextension of the knee) (",
"    <a class=\"graphic graphic_figure graphicRef51091 \" href=\"UTD.htm?41/16/42240\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Variable amounts of tibial tubercle prominence persist after symptoms have resolved [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/38\">",
"     38",
"    </a>",
"    ]. Patients and parents should be informed about this potential cosmetic sequela at the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/23,38\">",
"     23,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pain that persists after closure of the proximal tibial growth plate is uncommon. A residual ossicle is the most common cause; avulsion fracture of the tibial tubercle is another possibility. Plain radiographs of the tibial tuberosity should be obtained if these injuries are suspected.",
"   </p>",
"   <p>",
"    Residual ossicles in the patellar tendon occur in approximately 10 percent of children and adolescents with Osgood-Schlatter disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/9,18\">",
"     9,18",
"    </a>",
"    ]. Residual ossicles may be associated with symptoms that persist after closure of the proximal tibial growth plate (eg, pain with activity or direct pressure) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/22\">",
"     22",
"    </a>",
"    ]. Ossicle excision can be curative [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Surgical treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Persistent pain that is not associated with a residual ossicle may indicate avulsion fracture of the tibial tubercle, particularly in athletes involved in jumping sports [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/43\">",
"     43",
"    </a>",
"    ]. Tibial tubercle fractures occur more commonly among teenagers with a history of Osgood-Schlatter disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/44\">",
"     44",
"    </a>",
"    ] but remain uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. A causal relationship has not been demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genu recurvatum is a rare but serious complication of Osgood-Schlatter disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12392/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. It results from premature fusion of the anterior part of the upper tibial epiphyseal plate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/43/43697?source=see_link\">",
"       \"Patient information: Osgood-Schlatter disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osgood-Schlatter disease is an overuse injury caused by repetitive strain and chronic avulsion of the secondary ossification center of the tibial tubercle. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Osgood-Schlatter occurs most frequently in participants of sports that involve running, cutting, and jumping and who have recently undergone a rapid growth spurt. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common presenting complaint is anterior knee pain that increases gradually over time; the pain is exacerbated by direct trauma, kneeling, running, jumping, squatting, climbing stairs, or walking uphill, and is relieved by rest. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of Osgood-Schlatter is made clinically. The characteristic findings are tenderness and soft tissue or bony prominence of the tibial tubercle in a patient with an otherwise normal examination (including range of motion of the hip). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Imaging is not necessary to confirm the diagnosis in cases with characteristic features but may be necessary to exclude other conditions in patients with atypical complaints, such as pain at night, rest-related pain, acute onset of pain (especially after trauma), associated systemic complaints, or pain that is not directly over the tibial tubercle. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Osgood-Schlatter disease usually is a benign and self-limited condition. Symptoms generally resolve once the growth plate is ossified. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Nonsurgical treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Conservative measures are the mainstay of therapy. We suggest the following conservative measures (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Application of ice to the involved area after participating in sporting activities. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Pain control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Analgesics or nonsteroidal antiinflammatory drugs of limited duration as needed for pain. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Pain control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Continued sports participation, provided that the pain can be tolerated and resolves within 24 hours. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Activity continuation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Physical therapy to strengthen the quadriceps and stretch the quadriceps and hamstrings. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Physical therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with persistent pain that alters their ability to participate in sports for more than three months may benefit from injection of hyperosmolar dextrose (eg, 12.5 percent dextrose) by a sports medicine specialist or orthopedic surgeon.",
"     </li>",
"     <li>",
"      In addition, children and adolescents with Osgood-Schlatter disease and their parents should be educated regarding the anticipated disease course. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Education'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who have pain that persists after closure of the proximal tibial growth plate and is related to bony or cartilaginous ossicles may benefit from surgical excision. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Surgical treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications and sequelae of Osgood-Schlatter disease may include persistent prominence of the tibial tubercle, persistent pain (usually related to a residual ossicle), and genu recurvatum. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Complications and sequelae'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12392/abstract/1\">",
"      Osgood, RB. Lesions of the tibial tubercle occurring during adolescence. Boston Med Surg J 1903; 148:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12392/abstract/2\">",
"      Schlatter, C. Verletzungen des schnabelforminogen fortsatzes der oberen tibiaepiphyse. Beitre Klin Chir Tubing 1903; 38:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12392/abstract/3\">",
"      Kujala UM, Kvist M, Heinonen O. Osgood-Schlatter's disease in adolescent athletes. Retrospective study of incidence and duration. Am J Sports Med 1985; 13:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12392/abstract/4\">",
"      Krause BL, Williams JP, Catterall A. Natural history of Osgood-Schlatter disease. J Pediatr Orthop 1990; 10:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12392/abstract/5\">",
"      Stanitski CL. Knee overuse disorders in the pediatric and adolescent athlete. Instr Course Lect 1993; 42:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12392/abstract/6\">",
"      Duri ZA, Patel DV, Aichroth PM. The immature athlete. Clin Sports Med 2002; 21:461.",
"     </a>",
"    </li>",
"    <li>",
"     Willis RB. Sports medicine in the growing child. In: Lovell and Winter's Pediatric Orthopaedics, 6th, Morrissey RT, Weinstein SL.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1384.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12392/abstract/8\">",
"      Cassas KJ, Cassettari-Wayhs A. Childhood and adolescent sports-related overuse injuries. Am Fam Physician 2006; 73:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12392/abstract/9\">",
"      Mital MA, Matza RA, Cohen J. The so-called unresolved Osgood-Schlatter lesion: a concept based on fifteen surgically treated lesions. J Bone Joint Surg Am 1980; 62:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12392/abstract/10\">",
"      Gholve PA, Scher DM, Khakharia S, et al. Osgood Schlatter syndrome. Curr Opin Pediatr 2007; 19:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12392/abstract/11\">",
"      Ogden JA, Southwick WO. Osgood-Schlatter's disease and tibial tuberosity development. Clin Orthop Relat Res 1976; :180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12392/abstract/12\">",
"      Hirano A, Fukubayashi T, Ishii T, Ochiai N. Magnetic resonance imaging of Osgood-Schlatter disease: the course of the disease. Skeletal Radiol 2002; 31:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12392/abstract/13\">",
"      Rosenberg ZS, Kawelblum M, Cheung YY, et al. Osgood-Schlatter lesion: fracture or tendinitis? Scintigraphic, CT, and MR imaging features. Radiology 1992; 185:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12392/abstract/14\">",
"      Demirag B, Ozturk C, Yazici Z, Sarisozen B. The pathophysiology of Osgood-Schlatter disease: a magnetic resonance investigation. J Pediatr Orthop B 2004; 13:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12392/abstract/15\">",
"      Aparicio G, Abril JC, Calvo E, Alvarez L. Radiologic study of patellar height in Osgood-Schlatter disease. J Pediatr Orthop 1997; 17:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12392/abstract/16\">",
"      Andrisano A, Mignani G, Mazzetti M. Long term results in Osgood-Schlatters disease. Ital J Orthop Traumatol 1985; 11:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12392/abstract/17\">",
"      Clark, MC, Iwinski, HJ. The limping child: The challenges of an accurate assessment and diagnosis. Pediatr Emerg Med 1997; 2:123.",
"     </a>",
"    </li>",
"    <li>",
"     Micheli LJ. Osgood-Schlatter syndrome. In: The Sports Medicine Bible, Harper Perennial, New York 1995. p.137.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12392/abstract/19\">",
"      Dunn JF. Osgood-Schlatter disease. Am Fam Physician 1990; 41:173.",
"     </a>",
"    </li>",
"    <li>",
"     Micheli LJ, Purcell L. Osgood-Schlatter disease. In: The Adolescent Athlete: A Practical Approach, Spring, New York 2007. p.311.",
"    </li>",
"    <li>",
"     Osgood-Schlatter Disease. In: Essentials of Musculoskeletal Care, Greene WB.  (Ed), American Academy of Orthopedic Surgeons, Rosemont 2001. p.719.",
"    </li>",
"    <li>",
"     Stahli LT. Sports. In: Fundamentals of Pediatric Orthopedics, 2nd, Lippincott Raven, Philadelphia 1998. p.111.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12392/abstract/23\">",
"      Wall EJ. Osgood-schlatter disease: practical treatment for a self-limiting condition. Phys Sportsmed 1998; 26:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12392/abstract/24\">",
"      Chow SP, Lam JJ, Leong JC. Fracture of the tibial tubercle in the adolescent. J Bone Joint Surg Br 1990; 72:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12392/abstract/25\">",
"      Bloom RA, Gomori J, Milgrom C. Ossicles anterior to the proximal tibia. Clin Imaging 1993; 17:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12392/abstract/26\">",
"      Scotti DM, Sadhu VK, Heimberg F, O'Hara AE. Osgood-Schlatter's disease, an emphasis on soft tissue changes in roentgen diagnosis. Skeletal Radiol 1979; 4:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12392/abstract/27\">",
"      Schwend RM, Geiger J. Outpatient pediatric orthopedics. Common and important conditions. Pediatr Clin North Am 1998; 45:943.",
"     </a>",
"    </li>",
"    <li>",
"     Tachdijan MO. The knee and leg. In: Clinical Pediatric Orthopedics: The Art of Diagnosis and Principles of Management, Appleton and Lange, Stamford 1997. p.107.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12392/abstract/29\">",
"      D'Ambrosia RD, MacDonald GL. Pitfalls in the diagnosis of Osgood-Schlatter disease. Clin Orthop Relat Res 1975; :206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12392/abstract/30\">",
"      Bloom OJ, Mackler L, Barbee J. Clinical inquiries. What is the best treatment for Osgood-Schlatter disease? J Fam Pract 2004; 53:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12392/abstract/31\">",
"      Hussain, A, Hagroo, GA. Osgood-Schlatter disease. Sports Exer Injury 1996; 2:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12392/abstract/32\">",
"      Beovich, R, Fricker, PA. Osgood-Schlatter's disease. A review of the literature and an Australian series. Aust J Sci Med Sport 1988; 20:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12392/abstract/33\">",
"      Weiss JM, Jordan SS, Andersen JS, et al. Surgical treatment of unresolved Osgood-Schlatter disease: ossicle resection with tibial tubercleplasty. J Pediatr Orthop 2007; 27:844.",
"     </a>",
"    </li>",
"    <li>",
"     Stanitski CL. Patellofemoral mechanism. In: DeLee &amp; Drez's Orthopaedic Sports Medicine Principles and Practice, DeLee JC, Drez D, Miller MD.  (Eds), Saunders, Philadelphia 2003. p.1814.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12392/abstract/35\">",
"      Topol GA, Podesta LA, Reeves KD, et al. Hyperosmolar dextrose injection for recalcitrant Osgood-Schlatter disease. Pediatrics 2011; 128:e1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12392/abstract/36\">",
"      Rostron PK, Calver RF. Subcutaneous atrophy following methylprednisolone injection in Osgood-Schlatter epiphysitis. J Bone Joint Surg Am 1979; 61:627.",
"     </a>",
"    </li>",
"    <li>",
"     Tolo VT. The lower extremity. In: Lovell and Winter's Pediatric Orthopaedics, Morrissey RT, Weinstein SL.  (Eds), Lippincott- Raven, Philadelphia 1996. p.1063.",
"    </li>",
"    <li>",
"     Neuschwander DC. Peripatellar pathology. In: DeLee &amp; Drez's Orthopaedic Sports Medicine Principles and Practice, 2nd, DeLee JC, Drez D, Miller MD.  (Eds), Saunders, Philadelphia 2003. p.1867.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12392/abstract/39\">",
"      Orava S, Malinen L, Karpakka J, et al. Results of surgical treatment of unresolved Osgood-Schlatter lesion. Ann Chir Gynaecol 2000; 89:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12392/abstract/40\">",
"      Flowers MJ, Bhadreshwar DR. Tibial tuberosity excision for symptomatic Osgood-Schlatter disease. J Pediatr Orthop 1995; 15:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12392/abstract/41\">",
"      Binazzi R, Felli L, Vaccari V, Borelli P. Surgical treatment of unresolved Osgood-Schlatter lesion. Clin Orthop Relat Res 1993; :202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12392/abstract/42\">",
"      Pihlajam&auml;ki HK, Mattila VM, Parviainen M, et al. Long-term outcome after surgical treatment of unresolved Osgood-Schlatter disease in young men. J Bone Joint Surg Am 2009; 91:2350.",
"     </a>",
"    </li>",
"    <li>",
"     Pasque CB, McGinnis DW. Knee. In: Care of the Young Athlete, American Academy of Orthopedic Surgeons and American Academy of Pediatrics, Elk Grove Village 2000. p.377.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12392/abstract/44\">",
"      Wiss DA, Schilz JL, Zionts L. Type III fractures of the tibial tubercle in adolescents. J Orthop Trauma 1991; 5:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12392/abstract/45\">",
"      Bolesta MJ, Fitch RD. Tibial tubercle avulsions. J Pediatr Orthop 1986; 6:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12392/abstract/46\">",
"      Lynch MC, Walsh HP. Tibia recurvatum as a complication of Osgood-Schlatter's disease: a report of two cases. J Pediatr Orthop 1991; 11:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12392/abstract/47\">",
"      Bellicini C, Khoury JG. Correction of genu recurvatum secondary to Osgood-Schlatter disease: a case report. Iowa Orthop J 2006; 26:130.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6289 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.167.4.114-B39C775BF0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_6_12392=[""].join("\n");
var outline_f12_6_12392=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Nonsurgical treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Pain control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Activity continuation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Physical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Education",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Follow-up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      COMPLICATIONS AND SEQUELAE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6289\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6289|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/15/42225\" title=\"diagnostic image 1\">",
"      Osgood-Schlatter radiographic findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6289|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/6/20578\" title=\"figure 1\">",
"      Sagittal knee anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/50/16166\" title=\"figure 2\">",
"      Osgood Schlatter pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/17/23839\" title=\"figure 3\">",
"      Ely test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/16/42240\" title=\"figure 4\">",
"      Genu recurvatum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6289|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/17/5395\" title=\"picture 1\">",
"      Surface anatomy anterior knee",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5273?source=related_link\">",
"      Approach to the young athlete with acute knee pain or injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29223?source=related_link\">",
"      Approach to the young athlete with chronic knee pain or injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8726?source=related_link\">",
"      Causes of chronic knee pain in the young athlete",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/47/5882?source=related_link\">",
"      Clinical assessment of the child with suspected cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20087?source=related_link\">",
"      Clinical features of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13913?source=related_link\">",
"      Clinical manifestations and diagnosis of osteochondritis dissecans (OCD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=related_link\">",
"      Normal puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16729?source=related_link\">",
"      Overview of hip pain in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/43/43697?source=related_link\">",
"      Patient information: Osgood-Schlatter disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5957?source=related_link\">",
"      Proximal tibial fractures in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28455?source=related_link\">",
"      Traumatic causes of acute knee pain and injury in the young athlete",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4056?source=related_link\">",
"      Treatment of knee injuries in the young athlete",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_6_12393="Oophorectomy and ovarian cystectomy";
var content_f12_6_12393=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Oophorectomy and ovarian cystectomy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/6/12393/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/6/12393/contributors\">",
"     Fidel A Valea, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/6/12393/contributors\">",
"     William J Mann, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/6/12393/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/6/12393/contributors\">",
"     Howard T Sharp, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/6/12393/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/6/12393/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/6/12393/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian pathology can occur at any time from fetal life to menopause. The most common surgical procedures for benign ovarian disease will be reviewed here.",
"   </p>",
"   <p>",
"    General principles of the evaluation and management of an adnexal mass, elective oophorectomy at the time of hysterectomy, and surgical treatment of ovarian cancer are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=see_link\">",
"     \"Approach to the patient with an adnexal mass\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30905?source=see_link\">",
"     \"Management of an adnexal mass\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/21/15706?source=see_link\">",
"     \"Elective oophorectomy or ovarian conservation at the time of hysterectomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=see_link\">",
"     \"Epithelial ovarian cancer: Initial surgical management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OOPHORECTOMY VERSUS CYSTECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for ovarian surgery versus expectant management of an ovarian cyst depend upon the patient's age, findings on pelvic examination and ultrasound, and laboratory results. These issues are discussed in depth separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=see_link\">",
"     \"Approach to the patient with an adnexal mass\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19352?source=see_link\">",
"     \"Differential diagnosis of the adnexal mass\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When surgery is indicated for benign ovarian disease, preservation of ovarian tissue via cystectomy or enucleation of a solid tumor from the ovary is generally preferable to complete oophorectomy. When the ovary cannot be salvaged or insufficient viable tissue remains after attempts at conservation, oophorectomy is performed. In postmenopausal patients, no effort is made to preserve the ovary.",
"   </p>",
"   <p>",
"    Indications for oophorectomy include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benign ovarian neoplasms that are not amenable to treatment by a lesser procedure (eg, cystectomy, enucleation, partial oophorectomy)",
"     </li>",
"     <li>",
"      Elective or risk-reducing oophorectomy with or without hysterectomy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/21/15706?source=see_link\">",
"       \"Elective oophorectomy or ovarian conservation at the time of hysterectomy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Adnexal (ovarian) torsion with necrosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23690?source=see_link\">",
"       \"Ovarian and fallopian tube torsion\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Ovarian malignancy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=see_link\">",
"       \"Epithelial ovarian cancer: Initial surgical management\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tuboovarian abscess unresponsive to antibiotics (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36823?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of tuboovarian abscess\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Definitive surgery for endometriosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14810?source=see_link\">",
"       \"Overview of the treatment of endometriosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/18/9513?source=see_link\">",
"       \"Reproductive surgery for female infertility\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/46/5863?source=see_link\">",
"       \"Diagnosis and management of ovarian endometriomas\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Gastrointestinal or other metastatic cancer (eg, breast, lung, melanoma) &mdash; Gastrointestinal cancer often metastasizes to the ovary. In one study, ovarian metastases were encountered in 25 percent of patients with an adenocarcinoma of the gastrointestinal tract; the metastases were occult in approximately one-half of these cases [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12393/abstract/1\">",
"       1",
"      </a>",
"      ]. Therefore, oophorectomy and concomitant hysterectomy should be considered at the time of resection of the gastrointestinal cancer, especially in women approaching or beyond the menopausal transition.",
"     </li>",
"     <li>",
"      Male pseudohermaphrodites, in whom the procedure is termed 'gonadectomy' &mdash; An increased risk of gonadal malignancy occurs in phenotypic females with a Y chromosome in their karyotype [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12393/abstract/2-5\">",
"       2-5",
"      </a>",
"      ]. These individuals should have their gonads removed to avoid the 20 to 30 percent risk of malignant tumors arising in this tissue [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12393/abstract/5-7\">",
"       5-7",
"      </a>",
"      ]. Gonadectomy is delayed until after pubertal development in patients with complete androgen insensitivity, in which it is rare to develop a malignancy before 20 years of age. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5721?source=see_link&amp;anchor=H21#H21\">",
"       \"Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis\", section on 'Dysgerminoma'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The gonadal streaks can be difficult to see and may lie very close to the external iliac artery or be herniated into the inguinal canal (",
"    <a class=\"graphic graphic_figure graphicRef61927 \" href=\"UTD.htm?43/26/44450\">",
"     figure 1",
"    </a>",
"    ), thus laparotomy is the standard approach for both surgical ease and safety. Laparoscopic excision should only be attempted by experienced laparoscopists. There is no need to remove the uterus or the fallopian tubes; these organs can be preserved to permit future childbearing using donor oocytes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ASPIRATION AND FENESTRATION VERSUS CYSTECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspiration of cyst contents is",
"    <strong>",
"     NOT",
"    </strong>",
"    recommended because no tissue is obtained for histopathology, cytology of cyst fluid is not reliable for exclusion of malignancy, there is a high rate of recurrence (11 to 65 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12393/abstract/8\">",
"     8",
"    </a>",
"    ], and aspiration does not provide better results than simple observation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12393/abstract/9\">",
"     9",
"    </a>",
"    ]. These problems are less common with fenestration (ie, removing a full thickness, square portion of the cyst wall to create a window), but cystectomy is preferable. If the cyst is malignant, spillage of malignant cells into the peritoneal cavity is possible with both aspiration and fenestration.",
"   </p>",
"   <p>",
"    Aspiration followed by sclerotherapy via injection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    , alcohol, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    has been associated with a lower rate (4 to 38 percent) of cyst persistence or recurrence in observational series [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12393/abstract/8,10-13\">",
"     8,10-13",
"    </a>",
"    ]. However, it is not clear that this intervention is more effective than expectant management because the studies were not adequately controlled.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SURGICAL APPROACH",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Open laparotomy versus laparoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most ovarian surgeries are for benign disease and can be performed laparoscopically. The major advantages to laparoscopy over laparotomy are reductions in recovery time, hospital stay, cost, and adhesion formation, which is particularly important in women in whom fertility is an issue [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12393/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Limited data from randomized trials also showed less febrile morbidity and a lower frequency of urinary tract infection, postoperative pain and postoperative complications with laparoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12393/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17334?source=see_link\">",
"     \"Overview of conventional gynecologic laparoscopic surgery\"",
"    </a>",
"    .) Guidelines for preoperative referral to a gynecologic oncologist are described in the table (",
"    <a class=\"graphic graphic_table graphicRef55063 \" href=\"UTD.htm?7/38/7787\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A disadvantage of laparoscopic",
"    <span class=\"nowrap\">",
"     oophorectomy/cystectomy",
"    </span>",
"    is the potential for spill of cancer cells if the mass is malignant (see",
"    <a class=\"local\" href=\"#H25\">",
"     'Spillage of malignant cells'",
"    </a>",
"    below). Unfortunately, neither preoperative clinical and sonographic evaluation nor the laparoscopic appearance of the ovary can reliably predict which masses are malignant. However, it is unlikely that an inadvertent laparoscopic procedure for ovarian cancer will be performed if patients are carefully selected. A survey by the American Association of Gynecologic Laparoscopists reported unsuspected ovarian cancer was found in only 0.04 percent of 13,739 cases of laparoscopic ovarian cyst surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12393/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sonographic criteria suggestive of ovarian malignancy are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef79259 \" href=\"UTD.htm?1/0/1035\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12393/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34440?source=see_link\">",
"     \"Sonographic differentiation of benign versus malignant adnexal masses\"",
"    </a>",
"    .) In general, a thin-walled unilocular simple cyst is likely to be benign, even in postmenopausal women. Two series including approximately 1000 thin-walled unilocular cysts in both premenopausal and postmenopausal women found no malignant tumors under 75 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12393/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Thus, these cysts can usually be managed laparoscopically. An in-depth discussion of the approach to evaluation and management of adnexal masses can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=see_link\">",
"     \"Approach to the patient with an adnexal mass\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19352?source=see_link\">",
"     \"Differential diagnosis of the adnexal mass\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is increasing sentiment to evaluate some complex cysts with the laparoscope, since most of them are benign. There are no dogmatic recommendations for this group of patients and clinicians must individualize treatment according to their index of suspicion. The concern associated with the use of laparoscopy in this setting is that the prognosis may be worsened by cyst rupture if malignancy is encountered. Therefore, one must take into account the patient's age, medical condition, clinical examination (eg, fixed mass or mobile), sonographic appearance of the mass, and tumor markers (eg, CA-125) to gauge the likelihood of malignancy when deciding upon the proper operative approach. Laparoscopy should be reserved for those cases in which the risk of malignancy is very low. If a malignancy is encountered, the patient should immediately have the appropriate open surgical procedure for staging and definitive treatment, preferably with the assistance of a gynecologic oncologist (",
"    <a class=\"graphic graphic_table graphicRef75194 \" href=\"UTD.htm?40/8/41099\">",
"     table 3",
"    </a>",
"    ). Staging and treatment of ovarian cancer via a laparoscopic approach is under investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12393/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=see_link\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another approach is minilaparotomy, which some surgeons consider a minimally invasive procedure. Minilaparotomy has the advantages of a potentially shorter operating time and learning curve than laparoscopy and avoidance of pneumoperitoneum, but without the large incision associated with classical open laparotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12393/abstract/22\">",
"     22",
"    </a>",
"    ]. The procedure is performed by placing the patient in a steep Trendelenburg position and making a minimal suprapubic incision (4 to 9 cm) beneath the pubic hair line [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12393/abstract/23\">",
"     23",
"    </a>",
"    ]. The abdominal fascia is opened 2 to 3 cm above the skin incision and the peritoneum is opened manually. Narrow Deaver retractors are used to allow frequent repositioning to optimize exposure of the surgical field. The following criteria should be met if this approach is employed: use of narrow and light instruments; exteriorization of the target organ; combined, unidirectional maneuvering of all the retractors; and prompt hemostasis by electrocoagulating forceps.",
"   </p>",
"   <p>",
"    In summary, laparoscopy is the preferred technique for",
"    <span class=\"nowrap\">",
"     oophorectomy/cystectomy",
"    </span>",
"    because it is associated with a smaller scar, faster recovery, lower cost, and lower frequency of postoperative adhesion formation than laparotomy. Situations in which the traditional open method is safer and more appropriate than the laparoscopic approach are when the surgeon",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    assistants are not experienced in the use of an operative laparoscope, when there are dense adnexal adhesions, when the ovary is very large, or when there is a high suspicion of malignancy. Minilaparotomy is an alternative \"in-between\" approach.",
"   </p>",
"   <p>",
"    Surgeons must use good judgment and be selective in the cases chosen for laparoscopic treatment. The following criteria are generally accepted guidelines:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The laparoscopic approach is reasonable for patients whose preoperative evaluation suggests benign disease (",
"      <a class=\"graphic graphic_table graphicRef79259 \" href=\"UTD.htm?1/0/1035\">",
"       table 2",
"      </a>",
"      ). These patients include those with probable dermoids, endometriomas, or physiological cysts that have not resolved with conservative management or are associated with acute symptoms. A laparoscopy may be converted to a laparotomy if the surgeon encounters a difficult dissection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17334?source=see_link\">",
"       \"Overview of conventional gynecologic laparoscopic surgery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intraoperative findings suspicious for malignancy (ascites, enlarged nodes, matted bowel, excrescences, multiple nodular areas) usually warrant conversion to an open evaluation. However, a smooth appearance on the surface of the cyst does not exclude the possibility of a malignancy.",
"     </li>",
"     <li>",
"      Removing cysts in a specimen bag reduces both operating time and spillage. Controlled intraperitoneal spillage of benign cyst contents (eg, cystic teratoma) does not increase postoperative morbidity as long as the peritoneal cavity is copiously lavaged.",
"     </li>",
"     <li>",
"      Cysts that are complex should be removed, not fenestrated, given the possibility of malignancy and high recurrence rates.",
"     </li>",
"     <li>",
"      A solid adnexal mass that is small enough to be removed intact via colpotomy or via a laparoscopic bag can be managed laparoscopically. Solid masses can also be mobilized laparoscopically and then removed through a mini-laparotomy incision.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10499406\">",
"    <span class=\"h3\">",
"     Use of robotic or single port laparoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newer minimally invasive approaches, such as robot-assisted or single port laparoscopy (also referred to as laparoendoscopic single-site surgery [LESS]), may also be used for oophorectomy or ovarian cystectomy.",
"   </p>",
"   <p>",
"    There are few data regarding robot-assisted laparoscopic salpingo-oophorectomy. The only report is a retrospective cohort study comparing women who underwent adnexectomy using robot-assisted (n = 85) or conventional laparoscopy (n = 91) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12393/abstract/24\">",
"     24",
"    </a>",
"    ]. No differences were found between surgical approaches regarding blood loss, intraoperative complications, or length of hospital stay. Operative duration was 12 minutes longer for robotic-assisted versus conventional procedures. The authors commented that they prefer to approach large adnexal masses with conventional laparoscopy, because trocar placement is more flexible, manipulation of large masses is easier, and intraoperative drainage can be accomplished.",
"   </p>",
"   <p>",
"    Ovarian surgery using a LESS approach is a developing field [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12393/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. Improvements in postoperative pain and cosmetic results were reported by a randomized trial (n = 60) that compared LESS with conventional laparoscopy for oophorectomy or ovarian cystectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12393/abstract/29\">",
"     29",
"    </a>",
"    ]. Operative duration and complication rates were similar for the two approaches.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Oophorectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oophorectomy may be performed through an abdominal incision, laparoscopically, or vaginally (at the time of hysterectomy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Open or laparoscopic approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the abdomen is entered, pelvic and abdominal washings are obtained and saved to use for staging if a malignancy is subsequently diagnosed. The entire pelvis, abdomen and retroperitoneum (eg, diaphragm, omentum, viscera, kidneys) are inspected for sites suspicious for carcinoma (excrescences, thick adhesions, nodules, enlarged nodes) should be biopsied and sent for frozen section.",
"   </p>",
"   <p>",
"    If findings are consistent with benign disease, the infundibulopelvic ligament and ureter are identified. The peritoneum is incised parallel to the ovarian vessels and the retroperitoneal space is entered. Alternatively, the round ligament can be divided to enter the retroperitoneal space.",
"   </p>",
"   <p>",
"    Using either blunt dissection or meticulous sharp dissection with Metzenbaum scissors (preferable) or other laparoscopic instruments, the broad ligament is opened and the ureter identified on its medial, or posterior, leaf.",
"   </p>",
"   <p>",
"    If the fallopian tube is to be removed, the ovarian vessels are then elevated to allow good visualization of the nearby ureter, doubly clamped, divided, and the pedicles doubly ligated to ensure hemostasis (",
"    <a class=\"graphic graphic_figure graphicRef69337 graphicRef79076 graphicRef58049 \" href=\"UTD.htm?24/22/24938\">",
"     figure 2A-C",
"    </a>",
"    ). Both the ovarian ligament and fallopian tube are clamped parallel and just lateral to the uterine cornu and then excised; the cornu is then ligated.",
"   </p>",
"   <p>",
"    If the fallopian tube is to be preserved, the multiple tubal branches of the ovarian artery should be clamped and ligated inferior and parallel to the tube in a systematic fashion. This separates the ovary from the fallopian tube and allows clear visualization of the ovarian branch of the uterine artery. Subsequently, the ovarian artery can be clamped, divided, and ligated. The utero-ovarian ligament is then clamped parallel and just lateral to the uterine cornu and excised; the cornu is then ligated.",
"   </p>",
"   <p>",
"    Some surgeons advocate performing a wedge resection of the fallopian tube stump and approximating the surrounding cornual edge of myometrium to decrease the chance of a uteroperitoneal fistula, ensure hemostasis, and prevent the theoretical risk of a cornual ectopic pregnancy. There are no data to support or refute this approach, which may add to the total blood loss and duration of the procedure.",
"   </p>",
"   <p>",
"    In open cases, microsurgical techniques and fine absorbable suture material may help to minimize postsurgical tubal adhesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Laparoscopic instruments",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several methods for performing an oophorectomy with the laparoscope.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bipolar electrosurgery &mdash; The infundibulopelvic ligament is grasped with bipolar forceps, elevated off of the ureter, and desiccated after visually ascertaining that the ureter is clear of this area. The ligament is then transected with endoscopic scissors and the broad ligament incised up to the utero-ovarian ligament. The medial attachments of the adnexa to the uterus, including the blood supply, can also be desiccated with the bipolar forceps or tied off using endoscopic loop ties and then excised.",
"     </li>",
"     <li>",
"      Stapling devices &mdash; Endoscopic stapling devices are a less popular method for controlling the various attachments to the ovary since they are usually more difficult to manage, require larger trocars, and are more expensive. The ureter, which can be easily caught in the jaws of the stapling device, must be carefully identified and excluded from the area being crushed and stapled.",
"     </li>",
"     <li>",
"      Ultrasonic cutting and coagulation device &mdash; An ultrasonic cutting and coagulation device (eg, Harmonic Scalpel&reg;) uses ultrasonic vibration, which denatures protein and generates secondary heat, resulting in coagulation. The device contains a cutting blade which allows for fewer instrument changes. This device can be used to cut across the meso-ovarium, utero-ovarian ligament, or the ovarian vessels. Care must be taken to visualize the ureter and prevent catching it in the blades.",
"     </li>",
"     <li>",
"      Bipolar vessel sealing device &mdash; Bipolar vessel sealing devices (eg, Ligasure&trade;, Enseal&reg;, Gyrus-PKS&trade;) use bipolar current to seal vessels, and many of these devices have a blade which is activated to cut tissue. As with an ultrasonic cutting and coagulation device, care must be taken to ensure the ureter is free of blades before firing.",
"     </li>",
"     <li>",
"      Loop technique &mdash; The most common loop technique is to slip the ovary through two or three pre-tied loops that have been introduced through a separate puncture site. The adnexa must be free of adhesions and mobile before placing the loops; this occasionally requires lysis of adhesions and incising the mesosalpinx to facilitate placement. The loops are cinched down around the vascular pedicles (",
"      <a class=\"graphic graphic_figure graphicRef71204 \" href=\"UTD.htm?4/44/4802\">",
"       figure 3",
"      </a>",
"      ) and then the adnexa is excised distal to the loops. The ureter must be visualized before and after this procedure to insure that it has not been pulled into the pedicle or kinked. Visualization is achieved by observing peristalsis through the peritoneum or, preferably, by opening the peritoneum and directly observing the ureter.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Cystectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the abdomen is entered, pelvic and abdominal washings are obtained and saved to use for staging if a malignancy is subsequently diagnosed. The entire pelvis and abdomen (eg, diaphragm, viscera, omentum) are inspected for carcinoma; suspicious sites (excrescences, adhesions, nodules, enlarged nodes) should be biopsied and sent for frozen section.",
"   </p>",
"   <p>",
"    Before actually performing the cystectomy, all adhesions should be carefully divided to allow proper mobilization of the ovary and restore the normal relationship between it and the other pelvic structures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Open cystectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An elliptical incision is made over the thin ovarian cortex in the axis of the ovary and over its most dependent area (",
"    <a class=\"graphic graphic_figure graphicRef76556 graphicRef55587 \" href=\"UTD.htm?33/16/34055\">",
"     figure 4A-B",
"    </a>",
"    ). The area adjacent to the fallopian tube and the fimbria ovarica should be avoided to limit potential injury to the fallopian tube.",
"   </p>",
"   <p>",
"    In addition, risk adhesion formation is minimized by avoiding excessive handling of the ovary and keeping the operative field. After the initial incision, the back of the knife handle or Metzenbaum scissors can be used to develop the plane between the cyst wall and the ovarian cortex to shell out the cyst while applying counter traction with an Allis clamp on the cortex. Occasionally the base of the cyst is very adherent to the ovarian stroma and requires excision with Metzenbaum scissors or electrocautery.",
"   </p>",
"   <p>",
"    Every attempt should be made to remove the cyst intact; however, if the cyst ruptures, care should be taken to control the spill and avoid gross contamination of the abdominal cavity (see",
"    <a class=\"local\" href=\"#H25\">",
"     'Spillage of malignant cells'",
"    </a>",
"    below). This can usually be achieved by packing the surrounding areas with surgical packs and carefully placing a clamp across the defect in the cyst wall. In the event of a cyst rupture, the abdominal cavity should be copiously irrigated to decrease the risk of both pseudomyxoma peritonei and chemical peritonitis, admittedly rare occurrences.",
"   </p>",
"   <p>",
"    After removal of the cyst, the deep tissues of the ovary can be reapproximated or left open (if hemostasis is adequate). The ovarian cortex may appear thin, but should not be trimmed because this may remove viable ovarian tissue. Reoperation of these cases has revealed ovaries that have resumed normal shape and anatomic relationships despite their appearance at the initial surgery. Modified",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/54/36706?source=see_link\">",
"     oxidized regenerated cellulose",
"    </a>",
"    membranes (Interceed&trade;, not FDA approved for laparoscopic use) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/36/44612?source=see_link\">",
"     icodextrin",
"    </a>",
"    solution (Adept&reg;) applied over the ovarian defects appear to reduce the incidence and severity of postoperative adhesion formation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12393/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26359?source=see_link\">",
"     \"Preventing postoperative peritoneal adhesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If multiple cysts are present, the least number of incisions possible should be made on the surface of the ovary. An oophorectomy should not be performed even if a major portion of an ovary is removed. Pregnancies have been reported in women with less than 25 percent of one ovary remaining.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Laparoscopic cystectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laparoscope is inserted infraumbilically and puncture sites are placed in the midline suprapubically and 5 to 6 cm laterally on either side. The infraumbilical site is reserved for the camera, the midline suprapubic puncture site is generally used for",
"    <span class=\"nowrap\">",
"     suction/irrigation,",
"    </span>",
"    and the lateral sites are used for stabilization of the ovary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17334?source=see_link\">",
"     \"Overview of conventional gynecologic laparoscopic surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After a thorough inspection of the abdominal cavity and the ovarian cyst to visually confirm no suspicion of malignancy, the utero-ovarian ligament is grasped and the ovary stabilized. As with an open procedure, all adhesions should be lysed prior to beginning cyst removal. A cystotomy can then be performed, or if dissection around the cyst is possible, the cyst can be removed intact.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To perform a cystectomy &mdash; The cyst may then be punctured with a 16 to 18 gauge needle or with cautery. The cystotomy is extended to allow introduction of a",
"      <span class=\"nowrap\">",
"       suction/irrigator;",
"      </span>",
"      the cyst contents are aspirated and the cyst cavity is irrigated thoroughly.",
"      <br/>",
"      <br/>",
"      The cystotomy is then extended in the direction of the ovarian axis and the internal walls of the cyst are inspected. If no suspicious areas are encountered, the cyst wall is grasped and it is dissected off the ovarian stroma with blunt or sharp dissection using endoscopic scissors, electrosurgery, a blunt probe, or a laser. The forceps grasping the cyst wall can be rotated to assist in the dissection and actually peel away the cyst wall from the surrounding ovary (",
"      <a class=\"graphic graphic_figure graphicRef61558 graphicRef73354 graphicRef52353 \" href=\"UTD.htm?26/59/27577\">",
"       figure 5A-C",
"      </a>",
"      ). Incomplete areas of excision can be sharply excised or fulgurated to destroy the lining cells.",
"     </li>",
"     <li>",
"      Endometriomas &mdash; It is particularly important to remove all of the cyst when dealing with endometriomas to prevent recurrences, and improve reproductive outcome. Fulguration can be used to destroy areas which cannot be excised [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12393/abstract/31\">",
"       31",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/46/5863?source=see_link\">",
"       \"Diagnosis and management of ovarian endometriomas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mature teratomas (dermoid cysts) &mdash; When dermoid cystectomy is performed, care should be taken to irrigate extensively after cystotomy. Persistence of teratoma fluid can cause peritonitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5721?source=see_link&amp;anchor=H10#H10\">",
"     \"Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis\", section on 'Mature cystic teratoma (dermoid cyst)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some",
"    <span class=\"nowrap\">",
"     cysts/neoplasms",
"    </span>",
"    lend themselves to intact resection and retrieval through a specimen bag introduced into the peritoneal cavity or through a mini-laparotomy incision, taking care not to puncture the bag or spill its contents. The bag can be removed through a secondary port or through the infraumbilical trocar site after the port has been removed. However, an intact cyst may, in some cases, actually facilitate dissection from the ovarian stroma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17334?source=see_link\">",
"     \"Overview of conventional gynecologic laparoscopic surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the cyst bed is hemostatic, it can be left to heal by secondary intention. Any suturing that is done should avoid the surface of the ovary. Cautery is also very effective for hemostasis, but should be kept to a minimum to reduce tissue destruction.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/54/36706?source=see_link\">",
"     Oxidized regenerated cellulose",
"    </a>",
"    (Interceed, TC7) can be applied through the laparoscope to deter adhesion formation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12393/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Large cysts &mdash; A variety of approaches to laparoscopic removal of large cysts (10 cm or greater) have been suggested. Large cysts can be aspirated, either preoperatively, using ultrasound guidance [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12393/abstract/33,34\">",
"       33,34",
"      </a>",
"      ], or intraoperatively, after placing the cyst in a laparoscopic specimen bag [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12393/abstract/35\">",
"       35",
"      </a>",
"      ]. Performing open laparoscopy may avoid puncture of the cyst during initial placement of laparoscopic instruments [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12393/abstract/36,37\">",
"       36,37",
"      </a>",
"      ]. To reduce the risk of intraperitoneal spillage, laparoscopically guided minilaparotomy can be used for large cysts [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12393/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ureteral injuries have been reported with open or laparoscopic oophorectomy when ureteral identification was performed incorrectly. Although the ureter can be seen through the peritoneum in many patients, in others the peritoneum must be opened and varying degrees of dissection carried out to expose it. Additional potential complications related to the laparoscopic approach are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef80157 \" href=\"UTD.htm?6/45/6875\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Spillage of malignant cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concern regarding spillage of malignant cells stem from reports that cited cyst rupture as one of the factors that worsened the prognosis in early stage ovarian cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12393/abstract/39,40\">",
"     39,40",
"    </a>",
"    ], although this finding has been questioned by other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12393/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. In one of these latter series [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12393/abstract/41\">",
"     41",
"    </a>",
"    ], tumor grade, large volume ascites, and dense adhesions were the only factors predictive of relapse among 519 stage I epithelial ovarian cancer patients.",
"   </p>",
"   <p>",
"    In contrast, a retrospective study compared the",
"    <span class=\"nowrap\">",
"     recurrence/death",
"    </span>",
"    rates among 79 women with epithelial ovarian cancer of stage IA, stage IC (as a result of intraoperative rupture), or stage IC (without intraoperative rupture) (",
"    <a class=\"graphic graphic_table graphicRef51205 \" href=\"UTD.htm?14/43/15038\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12393/abstract/40\">",
"     40",
"    </a>",
"    ]. The authors found that the rate of recurrence or death was highest in women with stage IC disease, even if the source of positive washings was iatrogenic rupture.",
"   </p>",
"   <p>",
"    The theoretical risk of tumor spread by rupture of a malignant cyst appears to have some validity and, therefore, should be avoided. Cyst rupture can occur at laporotomy, laparoscopy, or spontaneously. Surgical stage is a consideration in deciding which patients receive chemotherapy. Many oncologists administer adjuvant chemotherapy to these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Ovarian remnant syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ovarian remnant syndrome (ORS) occurs in patients who have undergone bilateral oophorectomy and subsequently present with symptoms related to ovulatory function from ovarian tissue inadvertently left behind. In rare cases, the remaining ovarian tissue may be from congenital supernumerary ovaries. It should be distinguished from the residual ovary syndrome (ROS), in which the ovary was intentionally preserved and subsequently developed pathology.",
"   </p>",
"   <p>",
"    Failure to skeletonize the infundibulopelvic ligament and placement of a clamp that is not sufficiently lateral to the ovary may result in retention of a piece of the ovary in the pedicle, leading to ORS. This is more common when the procedure is complicated by dense adhesions (eg, endometriosis, pelvic inflammatory disease), neoplastic disease, and increased pelvic vascularity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12393/abstract/44\">",
"     44",
"    </a>",
"    ]. Intraoperative bleeding, anatomic variation, or deviation from sound surgical principles also contribute to incomplete removal of ovaries. Blunt dissection to free the ovaries from surrounding tissues must be avoided because it risks leaving behind remnants of the ovarian cortex, which can become neovascularized by the adjacent pelvic peritoneum or viscera [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12393/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The typical patient presents with cyclic pelvic pain and a mass, although the pain may be persistent with acute flare-ups. Occasionally, an asymptomatic mass is detected on pelvic or sonographic examination. Ureteral obstruction may occur.",
"   </p>",
"   <p>",
"    ORS is probably present if a follicle stimulating hormone (FSH) level is in the premenopausal range or if serum estradiol levels are normal after bilateral oophorectomy; however, some women with ORS have postmenopausal levels of FSH and estradiol [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12393/abstract/45\">",
"     45",
"    </a>",
"    ]. Other signs suggestive of the syndrome are (1) cyclic menstruation in a woman whose uterus had been retained at bilateral oophorectomy and (2) relief of symptoms after medical therapy which suppresses ovarian function (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     danazol",
"    </a>",
"    , gonadotropin-releasing hormone agonists, combined hormonal contraception). After unilateral oophorectomy, the diagnosis is suggested by the typical clinical manifestations combined with a pelvic mass on the side of the oophorectomy.",
"   </p>",
"   <p>",
"    In one large series (n = 186 cases), ultrasound examination showed a pelvic mass in 93 of 100 patients who had preoperative testing; computed tomograms were positive for a pelvic mass in 67 of 73 patients, and magnetic resonance imaging identified a mass in 7 of 9 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12393/abstract/45\">",
"     45",
"    </a>",
"    ]. If ORS is suspected, but imaging is negative, one group suggested repeated imaging after ovarian stimulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    citrate [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12393/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The surgical treatment of ORS is to excise the remaining ovarian tissue, a procedure that is usually difficult and requires meticulous dissection to delineate the normal anatomy in an otherwise abnormal pelvis. The ureter must be identified and both it and the bowel may have to be mobilized clear of the pelvic side wall. The remnant is usually encased in adhesions and frequently is retroperitoneal, therefore the best approach is through the retroperitoneum. Skilled and experienced surgeons may approach ovarian remnants with the laparoscope [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12393/abstract/47-50\">",
"     47-50",
"    </a>",
"    ], but it is prudent to have consent for laparotomy, which may be required to complete the procedure.",
"   </p>",
"   <p>",
"    The remnant may be difficult to delineate from the surrounding tissues if a definite mass or cyst is not present. Superovulating the remnant before the operation may facilitate identification and successful excision. The key to being sure the ovary is removed is to identify the infundibulopelvic ligament and to transect all tissue attachments of ovarian tissue allowing several millimeters of margin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Fertility following unilateral oophorectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few data regarding fertility following unilateral oophorectomy. Fertility following removal of one ovary had been studied most frequently in women with ovarian cancer or tumors of low malignant potential who undergo conservative surgery. In these patients, literature reviews have reported widely varying pregnancy rates, ranging from 42 to 88 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12393/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Regarding women undergoing in vitro fertilization, data are mixed regarding whether women with a single ovary have a lower conception rate [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12393/abstract/53\">",
"     53",
"    </a>",
"    ]. The impact of unilateral oophorectomy likely varies with age, since younger women have more follicles per ovary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5128?source=see_link&amp;anchor=H12#H12\">",
"     \"Ovarian tumors of low malignant potential\", section on 'Fertility preserving surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/20/2371?source=see_link\">",
"       \"Patient information: Ovarian cysts (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12647998\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The indications for ovarian surgery versus expectant management of an ovarian cyst depend upon the patient's age, findings on pelvic examination and with ultrasonography, and laboratory results. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Oophorectomy versus cystectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When surgery is indicated for benign ovarian disease, preservation of ovarian tissue via cystectomy or enucleation of a solid tumor from the ovary is generally preferable to complete oophorectomy. When the ovary cannot be salvaged or insufficient viable tissue remains after attempts at conservation, oophorectomy is performed. In postmenopausal patients, no effort is made to preserve the ovary. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Oophorectomy versus cystectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aspiration of cyst contents is",
"      <strong>",
"       NOT",
"      </strong>",
"      recommended because no tissue is obtained for histopathology, cytology of cyst fluid is not reliable for exclusion of malignancy, there is a high rate of recurrence (11 to 65 percent), and aspiration does not provide better results than simple observation. These problems are less common with fenestration (ie, removing a full thickness, square portion of the cyst wall to create a window), but cystectomy is preferable to either of these techniques. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Aspiration and fenestration versus cystectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When performing oophorectomy in a woman in whom malignancy is suspected, rupture of an ovarian cyst should be avoided to prevent tumor dissemination. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Spillage of malignant cells'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are few data regarding fertility following unilateral oophorectomy. The impact likely varies with age, since younger women have more follicles per ovary. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Fertility following unilateral oophorectomy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/1\">",
"      Barber HR. Ovarian cancer. CA Cancer J Clin 1986; 36:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/2\">",
"      SCULLY RE. Gonadoblastoma; a gonadal tumor related to the dysgerminoma (seminoma) and capable of sex-hormone production. Cancer 1953; 6:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/3\">",
"      Teter J, Boczkowski K. Occurrence of tumors in dysgenetic gonads. Cancer 1967; 20:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/4\">",
"      Andrews J. Streak gonads and the Y chromosome. J Obstet Gynaecol Br Commonw 1971; 78:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/5\">",
"      Dewhurst CJ, Ferreira HP, Gillett PG. Gonadal malignancy in XY females. J Obstet Gynaecol Br Commonw 1971; 78:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/6\">",
"      Simpson JL, Christakos AC, Horwith M, Silverman FS. Gonadal dysgenesis in individuals with apparently normal chromosomal complements: tabulation of cases and compilation of genetic data. Birth Defects Orig Artic Ser 1971; 7:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/7\">",
"      Barr ML, Carr DH, Plunkett ER, et al. Male pseudohermaphroditism and pure gonadal dysgenesis in sisters. Am J Obstet Gynecol 1967; 99:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/8\">",
"      Mesogitis S, Daskalakis G, Pilalis A, et al. Management of ovarian cysts with aspiration and methotrexate injection. Radiology 2005; 235:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/9\">",
"      Zanetta G, Lissoni A, Torri V, et al. Role of puncture and aspiration in expectant management of simple ovarian cysts: a randomised study. BMJ 1996; 313:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/10\">",
"      Kafali H, Yurtseven S, Atmaca F, Ozardali I. Management of non-neoplastic ovarian cysts with sclerotherapy. Int J Gynaecol Obstet 2003; 81:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/11\">",
"      Fisch JD, Sher G. Sclerotherapy with 5% tetracycline is a simple alternative to potentially complex surgical treatment of ovarian endometriomas before in vitro fertilization. Fertil Steril 2004; 82:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/12\">",
"      AbdRabbo S, Atta A. Aspiration and tetracycline sclerotherapy for management of simple ovarian cysts. Int J Gynaecol Obstet 1995; 50:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/13\">",
"      Bret PM, Atri M, Guibaud L, et al. Ovarian cysts in postmenopausal women: preliminary results with transvaginal alcohol sclerosis. Work in progress. Radiology 1992; 184:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/14\">",
"      Hidlebaugh DA, Vulgaropulos S, Orr RK. Treating adnexal masses. Operative laparoscopy vs. laparotomy. J Reprod Med 1997; 42:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/15\">",
"      Bisharah M, Tulandi T. Laparoscopic preservation of ovarian function: an underused procedure. Am J Obstet Gynecol 2003; 188:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/16\">",
"      Medeiros LR, Fachel JM, Garry R, et al. Laparoscopy versus laparotomy for benign ovarian tumours. Cochrane Database Syst Rev 2005; :CD004751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/17\">",
"      Hulka JF, Parker WH, Surrey MW, Phillips JM. Management of ovarian masses. AAGL 1990 survey. J Reprod Med 1992; 37:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/18\">",
"      Herrmann UJ. Sonographic patterns of ovarian tumors. Clin Obstet Gynecol 1993; 36:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/19\">",
"      Granberg S. Relationship of macroscopic appearance to the histologic diagnosis of ovarian tumors. Clin Obstet Gynecol 1993; 36:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/20\">",
"      Ekerhovd E, Wienerroith H, Staudach A, Granberg S. Preoperative assessment of unilocular adnexal cysts by transvaginal ultrasonography: a comparison between ultrasonographic morphologic imaging and histopathologic diagnosis. Am J Obstet Gynecol 2001; 184:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/21\">",
"      Tozzi R, K&ouml;hler C, Ferrara A, Schneider A. Laparoscopic treatment of early ovarian cancer: surgical and survival outcomes. Gynecol Oncol 2004; 93:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/22\">",
"      Fanfani F, Fagotti A, Ercoli A, et al. A prospective randomized study of laparoscopy and minilaparotomy in the management of benign adnexal masses. Hum Reprod 2004; 19:2367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/23\">",
"      Benedetti-Panici P, Maneschi F, Cutillo G, et al. Surgery by minilaparotomy in benign gynecologic disease. Obstet Gynecol 1996; 87:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/24\">",
"      Magrina JF, Espada M, Munoz R, et al. Robotic adnexectomy compared with laparoscopy for adnexal mass. Obstet Gynecol 2009; 114:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/25\">",
"      Lee YY, Kim TJ, Kim CJ, et al. Single port access laparoscopic adnexal surgery versus conventional laparoscopic adnexal surgery: a comparison of peri-operative outcomes. Eur J Obstet Gynecol Reprod Biol 2010; 151:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/26\">",
"      Fagotti A, Fanfani F, Rossitto C, et al. Laparoendoscopic single-site surgery for the treatment of benign adnexal disease: a prospective trial. Diagn Ther Endosc 2010; 2010:108258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/27\">",
"      Escobar PF, Bedaiwy MA, Fader AN, Falcone T. Laparoendoscopic single-site (LESS) surgery in patients with benign adnexal disease. Fertil Steril 2010; 93:2074.e7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/28\">",
"      Kim WC, Lee JE, Kwon YS, et al. Laparoendoscopic single-site surgery (LESS) for adnexal tumors: one surgeon's initial experience over a one-year period. Eur J Obstet Gynecol Reprod Biol 2011; 158:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/29\">",
"      Fagotti A, Bottoni C, Vizzielli G, et al. Postoperative pain after conventional laparoscopy and laparoendoscopic single site surgery (LESS) for benign adnexal disease: a randomized trial. Fertil Steril 2011; 96:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/30\">",
"      Prevention of postsurgical adhesions by INTERCEED(TC7), an absorbable adhesion barrier: a prospective randomized multicenter clinical study. INTERCEED(TC7) Adhesion Barrier Study Group. Fertil Steril 1989; 51:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/31\">",
"      Hart RJ, Hickey M, Maouris P, et al. Excisional surgery versus ablative surgery for ovarian endometriomata. Cochrane Database Syst Rev 2005; :CD004992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/32\">",
"      Diamond, MP, Cunningham, T, Linsky, CB, et al. Laparoscopic application of Interceed (TC7) in the pig. J Gynecol Surg 1989; 5:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/33\">",
"      Nagele F, Magos AL. Combined ultrasonographically guided drainage and laparoscopic excision of a large ovarian cyst. Am J Obstet Gynecol 1996; 175:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/34\">",
"      Eltabbakh GH, Kaiser JR. Laparoscopic management of a large ovarian cyst in an adolescent. A case report. J Reprod Med 2000; 45:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/35\">",
"      Ghezzi F, Cromi A, Bergamini V, et al. Should adnexal mass size influence surgical approach? A series of 186 laparoscopically managed large adnexal masses. BJOG 2008; 115:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/36\">",
"      Sagiv R, Golan A, Glezerman M. Laparoscopic management of extremely large ovarian cysts. Obstet Gynecol 2005; 105:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/37\">",
"      Eltabbakh GH, Charboneau AM, Eltabbakh NG. Laparoscopic surgery for large benign ovarian cysts. Gynecol Oncol 2008; 108:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/38\">",
"      Panici PB, Palaia I, Bellati F, et al. Laparoscopy compared with laparoscopically guided minilaparotomy for large adnexal masses: a randomized controlled trial. Obstet Gynecol 2007; 110:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/39\">",
"      Webb MJ, Decker DG, Mussey E, Williams TJ. Factor influencing survival in Stage I ovarian cancer. Am J Obstet Gynecol 1973; 116:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/40\">",
"      Sainz de la Cuesta R, Goff BA, Fuller AF Jr, et al. Prognostic importance of intraoperative rupture of malignant ovarian epithelial neoplasms. Obstet Gynecol 1994; 84:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/41\">",
"      Dembo AJ, Davy M, Stenwig AE, et al. Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1990; 75:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/42\">",
"      Sevelda P, Dittrich C, Salzer H. Prognostic value of the rupture of the capsule in stage I epithelial ovarian carcinoma. Gynecol Oncol 1989; 35:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/43\">",
"      Sj&ouml;vall K, Nilsson B, Einhorn N. Different types of rupture of the tumor capsule and the impact on survival in early ovarian carcinoma. Int J Gynecol Cancer 1994; 4:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/44\">",
"      Symmonds RE, Pettit PD. Ovarian remnant syndrome. Obstet Gynecol 1979; 54:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/45\">",
"      Magtibay PM, Nyholm JL, Hernandez JL, Podratz KC. Ovarian remnant syndrome. Am J Obstet Gynecol 2005; 193:2062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/46\">",
"      Kaminski PF, Sorosky JI, Mandell MJ, et al. Clomiphene citrate stimulation as an adjunct in locating ovarian tissue in ovarian remnant syndrome. Obstet Gynecol 1990; 76:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/47\">",
"      Nezhat C, Kearney S, Malik S, et al. Laparoscopic management of ovarian remnant. Fertil Steril 2005; 83:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/48\">",
"      Abu-Rafeh B, Vilos GA, Misra M. Frequency and laparoscopic management of ovarian remnant syndrome. J Am Assoc Gynecol Laparosc 2003; 10:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/49\">",
"      El-Minawi AM, Howard FM. Operative laparoscopic treatment of ovarian retention syndrome. J Am Assoc Gynecol Laparosc 1999; 6:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/50\">",
"      Kho RM, Magrina JF, Magtibay PM. Pathologic findings and outcomes of a minimally invasive approach to ovarian remnant syndrome. Fertil Steril 2007; 87:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/51\">",
"      Ayhan A, Celik H, Taskiran C, et al. Oncologic and reproductive outcome after fertility-saving surgery in ovarian cancer. Eur J Gynaecol Oncol 2003; 24:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/52\">",
"      Swanton A, Bankhead CR, Kehoe S. Pregnancy rates after conservative treatment for borderline ovarian tumours: a systematic review. Eur J Obstet Gynecol Reprod Biol 2007; 135:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12393/abstract/53\">",
"      Lass A. The fertility potential of women with a single ovary. Hum Reprod Update 1999; 5:546.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3304 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-69ABC6F150-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_6_12393=[""].join("\n");
var outline_f12_6_12393=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12647998\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OOPHORECTOMY VERSUS CYSTECTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ASPIRATION AND FENESTRATION VERSUS CYSTECTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SURGICAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Open laparotomy versus laparoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10499406\">",
"      - Use of robotic or single port laparoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Oophorectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Open or laparoscopic approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Laparoscopic instruments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Cystectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Open cystectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Laparoscopic cystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      POSTOPERATIVE ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Spillage of malignant cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Ovarian remnant syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Fertility following unilateral oophorectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12647998\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3304\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3304|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/26/44450\" title=\"figure 1\">",
"      Streak ovaries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/60/42949\" title=\"figure 2A\">",
"      Open oophorectomy a",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/0/24578\" title=\"figure 2B\">",
"      Open oophorectomy b",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/50/23331\" title=\"figure 2C\">",
"      Open oophorectomy c",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/44/4802\" title=\"figure 3\">",
"      Laparoscopic oophorectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/35/13875\" title=\"figure 4A\">",
"      Open cystectomy ab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/56/33665\" title=\"figure 4B\">",
"      Open cystectomy cde",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/15/30961\" title=\"figure 5A\">",
"      Laparoscopic cystectomy a",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/8/16515\" title=\"figure 5B\">",
"      Laparoscopic cystectomy b",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/33/37392\" title=\"figure 5C\">",
"      Laparoscopic cystectomy cd",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3304|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/38/7787\" title=\"table 1\">",
"      Referral to gyn oncologist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/0/1035\" title=\"table 2\">",
"      Sonographic findings ovarian CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/8/41099\" title=\"table 3\">",
"      Steps in staging ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/45/6875\" title=\"table 4\">",
"      Complications of oophorectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/43/15038\" title=\"table 5\">",
"      Staging ovarian peritoneal carcinoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=related_link\">",
"      Approach to the patient with an adnexal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/46/5863?source=related_link\">",
"      Diagnosis and management of ovarian endometriomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19352?source=related_link\">",
"      Differential diagnosis of the adnexal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/21/15706?source=related_link\">",
"      Elective oophorectomy or ovarian conservation at the time of hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36823?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of tuboovarian abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=related_link\">",
"      Epithelial ovarian cancer: Initial surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=related_link\">",
"      First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30905?source=related_link\">",
"      Management of an adnexal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23690?source=related_link\">",
"      Ovarian and fallopian tube torsion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5721?source=related_link\">",
"      Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5128?source=related_link\">",
"      Ovarian tumors of low malignant potential",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17334?source=related_link\">",
"      Overview of conventional gynecologic laparoscopic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14810?source=related_link\">",
"      Overview of the treatment of endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/20/2371?source=related_link\">",
"      Patient information: Ovarian cysts (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26359?source=related_link\">",
"      Preventing postoperative peritoneal adhesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/18/9513?source=related_link\">",
"      Reproductive surgery for female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34440?source=related_link\">",
"      Sonographic differentiation of benign versus malignant adnexal masses",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_6_12394="Lung cancer in never smokers";
var content_f12_6_12394=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Lung cancer in never smokers",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/6/12394/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/6/12394/contributors\">",
"     Heather Wakelee, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/6/12394/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/6/12394/contributors\">",
"     James R Jett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/6/12394/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/6/12394/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/6/12394/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung cancer is the leading cause of cancer death worldwide, causing over 1,350,000 deaths per year [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/1\">",
"     1",
"    </a>",
"    ]. Exposure to tobacco smoke is the primary etiologic factor responsible for lung cancer, and its importance is illustrated by the decline in lung cancer incidence and mortality in the United States that has accompanied the decline in smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=see_link&amp;anchor=H2#H2\">",
"     \"Cigarette smoking and other risk factors for lung cancer\", section on 'Smoking'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the predominance of tobacco smoking as its presumed etiology, lung cancer is also a significant health problem in those with no history of smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Emerging information supports the notion that lung cancer in never smokers is distinct enough from an epidemiologic and biologic standpoint to be considered a separate entity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. Furthermore, as the numbers of never smokers in the United States and other countries rise, the issue of lung cancer in this group becomes even more critical.",
"   </p>",
"   <p>",
"    The epidemiology, risk factors, biologic differences, and potential implications for treatment of lung cancer in never smokers are reviewed here. General aspects of lung cancer biology and management are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16282?source=see_link\">",
"     \"Overview of the risk factors, pathology, and clinical manifestations of lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13273?source=see_link\">",
"     \"Overview of the initial evaluation, treatment and prognosis of lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/57/21401?source=see_link\">",
"     \"Overview of the treatment of advanced non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the term \"never smoker\" refers to individuals who have smoked fewer than 100 cigarettes in their lifetime. Firm data on the incidence of lung cancer in never smokers is difficult to ascertain, because most population-based cancer registries, including the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) database, do not collect patient smoking information. SEER data have been linked with population-based tobacco use information [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/9,10\">",
"     9,10",
"    </a>",
"    ], but this only allows for estimates of lung cancer in never smokers within broad geographic areas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Worldwide, lung cancer in never smokers comprises an estimated 15 to 20 percent of cases in men and over 50 percent in women [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/11\">",
"     11",
"    </a>",
"    ]. There are major geographic differences, particularly in Asia, where 60 to 80 percent of women with the disease are never smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/3\">",
"     3",
"    </a>",
"    ]. The incidence of small cell lung cancer in never smokers is exceedingly small [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/12\">",
"     12",
"    </a>",
"    ], and this discussion will therefore focus on non-small cell lung cancer (NSCLC).",
"   </p>",
"   <p>",
"    In one analysis in the United States, an estimated 19 percent of women with lung cancer had never-smoked, compared to about 9 percent of men with the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/13\">",
"     13",
"    </a>",
"    ]. These results are based upon an analysis of data from patients in five large United States cohort studies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/14-19\">",
"     14-19",
"    </a>",
"    ]. The age-adjusted incidence rate for lung cancer in never smokers aged 40 to 79 years ranged from 11.2 to 13.7 per 100,000 person-years for men and from 15.2 to 20.8 per 100,000 person-years for women. These incidence rates are similar to those for myeloma in men or cervical cancer in women in this country [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/20\">",
"     20",
"    </a>",
"    ]. In contrast, the age-adjusted rates of lung cancer in current smokers in the same cohorts were approximately 12 to 30 times higher.",
"   </p>",
"   <p>",
"    An analysis of lung cancer patients diagnosed between 1991 and 2005 in Southern California utilized a novel text-mining programming algorithm to evaluate smoking status based on information from electronic medical record abstracts in the regional cancer registry. This study determined that 8.9 percent of over 25,000 patients with known smoking status were never smokers, including 6 percent of men and 14 percent of women [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another analysis of 13 cohorts and 22 cancer registries, however, did not find any apparent difference in the incidence rate of lung cancer in never smokers by sex overall, although women had a higher incidence rate than men among never smokers aged 40 to 59 years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/23\">",
"     23",
"    </a>",
"    ]. In this multinational analysis, the age-standardized incidence rates for lung cancer (per 100,000 using the 2000 world population age standard) for women were 12.4 for women of European descent, 15.0 for Asian women, and 19.4 for African American women. This compared to rates of 11.2, 12.9 and 12.3, respectively, for men of European, Asian, and African-American background.",
"   </p>",
"   <p>",
"    Whether the incidence of lung cancer in never smokers is changing is not clear, with studies yielding conflicting results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study from the Swedish construction worker's health care program, which is linked to their national cancer registry, showed a substantial increase in the age-adjusted incidence rate of non-smoking lung cancer comparing the period 1976 to 1980 with 1991 to 1995 (1.5 versus 5.4 per 100,000) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two American Cancer Society prevention study cohorts found a statistically significant but smaller increase in the mortality rate in women due to non-smoking associated lung cancer comparing the period 1959 to 1972 with 1982 to 2000 (12.3 to 14.7 per 100,000) in 1982-2000 [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/25\">",
"       25",
"      </a>",
"      ]. The rates did not change over time for men.",
"     </li>",
"     <li>",
"      Indirect evidence comes from a series of nearly 12,000 patients with lung cancer in Southern California [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/26\">",
"       26",
"      </a>",
"      ]. Comparing the interval 1995 to 1999 with 1999 to 2003, the percentage of never smokers with bronchioloalveolar carcinoma increased from 19 to 26 percent, while the percentage with other forms of lung cancer went from 8.6 to 9.4 percent.",
"     </li>",
"     <li>",
"      Data collected from cancer registries in Japan and Southern California with smoking information focused on lung cancer in never-smokers over two time periods, 1991 to 1996 and 1997 to 2001, and did not show a substantial numerical change in the percent of lung cancer patients who were never-smokers during the two time periods (28 and 31 percent versus 7.2 and 7.4 percent for the Japanese and Southern Californian registries at earlier and later time periods, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Available data from the United Kingdom does not support an increase in the incidence of lung cancer in never smokers. In a comparison of two case-control studies done at the same hospitals and community settings in 1950 and in 1990, the percentage of never smokers among male lung cancer cases did not change, although the percentage of never smokers among the controls increased from 4.5 to 19 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/28\">",
"       28",
"      </a>",
"      ]. The percentage of lung cancer in never smokers who were women, dropped dramatically during this time period, while the rate of smoking in the controls dropped less dramatically.",
"     </li>",
"     <li>",
"      A single institution evaluation from Japan found that over the 30-year period 1974 to 2004 the proportion of never smoking, early stage NSCLC patients increased from approximately 16 to 33 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/5\">",
"       5",
"      </a>",
"      ]. The large pooled analysis of 13 cohorts compared recent observed rates to those in Connecticut in the 1930s when smoking was very rare in women and found no substantial change over time [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cancer registry data will need to collect information on the smoking status of patients in order to carefully examine trends in the incidence rate of lung cancer among never smokers. Self-reported smoking status can be challenging to obtain, but the validity of this method has been verified in several studies that have shown only small smoker misclassification rates [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Sex",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the fact that a higher percentage of women with lung cancer are never smokers compared to men, as reported in several analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/3,11,13,31\">",
"     3,11,13,31",
"    </a>",
"    ], the age-adjusted mortality rate from lung cancer among never smokers was higher in men than women in two American Cancer Society cancer prevention study cohorts [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/25\">",
"     25",
"    </a>",
"    ]. These two cohorts formed the bulk of patients of European ancestry in a larger pooled analysis of 13 cohort studies and multiple cancer registries that showed age-standardized lung cancer mortality rates of 12.0 per 100,000 for never smoking men and 9.5 per 100,000 for never smoking women of European ancestry. In Asians, the rates were 26.0 and 16.1 per 100,000 for men and women, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/23\">",
"     23",
"    </a>",
"    ]. Women with lung cancer live longer than men, but how much this explains the differences seen between incidence and mortality is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10072?source=see_link&amp;anchor=H10#H10\">",
"     \"Women and lung cancer\", section on 'Outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, in a Japanese study, 33 percent of lung cancer deaths in men and 85 percent of lung cancer deaths in women were not due to cigarette smoking. In Japan, the percentage of women with lung cancer who are never smokers is much higher [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Ethnicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of smoking-associated lung cancer differs by",
"    <span class=\"nowrap\">",
"     race/ethnicity.",
"    </span>",
"    &nbsp;Accurate data on differences in rates of lung cancer among never smokers based upon race or ethnicity are extremely limited.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A Southern California analysis of over 20,000 patients found that for women, 46 percent of all lung cancer in Asian Pacific Islanders was in never smokers compared to 25 percent in Hispanics, 11 percent in African American and 10 percent in non-Hispanic Whites [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A Northern California analysis of lung cancer cases diagnosed from 1998 to 2008 found that, for women, of all lung cancer cases identified, 71 percent of lung cancer in",
"      <span class=\"nowrap\">",
"       Asian/Pacific",
"      </span>",
"      Islanders was in never smokers, compared to 35 percent of cases in Hispanic women and 40 percent in non-Hispanic whites [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/35\">",
"       35",
"      </a>",
"      ]. This study also looked at survival differences in these groups.",
"     </li>",
"     <li>",
"      Further data on this topic comes from a large pooled analysis of cohort and registry data that shows wide variability in incidence and mortality from lung cancer in never smokers, even within certain Asian countries, including China and Thailand, but overall increased rates in African Americans compared to other ethnic groups [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More research is needed to better understand the",
"    <span class=\"nowrap\">",
"     racial/ethnic",
"    </span>",
"    variations with this disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=see_link&amp;anchor=H8#H8\">",
"     \"Cigarette smoking and other risk factors for lung cancer\", section on 'Race'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although it was been postulated that lung cancer occurs at a younger age in never smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/36\">",
"     36",
"    </a>",
"    ], this has only be validated in some [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/31\">",
"     31",
"    </a>",
"    ] but not all recent cohort analyses in Western populations [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/13\">",
"     13",
"    </a>",
"    ]. In studies from Asia, however, a younger age at diagnosis is characteristic of lung cancer in never smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The known and potential causes of lung cancer are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=see_link\">",
"     \"Cigarette smoking and other risk factors for lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The causative factors for lung cancer in never-smokers are not well understood. The risk factors that are considered to be most important among never smokers are discussed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Secondhand smoke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondhand smoke is an important risk factor for lung cancer among never smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/29,38-40\">",
"     29,38-40",
"    </a>",
"    ]. However, the extent of this problem is not clear.",
"   </p>",
"   <p>",
"    Several studies suggest that approximately 15 to 35 percent of lung cancer among never smokers is due to secondhand smoke [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/41-45\">",
"     41-45",
"    </a>",
"    ], and that risk may be increased in those with exposure prior to age 25 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A recent study from France of 1493 lung cancer patients found that 79 percent of women and 21 percent of men who were never smokers had secondhand smoke exposure [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A population based case-control study in Canada of 445 cases and 948 controls found no association between exposure to secondhand smoke at home or the workplace and development of lung cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A population based-prospective study in Japan reported a HR of 2.03 (95% CI 1.07-3.86) for development of adenocarcinoma for never-smoking women who lived with a smoking husband as compared to never-smoking women with a non-smoking spouse [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A US case-control study reported an increase in lung cancer risk in never-smokers with secondhand smoke exposure during childhood (odds ratio 2.5; 95% CI 1.04-4.90) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a report based upon the largest sample, analysis from a case-control study in Europe of 520,000 people estimated that the proportion of lung cancer related to secondhand smoke was 16 to 24 percent in non-smokers [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/44\">",
"       44",
"      </a>",
"      ]. An additional 5 to 7 percent of lung cancer among never smokers was thought to be due to air pollution.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Radon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radon is a gaseous decay product of uranium-238 and radium-226, which is capable of damaging respiratory epithelium via the emission of alpha particles. The increased risk of lung cancer among uranium miners has been more clearly established and is thought to be due to radiation from radon [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=see_link&amp;anchor=H19#H19\">",
"     \"Cigarette smoking and other risk factors for lung cancer\", section on 'Radon'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radon is present in soil, rock, and groundwater, and it can accumulate in homes. Exposure to radon within the home may play a role in the development of lung cancer in never smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/50-52\">",
"     50-52",
"    </a>",
"    ], although this is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Environmental exposures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other occupational exposures are known to increase lung cancer risk in smokers, and to a lesser extent, in never-smokers as well.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Common toxins of this sort include asbestos, chromium, and arsenic [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/54-57\">",
"       54-57",
"      </a>",
"      ]. A recent report linked occupational exposure to organic dust as a risk factor for lung cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/58\">",
"       58",
"      </a>",
"      ]. A Dutch analysis of occupational asbestos exposure found a relative risk of lung cancer of 3.5 after controlling for age, smoking, and other factors [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/57\">",
"       57",
"      </a>",
"      ]. In a French study of 1493 cases, some occupational exposure was identified in 9.4 percent of women and 48.6 percent of men who developed lung cancer as never smokers [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/45\">",
"       45",
"      </a>",
"      ]. In a Canadian case-control study, the odds ratio for lung cancer risk from occupational exposures in never-smokers was 2.1 (95% CI 1.3-3.3) but was higher for exposure to solvents, paints, or thinners (OR 2.8, 95% CI 1.6-5.0) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/31\">",
"       31",
"      </a>",
"      ]. A meta-analysis focused on lung cancer risk in painters reported a relative risk for lung cancer in all painters of 1.35 (95% CI 1.29-1.41), but 2.0 (95% CI 10.9-3.67) in the never-smokers [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Arsenic has implicated as a cause of lung cancer where it contaminates drinking water, such as in some areas of Taiwan and Chile [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/60,61\">",
"       60,61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Various dietary factors have been studied as possible causes of lung cancer, but none are clearly implicated. Higher intake of fruits and vegetables may be protective against lung cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/33,62,63\">",
"       33,62,63",
"      </a>",
"      ]. A case-control study from Italy found a relative risk for lung cancer of 2.4 (95% CI 1.4-4.0) for the highest versus lowest quartiles of red meat consumption in never smokers [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/64\">",
"       64",
"      </a>",
"      ], and another report indicated that higher consumption of fish may protect against lung cancer in never smokers [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/65\">",
"       65",
"      </a>",
"      ]. A recent US study focused exclusively in never-smokers reported a reduced risk of lung cancer in those with the &ldquo;healthiest&rdquo; dietary patterns (ie, high consumption of fruits and vegetables and of low-fat goods) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Indoor air pollutants such as vapors from cooking oil and the smoke from burning coal have been linked to lung cancer, particularly in Asia [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/67-70\">",
"       67-70",
"      </a>",
"      ], although there is some controversy about the importance of this [",
"      <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/71-73\">",
"       71-73",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Lung disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of lung cancer among never smokers is increased in those with prior damage to the lungs from underlying pulmonary disease or exposure to radiation or chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/31,74-77\">",
"     31,74-77",
"    </a>",
"    ]. The magnitude of this risk is unclear because the vast majority of pulmonary disease is related to smoking. When one looks at idiopathic pulmonary fibrosis, the literature is conflicting on association with lung cancer, though an association does seem to be supported by the majority of studies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=see_link&amp;anchor=H22#H22\">",
"     \"Cigarette smoking and other risk factors for lung cancer\", section on 'Inflammation and benign lung disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H551742669\">",
"    <span class=\"h2\">",
"     Oncogenic viruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;A viral etiology for some lung cancer is under investigation, with a particular focus on the role of human papillomavirus (HPV) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/80,81\">",
"     80,81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a case control study of 141 lung cancer patients and 60 noncancer controls from Taiwan, HPV serotypes 16 and 18 were significantly more common among those with lung cancer (55 versus 27 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/82\">",
"     82",
"    </a>",
"    ]. This association was most prominent among older nonsmoking women. However, this high incidence of HPV positivity was not observed in one series of Caucasian patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Speculation has also been generated by similarities between bronchioloalveolar carcinoma (BAC) and the retrovirus-induced ovine pulmonary adenocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/84\">",
"     84",
"    </a>",
"    ], though there is no putative human virus associated with BAC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have shown an association between lung cancer in never smokers and a family history of lung cancer, suggesting a role for genetic factors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/31,39,85-89\">",
"     31,39,85-89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, in a case-control study of 257 cases of lung cancer among never smokers and an equivalent number of control never smokers, lung cancer was significantly more common among those with a positive family history (odds ratio 7.2) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/88\">",
"     88",
"    </a>",
"    ]. In another case-control study that included over 2400 relatives of 316 never smoker lung cancer cases, there was a 25 percent excess risk of cancer among first degree relatives of cases, particularly of young onset lung cancer in smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/89\">",
"     89",
"    </a>",
"    ]. In an analysis from the Environment And Genetics in Lung cancer Etiology (EAGLE) study, the relative risk of lung cancer associated with a positive family history, adjusted for age, gender, residence, education, and smoking, was 1.57 (95% CI 1.25-1.98) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The specific genetic factors involved have not been established. Studies have suggested susceptibility loci for lung cancer in never-smokers at various locations including chromosomes 6q [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/91\">",
"     91",
"    </a>",
"    ], 5p15.33 (",
"    <em>",
"     TERT",
"    </em>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/92-94\">",
"     92-94",
"    </a>",
"    ], 13q31.3 (",
"    <em>",
"     GPC5",
"    </em>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/95\">",
"     95",
"    </a>",
"    ], 15q25, 6p21 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/96\">",
"     96",
"    </a>",
"    ], and most recently in a Korean population at 18p11.22 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/97\">",
"     97",
"    </a>",
"    ]. However, the results of this genome-wide association (GWA) studies have not been consistent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/98\">",
"     98",
"    </a>",
"    ]. Others have shown susceptibility related to germline mutations in the EGFR pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/99\">",
"     99",
"    </a>",
"    ], polymorphisms in the cytochrome p450 enzymes CYP1A1 and CYP1B1 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/100-102\">",
"     100-102",
"    </a>",
"    ], as well as polymorphisms in MLH1 and MSH2, DNA mismatch repair genes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/103,104\">",
"     103,104",
"    </a>",
"    ], other DNA repair genes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/105\">",
"     105",
"    </a>",
"    ], and glutathione-S-transferases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/106,107\">",
"     106,107",
"    </a>",
"    ]. Suboptimal DNA repair capacity, as measured by the host-cell reactivation assay in a case-control study of never smokers, nearly doubled the risk of lung cancer (RR=1.92, 95% CI 1.3-2.9) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Estrogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of estrogens and other female hormones in lung cancer risk in women is uncertain, regardless of smoking status. Multiple studies have shown that the majority of non-small cell lung cancers express the estrogen-receptor beta [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/109-111\">",
"     109-111",
"    </a>",
"    ] and that the expression of this receptor is more common in never smokers compare to smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical implications of these laboratory studies are unclear. Multiple studies have looked at the relationship of lung cancer incidence to early menopause [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/113,114\">",
"     113,114",
"    </a>",
"    ], use of hormone therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/115,116\">",
"     115,116",
"    </a>",
"    ], age at first birth [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/117\">",
"     117",
"    </a>",
"    ], number of children [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/118\">",
"     118",
"    </a>",
"    ], and use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/119\">",
"     119",
"    </a>",
"    ]. However, the results have been inconsistent in establishing a relationship. Data from the randomized Women&rsquo;s Health Initiative (WHI) trial indicated that women assigned to postmenopausal estrogen and progesterone had a higher risk of death from lung cancer without a higher incidence of the disease compared to women assigned to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/120\">",
"     120",
"    </a>",
"    ]. However, women randomized to estrogen alone had no such increase in lung cancer mortality, nor in lung cancer incidence, compared to those on placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/121\">",
"     121",
"    </a>",
"    ]. The association to smoking status has yet to be established in this study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     BIOLOGIC DIFFERENCES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenocarcinoma is more common in never smokers, light smokers, and former smokers while squamous cell carcinoma and small cell lung cancer are seen with a higher incidence in heavy smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In a review of published reports on the histology of lung cancer that included smoking data, adenocarcinoma was more common than squamous cell carcinoma among nonsmokers (62 versus 18 percent, based upon 5144 cases). In contrast, adenocarcinoma was less frequent among smokers (19 versus 53 percent in 21,853 cases) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/3\">",
"     3",
"    </a>",
"    ]. More recent series of lung cancer in never smokers continue to report adenocarcinoma as the most common histology [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/13,34,37\">",
"     13,34,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Molecular biology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contemporary advances in the understanding of the molecular biology of lung cancer have led to the identification of substantial differences between never smokers compared to smokers with lung cancer. These factors are arguably more important than any clinical differences.",
"   </p>",
"   <p>",
"    One of the most apparent differences between lung cancer in never smokers versus current and former smokers is in the expression and mutations of the epidermal growth factor receptor (EGFR). Mutations in the EGFR gene are more common in lung tumors from never smokers compared to smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/122-127\">",
"     122-127",
"    </a>",
"    ]. Several analyses of patients with the most common activating mutations in the EGFR gene (predominantly deletions in exon 19 and the L858R mutation on exon 21) report that the frequency of the mutations, especially exon 19 and 21 mutations, is much higher in never smokers than ever smokers (p&lt;.001) in both men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/128,129\">",
"     128,129",
"    </a>",
"    ]. In addition, a distinct immunohistochemical profile of the EGFR pathway has also been identified in never versus current smokers, even in the absence of EGFR mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/130\">",
"     130",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Second-hand exposure to tobacco smoke appears to contribute to a decreased incidence of EGFR mutations. In a Korean study of 179 never smokers with NSCLC, EGFR mutations were significantly less frequent in those with a positive history of second-hand tobacco smoke (39 versus 61 percent), and there was a progressive decrease in the incidence with increasing second-hand tobacco smoke exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/131\">",
"     131",
"    </a>",
"    ]. This is in contrast to a Japanese publication focused on 126 never-smokers with NSCLC which reported an increased in EGFR activating mutations with increasing SHS exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/132\">",
"     132",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    KRAS mutations have been thought to be more common in lung cancer patients who are ever smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/127,133\">",
"     127,133",
"    </a>",
"    ]. An analysis of 482 lung adenocarcinomas, however, found that the rate of KRAS mutations in codons 12 and 13 was not significantly different in never smokers (15 percent) compared to former smokers (22 percent) and current smokers (25 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/134\">",
"     134",
"    </a>",
"    ]. The nature of the mutations was significantly different though, with more transition mutations (G to A) compared to transversion mutations (G to T or G to C) in tumors from patients with a smoking history.",
"   </p>",
"   <p>",
"    A fusion gene comprising portions of the echinoderm microtubule-associated protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene in NSCLC is found in 3 to 7 percent of NSCLC and appears to be mutually exclusive with EGFR and KRAS mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/135\">",
"     135",
"    </a>",
"    ]. This frequency is higher in those who develop lung cancer as never smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/135-137\">",
"     135-137",
"    </a>",
"    ]. The rate of ALK fusion oncogene positivity was nearly 20 percent of NSCLC in one study from China and 42 percent in those patients in that analysis who were known to have wildtype EGFR and KRAS [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/138\">",
"     138",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/58/30631?source=see_link\">",
"     Crizotinib",
"    </a>",
"    , an inhibitor of the ALK fusion protein, was recently approved for the treatment of these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40440?source=see_link\">",
"     \"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Differences have also been observed in the expression patterns and mutations for other genes when never smokers are compared to smokers. Examples of these include p53 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/133,139\">",
"     133,139",
"    </a>",
"    ], the NER family of proteins, including ERCC1, involved in DNA repair [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/140\">",
"     140",
"    </a>",
"    ], p38 (downstream of mitogen-activated protein kinase [MAPK]) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/141\">",
"     141",
"    </a>",
"    ], ataxia telangiectasia mutated (ATM) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/142\">",
"     142",
"    </a>",
"    ], nitrotyrosine (a marker of nitric oxide protein damage) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/133\">",
"     133",
"    </a>",
"    ], other chromosomal abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/143,144\">",
"     143,144",
"    </a>",
"    ] and methylation of p16 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/145,146\">",
"     145,146",
"    </a>",
"    ]. The microRNA-21 (miR-21) appears to be increased in lung cancer in never smokers, particularly in those with EGFR mutations and may play a significant role in lung carcinogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/147\">",
"     147",
"    </a>",
"    ]. Additionally, mitochondrial DNA mutations in the respiratory complex-I have been reported to differ between never-smokers and smokers with lung cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/148\">",
"     148",
"    </a>",
"    ]. More recent work has unexpectedly correlated increased genomic instability in never smoking patients with NSCLC compared to those with a smoking history [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/149\">",
"     149",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Focused efforts to determine frequencies of the known &ldquo;driver&rdquo; mutations in NSCLC (ie, those mutations that appear to be the driving force in a cancer) are ongoing in multiple collaborations. The National Cancer Institute&rsquo;s Lung Cancer Mutation Consortium presented data at the American Society of Clinical Oncology (ASCO) 2011 annual meeting and for the first approximately 800 patients tested reported mutation frequencies of 25 percent KRAS; 23 percent EGFR; 6 percent ALK rearrangements; 3 percent or less each of BRAF; PIK3CA; MET amplification; HER2; MEK1; NRAS [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/150\">",
"     150",
"    </a>",
"    ]. Though those results are for adenocarcinomas in general, the identification of such mutations in over 60 percent of patients sampled and the mutually exclusive nature of the majority of those mutations indicate how far we have come in our biological understanding of adenocarcinoma, the most frequent histology in never-smokers. A recent report from Korean looked at 229 tumors from never-smokers and reported a frequency of EGFR mutations, ALK gene rearrangements, and KRAS mutations of 48, 8, and 4 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/151\">",
"     151",
"    </a>",
"    ], and a surgical series of 52 never-smoker lung cancer patients in China identified known driver mutations in 90 percent, predominantly EGFR mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/152\">",
"     152",
"    </a>",
"    ]. This provides further support to the assertion that targetable oncogenic mutant kinases can now be identified in the majority of lung adenocarcinomas from never-smokers, especially in East Asian patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether or not patients with non-small cell lung cancer who are never smokers have a better response to standard treatment",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a better prognosis than those with a positive smoking history is uncertain. Some observational studies have demonstrated a better outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/26,153-157\">",
"     26,153-157",
"    </a>",
"    ], although this has not been true in all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/158-160\">",
"     158-160",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, in an analysis of 12,000 patients from California, smokers had a shorter survival compared to never smokers (hazard ratio for death 1.09, 95% CI 1.00-1.18) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/26\">",
"     26",
"    </a>",
"    ]. Similarly, in another study of patients with lung adenocarcinoma comparing 132 never smokers with 522 current smokers, it was found that the five-year survival was significantly better among never smokers (23 versus 16 percent), a difference that was significant on multivariate analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/153\">",
"     153",
"    </a>",
"    ]. In contrast, in another study of 254 patients with lung cancer, the five-year survival was not significantly different in never-smokers compared to smokers (27 versus 31 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/158\">",
"     158",
"    </a>",
"    ]. More recently, a much larger lung cancer registry trial, which included over 15,000 Japanese and over 13,000 Caucasian patients from Southern California, demonstrated a statistically significant improvement in survival for the patients with no smoking history [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/27\">",
"     27",
"    </a>",
"    ]. In an expanded analysis of 26,957 NSCLC patients from Japan, the median overall survival was significantly longer for never-smokers compared to ever smokers (30 versus 19 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/161\">",
"     161",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     EGFR inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically important differences in treatment response are seen with EGFR tyrosine kinase inhibitors (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    ). Higher response rates and better survival have been reported in never smokers with these drugs compared to current or former smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/124,162,163\">",
"     124,162,163",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the phase III trial in which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    was compared to supportive case as second-line therapy in patients with advanced NSCLC, a statistically significant survival benefit was seen in never smokers (HR 0.67 compared to supportive care) while the survival difference in ever smokers was not significant (HR 0.92) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/162\">",
"     162",
"    </a>",
"    ]. Similarly, in the phase III trial in which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    was compared to supportive care, a history of never smoking was a significant independent predictor of improved survival with erlotinib therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/163\">",
"     163",
"    </a>",
"    ]. These trials are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/36/40520?source=see_link&amp;anchor=H1137259613#H1137259613\">",
"     \"Second-line therapy for patients with previously treated advanced non-small cell lung cancer\", section on 'EGFR inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, never smoking status is likely a surrogate for EGFR activating mutations, which are a very strong predictor of response with EGFR tyrosine kinase inhibitors. The iPASS and First-Signal trials comparing first-line",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    versus chemotherapy for never smoking Asian patients with advanced stage NSCLC emphasize this point [",
"    <a class=\"abstract\" href=\"UTD.htm?12/6/12394/abstract/164,165\">",
"     164,165",
"    </a>",
"    ]. In both studies, high frequencies of EGFR mutations were found among never smokers, and gefitinib conferred an overall progression-free survival (PFS) benefit. In both studies, only those with the mutations had a PFS benefit with the EGFR-TKI when the patients were divided into those with and without EGFR activating mutations, and those without the mutations did better with first-line chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31816?source=see_link\">",
"     \"Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although most cases of lung cancer are due to tobacco smoking, lung cancer among never smokers is an important problem, with an incidence in men in the United States similar to that of multiple myeloma and in women similar to that of cervical cancer. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the etiology for lung cancer among never smokers is not always clear, risk factors include second hand tobacco smoke, radon, and other environmental exposures. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Risk factors'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=see_link\">",
"       \"Cigarette smoking and other risk factors for lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Adenocarcinoma is the most common pathology among never smokers and is more common than among ever smokers. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are important differences at the molecular level between lung cancers arising in never smokers and those in smokers. The best understood of these are the abnormalities in the EGFR pathway. These EGFR pathway abnormalities seen in never smokers have been associated with a particular responsiveness to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"       erlotinib",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"       gefitinib",
"      </a>",
"      , agents that inhibit EGFR tyrosine kinase. The ALK fusion oncogene is another molecular variant in NSCLC that is seen more frequently in never smokers and for which targeted therapy is now available. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Molecular biology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/1\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/2\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/3\">",
"      Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers--a different disease. Nat Rev Cancer 2007; 7:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/4\">",
"      Subramanian J, Govindan R. Lung cancer in never smokers: a review. J Clin Oncol 2007; 25:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/5\">",
"      Yano T, Miura N, Takenaka T, et al. Never-smoking nonsmall cell lung cancer as a separate entity: clinicopathologic features and survival. Cancer 2008; 113:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/6\">",
"      Subramanian J, Govindan R. Molecular genetics of lung cancer in people who have never smoked. Lancet Oncol 2008; 9:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/7\">",
"      Subramanian J, Govindan R. Lung cancer in 'Never-smokers': a unique entity. Oncology (Williston Park) 2010; 24:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/8\">",
"      Rudin CM, Avila-Tang E, Harris CC, et al. Lung cancer in never smokers: molecular profiles and therapeutic implications. Clin Cancer Res 2009; 15:5646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/9\">",
"      Wingo PA, Ries LA, Giovino GA, et al. Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst 1999; 91:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/10\">",
"      Jemal A, Thun MJ, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008; 100:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/11\">",
"      Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/12\">",
"      Kurahara Y, Kawaguchi T, Tachibana K, et al. Small-cell lung cancer in never-smokers: a case series with information on family history of cancer and environmental tobacco smoke. Clin Lung Cancer 2012; 13:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/13\">",
"      Wakelee HA, Chang ET, Gomez SL, et al. Lung cancer incidence in never smokers. J Clin Oncol 2007; 25:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/14\">",
"      Bain C, Feskanich D, Speizer FE, et al. Lung cancer rates in men and women with comparable histories of smoking. J Natl Cancer Inst 2004; 96:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/15\">",
"      Colditz GA, Manson JE, Hankinson SE. The Nurses' Health Study: 20-year contribution to the understanding of health among women. J Womens Health 1997; 6:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/16\">",
"      Bernstein L, Allen M, Anton-Culver H, et al. High breast cancer incidence rates among California teachers: results from the California Teachers Study (United States). Cancer Causes Control 2002; 13:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/17\">",
"      Kolonel LN, Henderson BE, Hankin JH, et al. A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J Epidemiol 2000; 151:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/18\">",
"      Haiman CA, Stram DO, Wilkens LR, et al. Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med 2006; 354:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/19\">",
"      Yong LC, Brown CC, Schatzkin A, et al. Intake of vitamins E, C, and A and risk of lung cancer. The NHANES I epidemiologic followup study. First National Health and Nutrition Examination Survey. Am J Epidemiol 1997; 146:231.",
"     </a>",
"    </li>",
"    <li>",
"     Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Seer*Stat Database: Incidence - SEER 13 Regs Public-Use, Nov 2004 Sub for Expanded Races (1992-2002). National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. Released April 2005, based on the November 2004 submission. 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/21\">",
"      Ou, SH, Ziogas, A, Zell, JA. Epidemiology study of never-smokers with non-small cell lung cancer (NSCLC): High percentages of Asian and Hispanic female never-smokers and the significance of Asian ethnicity (abstract 8004). J Clin Oncol 2008; 26:15s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/22\">",
"      Ou SH, Ziogas A, Zell JA. Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status. J Thorac Oncol 2009; 4:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/23\">",
"      Thun MJ, Hannan LM, Adams-Campbell LL, et al. Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies. PLoS Med 2008; 5:e185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/24\">",
"      Boffetta P, J&auml;rvholm B, Brennan P, Nyr&eacute;n O. Incidence of lung cancer in a large cohort of non-smoking men from Sweden. Int J Cancer 2001; 94:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/25\">",
"      Thun MJ, Henley SJ, Burns D, et al. Lung cancer death rates in lifelong nonsmokers. J Natl Cancer Inst 2006; 98:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/26\">",
"      Zell JA, Ou SH, Ziogas A, Anton-Culver H. Epidemiology of bronchioloalveolar carcinoma: improvement in survival after release of the 1999 WHO classification of lung tumors. J Clin Oncol 2005; 23:8396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/27\">",
"      Kawaguchi T, Matsumura A, Fukai S, et al. Japanese ethnicity compared with Caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small cell lung cancer: a collaborative epidemiologic study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry databases. J Thorac Oncol 2010; 5:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/28\">",
"      Peto R, Darby S, Deo H, et al. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 2000; 321:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/29\">",
"      Nyberg F, Agudo A, Boffetta P, et al. A European validation study of smoking and environmental tobacco smoke exposure in nonsmoking lung cancer cases and controls. Cancer Causes Control 1998; 9:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/30\">",
"      Wells AJ, English PB, Posner SF, et al. Misclassification rates for current smokers misclassified as nonsmokers. Am J Public Health 1998; 88:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/31\">",
"      Brenner DR, Hung RJ, Tsao MS, et al. Lung cancer risk in never-smokers: a population-based case-control study of epidemiologic risk factors. BMC Cancer 2010; 10:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/32\">",
"      Donington JS, Le QT, Wakelee HA. Lung cancer in women: exploring sex differences in susceptibility, biology, and therapeutic response. Clin Lung Cancer 2006; 8:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/33\">",
"      Wakai K, Ando M, Ozasa K, et al. Updated information on risk factors for lung cancer: findings from the JACC Study. J Epidemiol 2005; 15 Suppl 2:S134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/34\">",
"      Kawaguchi T, Takada M, Kubo A, et al. Gender, histology, and time of diagnosis are important factors for prognosis: analysis of 1499 never-smokers with advanced non-small cell lung cancer in Japan. J Thorac Oncol 2010; 5:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/35\">",
"      Gomez SL, Chang ET, Shema SJ, et al. Survival following non-small cell lung cancer among Asian/Pacific Islander, Latina, and Non-Hispanic white women who have never smoked. Cancer Epidemiol Biomarkers Prev 2011; 20:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/36\">",
"      Liu NS, Spitz MR, Kemp BL, et al. Adenocarcinoma of the lung in young patients: the M. D. Anderson experience. Cancer 2000; 88:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/37\">",
"      Toh CK, Gao F, Lim WT, et al. Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol 2006; 24:2245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/38\">",
"      Brennan P, Buffler PA, Reynolds P, et al. Secondhand smoke exposure in adulthood and risk of lung cancer among never smokers: a pooled analysis of two large studies. Int J Cancer 2004; 109:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/39\">",
"      Gorlova OY, Zhang Y, Schabath MB, et al. Never smokers and lung cancer risk: a case-control study of epidemiological factors. Int J Cancer 2006; 118:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/40\">",
"      Vineis P, Airoldi L, Veglia F, et al. Environmental tobacco smoke and risk of respiratory cancer and chronic obstructive pulmonary disease in former smokers and never smokers in the EPIC prospective study. BMJ 2005; 330:277.",
"     </a>",
"    </li>",
"    <li>",
"     Wu A. Carcinogenic effects. In: Health Effects of Exposure to Environmental Tobacco Smoke, Shopland DR, Zeise L, Dunn A (Eds), National Cancer Institute, Bethesda, MD 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/42\">",
"      Vineis P, Alavanja M, Buffler P, et al. Tobacco and cancer: recent epidemiological evidence. J Natl Cancer Inst 2004; 96:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/43\">",
"      IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum 2004; 83:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/44\">",
"      Vineis P, Hoek G, Krzyzanowski M, et al. Lung cancers attributable to environmental tobacco smoke and air pollution in non-smokers in different European countries: a prospective study. Environ Health 2007; 6:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/45\">",
"      Cl&eacute;ment-Duch&ecirc;ne C, Vignaud JM, Stoufflet A, et al. Characteristics of never smoker lung cancer including environmental and occupational risk factors. Lung Cancer 2010; 67:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/46\">",
"      Asomaning K, Miller DP, Liu G, et al. Second hand smoke, age of exposure and lung cancer risk. Lung Cancer 2008; 61:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/47\">",
"      Kurahashi N, Inoue M, Liu Y, et al. Passive smoking and lung cancer in Japanese non-smoking women: a prospective study. Int J Cancer 2008; 122:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/48\">",
"      Olivo-Marston SE, Yang P, Mechanic LE, et al. Childhood exposure to secondhand smoke and functional mannose binding lectin polymorphisms are associated with increased lung cancer risk. Cancer Epidemiol Biomarkers Prev 2009; 18:3375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/49\">",
"      Leuraud K, Schnelzer M, Tomasek L, et al. Radon, smoking and lung cancer risk: results of a joint analysis of three European case-control studies among uranium miners. Radiat Res 2011; 176:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/50\">",
"      Samet JM. Radon and lung cancer. J Natl Cancer Inst 1989; 81:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/51\">",
"      Krewski D, Lubin JH, Zielinski JM, et al. A combined analysis of North American case-control studies of residential radon and lung cancer. J Toxicol Environ Health A 2006; 69:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/52\">",
"      Darby S, Hill D, Auvinen A, et al. Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies. BMJ 2005; 330:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/53\">",
"      Sandler DP, Weinberg CR, Shore DL, et al. Indoor radon and lung cancer risk in connecticut and utah. J Toxicol Environ Health A 2006; 69:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/54\">",
"      Alberg AJ, Brock MV, Samet JM. Epidemiology of lung cancer: looking to the future. J Clin Oncol 2005; 23:3175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/55\">",
"      Gottschall EB. Occupational and environmental thoracic malignancies. J Thorac Imaging 2002; 17:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/56\">",
"      Neuberger JS, Field RW. Occupation and lung cancer in nonsmokers. Rev Environ Health 2003; 18:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/57\">",
"      van Loon AJ, Kant IJ, Swaen GM, et al. Occupational exposure to carcinogens and risk of lung cancer: results from The Netherlands cohort study. Occup Environ Med 1997; 54:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/58\">",
"      Peters S, Kromhout H, Olsson AC, et al. Occupational exposure to organic dust increases lung cancer risk in the general population. Thorax 2012; 67:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/59\">",
"      Guha N, Merletti F, Steenland NK, et al. Lung cancer risk in painters: a meta-analysis. Environ Health Perspect 2010; 118:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/60\">",
"      Chen CL, Hsu LI, Chiou HY, et al. Ingested arsenic, cigarette smoking, and lung cancer risk: a follow-up study in arseniasis-endemic areas in Taiwan. JAMA 2004; 292:2984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/61\">",
"      Ferreccio C, Gonz&aacute;lez C, Milosavjlevic V, et al. Lung cancer and arsenic concentrations in drinking water in Chile. Epidemiology 2000; 11:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/62\">",
"      Feskanich D, Ziegler RG, Michaud DS, et al. Prospective study of fruit and vegetable consumption and risk of lung cancer among men and women. J Natl Cancer Inst 2000; 92:1812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/63\">",
"      Galeone C, Negri E, Pelucchi C, et al. Dietary intake of fruit and vegetable and lung cancer risk: a case-control study in Harbin, northeast China. Ann Oncol 2007; 18:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/64\">",
"      Lam TK, Cross AJ, Consonni D, et al. Intakes of red meat, processed meat, and meat mutagens increase lung cancer risk. Cancer Res 2009; 69:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/65\">",
"      Lim WY, Chuah KL, Eng P, et al. Meat consumption and risk of lung cancer among never-smoking women. Nutr Cancer 2011; 63:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/66\">",
"      Gorlova OY, Weng SF, Hernandez L, et al. Dietary patterns affect lung cancer risk in never smokers. Nutr Cancer 2011; 63:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/67\">",
"      Boffetta P, Nyberg F. Contribution of environmental factors to cancer risk. Br Med Bull 2003; 68:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/68\">",
"      Yu IT, Chiu YL, Au JS, et al. Dose-response relationship between cooking fumes exposures and lung cancer among Chinese nonsmoking women. Cancer Res 2006; 66:4961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/69\">",
"      Ko YC, Cheng LS, Lee CH, et al. Chinese food cooking and lung cancer in women nonsmokers. Am J Epidemiol 2000; 151:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/70\">",
"      Kleinerman RA, Wang Z, Wang L, et al. Lung cancer and indoor exposure to coal and biomass in rural China. J Occup Environ Med 2002; 44:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/71\">",
"      Gao YT, Blot WJ, Zheng W, et al. Lung cancer among Chinese women. Int J Cancer 1987; 40:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/72\">",
"      Wang TJ, Zhou BS, Shi JP. Lung cancer in nonsmoking Chinese women: a case-control study. Lung Cancer 1996; 14 Suppl 1:S93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/73\">",
"      Shen XB, Wang GX, Huang YZ, et al. Analysis and estimates of attributable risk factors for lung cancer in Nanjing, China. Lung Cancer 1996; 14 Suppl 1:S107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/74\">",
"      Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002; 94:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/75\">",
"      Littman AJ, Thornquist MD, White E, et al. Prior lung disease and risk of lung cancer in a large prospective study. Cancer Causes Control 2004; 15:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/76\">",
"      Mayne ST, Buenconsejo J, Janerich DT. Previous lung disease and risk of lung cancer among men and women nonsmokers. Am J Epidemiol 1999; 149:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/77\">",
"      Wu AH, Fontham ET, Reynolds P, et al. Previous lung disease and risk of lung cancer among lifetime nonsmoking women in the United States. Am J Epidemiol 1995; 141:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/78\">",
"      Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med 2000; 161:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/79\">",
"      Wells C, Mannino DM. Pulmonary fibrosis and lung cancer in the United States: analysis of the multiple cause of death mortality data, 1979 through 1991. South Med J 1996; 89:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/80\">",
"      Ciotti M, Giuliani L, Ambrogi V, et al. Detection and expression of human papillomavirus oncogenes in non-small cell lung cancer. Oncol Rep 2006; 16:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/81\">",
"      Chen YC, Chen JH, Richard K, et al. Lung adenocarcinoma and human papillomavirus infection. Cancer 2004; 101:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/82\">",
"      Cheng YW, Chiou HL, Sheu GT, et al. The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women. Cancer Res 2001; 61:2799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/83\">",
"      Bohlmeyer T, Le TN, Shroyer AL, et al. Detection of human papillomavirus in squamous cell carcinomas of the lung by polymerase chain reaction. Am J Respir Cell Mol Biol 1998; 18:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/84\">",
"      Mornex JF, Thivolet F, De las Heras M, Leroux C. Pathology of human bronchioloalveolar carcinoma and its relationship to the ovine disease. Curr Top Microbiol Immunol 2003; 275:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/85\">",
"      Wu AH, Fontham ET, Reynolds P, et al. Family history of cancer and risk of lung cancer among lifetime nonsmoking women in the United States. Am J Epidemiol 1996; 143:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/86\">",
"      Brownson RC, Alavanja MC, Caporaso N, et al. Family history of cancer and risk of lung cancer in lifetime non-smokers and long-term ex-smokers. Int J Epidemiol 1997; 26:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/87\">",
"      Wu PF, Lee CH, Wang MJ, et al. Cancer aggregation and complex segregation analysis of families with female non-smoking lung cancer probands in Taiwan. Eur J Cancer 2004; 40:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/88\">",
"      Schwartz AG, Yang P, Swanson GM. Familial risk of lung cancer among nonsmokers and their relatives. Am J Epidemiol 1996; 144:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/89\">",
"      Gorlova OY, Weng SF, Zhang Y, et al. Aggregation of cancer among relatives of never-smoking lung cancer patients. Int J Cancer 2007; 121:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/90\">",
"      Gao Y, Goldstein AM, Consonni D, et al. Family history of cancer and nonmalignant lung diseases as risk factors for lung cancer. Int J Cancer 2009; 125:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/91\">",
"      Amos CI, Pinney SM, Li Y, et al. A susceptibility locus on chromosome 6q greatly increases lung cancer risk among light and never smokers. Cancer Res 2010; 70:2359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/92\">",
"      Wang Y, Broderick P, Webb E, et al. Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet 2008; 40:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/93\">",
"      Wang Y, Broderick P, Matakidou A, et al. Role of 5p15.33 (TERT-CLPTM1L), 6p21.33 and 15q25.1 (CHRNA5-CHRNA3) variation and lung cancer risk in never-smokers. Carcinogenesis 2010; 31:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/94\">",
"      Hsiung CA, Lan Q, Hong YC, et al. The 5p15.33 locus is associated with risk of lung adenocarcinoma in never-smoking females in Asia. PLoS Genet 2010; 6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/95\">",
"      Li Y, Sheu CC, Ye Y, et al. Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol 2010; 11:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/96\">",
"      Truong T, Hung RJ, Amos CI, et al. Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium. J Natl Cancer Inst 2010; 102:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/97\">",
"      Ahn MJ, Won HH, Lee J, et al. The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populations. Hum Genet 2012; 131:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/98\">",
"      Yang P, Li Y, Jiang R, et al. A rigorous and comprehensive validation: common genetic variations and lung cancer. Cancer Epidemiol Biomarkers Prev 2010; 19:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/99\">",
"      Bell DW, Gore I, Okimoto RA, et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 2005; 37:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/100\">",
"      Raimondi S, Boffetta P, Anttila S, et al. Metabolic gene polymorphisms and lung cancer risk in non-smokers. An update of the GSEC study. Mutat Res 2005; 592:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/101\">",
"      Wenzlaff AS, Cote ML, Bock CH, et al. CYP1A1 and CYP1B1 polymorphisms and risk of lung cancer among never smokers: a population-based study. Carcinogenesis 2005; 26:2207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/102\">",
"      Taioli E, Gaspari L, Benhamou S, et al. Polymorphisms in CYP1A1, GSTM1, GSTT1 and lung cancer below the age of 45 years. Int J Epidemiol 2003; 32:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/103\">",
"      Jung CY, Choi JE, Park JM, et al. Polymorphisms in the hMSH2 gene and the risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev 2006; 15:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/104\">",
"      Lo YL, Hsiao CF, Jou YS, et al. Polymorphisms of MLH1 and MSH2 genes and the risk of lung cancer among never smokers. Lung Cancer 2011; 72:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/105\">",
"      Schwartz AG, Prysak GM, Bock CH, Cote ML. The molecular epidemiology of lung cancer. Carcinogenesis 2007; 28:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/106\">",
"      Bonner MR, Bennett WP, Xiong W, et al. Radon, secondhand smoke, glutathione-S-transferase M1 and lung cancer among women. Int J Cancer 2006; 119:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/107\">",
"      Wenzlaff AS, Cote ML, Bock CH, et al. GSTM1, GSTT1 and GSTP1 polymorphisms, environmental tobacco smoke exposure and risk of lung cancer among never smokers: a population-based study. Carcinogenesis 2005; 26:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/108\">",
"      Gorlova OY, Weng SF, Zhang Y, et al. DNA repair capacity and lung cancer risk in never smokers. Cancer Epidemiol Biomarkers Prev 2008; 17:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/109\">",
"      Mosselman S, Polman J, Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 1996; 392:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/110\">",
"      Stabile LP, Davis AL, Gubish CT, et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res 2002; 62:2141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/111\">",
"      Mollerup S, J&oslash;rgensen K, Berge G, Haugen A. Expression of estrogen receptors alpha and beta in human lung tissue and cell lines. Lung Cancer 2002; 37:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/112\">",
"      Wu CT, Chang YL, Shih JY, Lee YC. The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. J Thorac Cardiovasc Surg 2005; 130:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/113\">",
"      Taioli E, Wynder EL. Re: Endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst 1994; 86:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/114\">",
"      Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/115\">",
"      Schwartz AG, Wenzlaff AS, Prysak GM, et al. Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women. J Clin Oncol 2007; 25:5785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/116\">",
"      Oh SW, Myung SK, Park JY, et al. Hormone therapy and risk of lung cancer: a meta-analysis. J Womens Health (Larchmt) 2010; 19:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/117\">",
"      Kabat GC, Miller AB, Rohan TE. Reproductive and hormonal factors and risk of lung cancer in women: a prospective cohort study. Int J Cancer 2007; 120:2214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/118\">",
"      Paulus JK, Asomaning K, Kraft P, et al. Parity and risk of lung cancer in women. Am J Epidemiol 2010; 171:557.",
"     </a>",
"    </li>",
"    <li>",
"     Patel JD, Gray RG, Stewart JA, et al. Tamoxifen does not reduce the risk of lung cancer in women. J CLin Oncol 2005; 23:673s (abstract).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/120\">",
"      Chlebowski RT, Schwartz AG, Wakelee H, et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet 2009; 374:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/121\">",
"      Chlebowski RT, Anderson GL, Manson JE, et al. Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial. J Natl Cancer Inst 2010; 102:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/122\">",
"      Sonobe M, Manabe T, Wada H, Tanaka F. Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. Br J Cancer 2005; 93:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/123\">",
"      Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004; 64:8919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/124\">",
"      Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005; 353:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/125\">",
"      Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from \"never smokers\" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101:13306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/126\">",
"      Pham D, Kris MG, Riely GJ, et al. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol 2006; 24:1700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/127\">",
"      Tam IY, Chung LP, Suen WS, et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res 2006; 12:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/128\">",
"      Toyooka S, Matsuo K, Shigematsu H, et al. The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer. Clin Cancer Res 2007; 13:5763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/129\">",
"      Lee YJ, Shim HS, Kang YA, et al. Dose effect of cigarette smoking on frequency and spectrum of epidermal growth factor receptor gene mutations in Korean patients with non-small cell lung cancer. J Cancer Res Clin Oncol 2010; 136:1937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/130\">",
"      Dutu T, Michiels S, Fouret P, et al. Differential expression of biomarkers in lung adenocarcinoma: a comparative study between smokers and never-smokers. Ann Oncol 2005; 16:1906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/131\">",
"      Lee YJ, Cho BC, Jee SH, et al. Impact of environmental tobacco smoke on the incidence of mutations in epidermal growth factor receptor gene in never-smoker patients with non-small-cell lung cancer. J Clin Oncol 2010; 28:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/132\">",
"      Kawaguchi T, Ando M, Kubo A, et al. Long exposure of environmental tobacco smoke associated with activating EGFR mutations in never-smokers with non-small cell lung cancer. Clin Cancer Res 2011; 17:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/133\">",
"      Le Calvez F, Mukeria A, Hunt JD, et al. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res 2005; 65:5076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/134\">",
"      Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008; 14:5731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/135\">",
"      Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27:4247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/136\">",
"      Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009; 15:5216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/137\">",
"      Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/138\">",
"      Zhang X, Zhang S, Yang X, et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer 2010; 9:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/139\">",
"      Toyooka S, Tsuda T, Gazdar AF. The TP53 gene, tobacco exposure, and lung cancer. Hum Mutat 2003; 21:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/140\">",
"      Planchard D, Domont J, Taranchon E, et al. The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinoma. Ann Oncol 2009; 20:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/141\">",
"      Mountzios G, Planchard D, Besse B, et al. Mitogen-activated protein kinase activation in lung adenocarcinoma: a comparative study between ever smokers and never smokers. Clin Cancer Res 2008; 14:4096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/142\">",
"      Lo YL, Hsiao CF, Jou YS, et al. ATM polymorphisms and risk of lung cancer among never smokers. Lung Cancer 2010; 69:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/143\">",
"      Wong MP, Fung LF, Wang E, et al. Chromosomal aberrations of primary lung adenocarcinomas in nonsmokers. Cancer 2003; 97:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/144\">",
"      Sanchez-Cespedes M, Ahrendt SA, Piantadosi S, et al. Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. Cancer Res 2001; 61:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/145\">",
"      Divine KK, Pulling LC, Marron-Terada PG, et al. Multiplicity of abnormal promoter methylation in lung adenocarcinomas from smokers and never smokers. Int J Cancer 2005; 114:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/146\">",
"      Tessema M, Yu YY, Stidley CA, et al. Concomitant promoter methylation of multiple genes in lung adenocarcinomas from current, former and never smokers. Carcinogenesis 2009; 30:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/147\">",
"      Seike M, Goto A, Okano T, et al. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci U S A 2009; 106:12085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/148\">",
"      Dasgupta S, Soudry E, Mukhopadhyay N, et al. Mitochondrial DNA mutations in respiratory complex-I in never-smoker lung cancer patients contribute to lung cancer progression and associated with EGFR gene mutation. J Cell Physiol 2012; 227:2451.",
"     </a>",
"    </li>",
"    <li>",
"     Thu K, Becker D, Chari R. Lung adenocarcinoma genomes of never smokers exhibit a greater extent of genomic instability than those of smokers. Abstract O07.02. Proceedings of the 14th World Conference on Lung Cancer, Book 1. Journal of Thoracic Oncology Vol 6(1), 2011, pS301.",
"    </li>",
"    <li>",
"     Kris MG, et al. J Clin Oncol 2011; 29(suppl):abstr# CRA7506.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/151\">",
"      Kim HR, Shim HS, Chung JH, et al. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer 2012; 118:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/152\">",
"      Sun Y, Ren Y, Fang Z, et al. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol 2010; 28:4616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/153\">",
"      Nordquist LT, Simon GR, Cantor A, et al. Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung. Chest 2004; 126:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/154\">",
"      Sardari Nia P, Weyler J, Colpaert C, et al. Prognostic value of smoking status in operated non-small cell lung cancer. Lung Cancer 2005; 47:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/155\">",
"      Bryant A, Cerfolio RJ. Differences in epidemiology, histology, and survival between cigarette smokers and never-smokers who develop non-small cell lung cancer. Chest 2007; 132:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/156\">",
"      Tsao AS, Liu D, Lee JJ, et al. Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer 2006; 106:2428.",
"     </a>",
"    </li>",
"    <li>",
"     Yano T, Miura N, Takenaka T, et al. Surgical results of non-small cell lung cancer in never-smokers as a separate entity (abstract). J Clin Oncol 2008; 26:398s. (Abstract available online at www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD, accessed on June 4, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/158\">",
"      Subramanian J, Velcheti V, Gao F, Govindan R. Presentation and stage-specific outcomes of lifelong never-smokers with non-small cell lung cancer (NSCLC). J Thorac Oncol 2007; 2:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/159\">",
"      Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23:5892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/160\">",
"      Meguid RA, Hooker CM, Harris J, et al. Long-term survival outcomes by smoking status in surgical and nonsurgical patients with non-small cell lung cancer: comparing never smokers and current smokers. Chest 2010; 138:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/161\">",
"      Kawaguchi T, Takada M, Kubo A, et al. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol 2010; 5:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/162\">",
"      Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/6/12394/abstract/163\">",
"      Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123.",
"     </a>",
"    </li>",
"    <li>",
"     Mok TS, et al. Clinical Outcomes of patients with epidermal growth factor receptor (EGFR) mutations (mut) in IPASS (abstract B9.5). International Association for the Study of Lung Cancer 13th World Conference on Lung Cancer Proceedings. July 31 to Aug 4, 2009 San Francisco, CA.",
"    </li>",
"    <li>",
"     Lee JS, et al. A randomized phase III study of gefitinib versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung (abstract PR.4). International Association for the Study of Lung Cancer 13th World Conference on Lung Cancer Proceedings. July 31 to Aug 4, 2009, San Francisco, CA.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4600 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-194.187.108.93-9EF4B3CCD6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_6_12394=[""].join("\n");
var outline_f12_6_12394=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Sex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Ethnicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Secondhand smoke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Radon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Environmental exposures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Lung disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H551742669\">",
"      Oncogenic viruses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Estrogens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      BIOLOGIC DIFFERENCES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Molecular biology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      EGFR inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40440?source=related_link\">",
"      Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=related_link\">",
"      Cigarette smoking and other risk factors for lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31816?source=related_link\">",
"      Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13273?source=related_link\">",
"      Overview of the initial evaluation, treatment and prognosis of lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16282?source=related_link\">",
"      Overview of the risk factors, pathology, and clinical manifestations of lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/57/21401?source=related_link\">",
"      Overview of the treatment of advanced non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/36/40520?source=related_link\">",
"      Second-line therapy for patients with previously treated advanced non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10072?source=related_link\">",
"      Women and lung cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_6_12395="Darrows solution";
var content_f12_6_12395=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Darrow's solution (full strength) for intravenous rehydration",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Injection solution (full strength)*",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Potassium 35 mmol/L (35 mEq)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sodium 121 mmol/L (121 mEq)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chloride 103 mmol/L (103 mEq)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lactate 53 mmol/L (53 mEq)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    When intravenous rehydration is indicated for children with severe malnutrition, Darrow's solution is administered at half-strength by diluting with an equal amount of 5 percent dextrose water (see \"Severe malnutrition in children in developing countries: Treatment\").",
"    <div class=\"footnotes\">",
"     * The osmolarity of full-strength Darrow's solution is 312 mOsm/L.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     The composition of individual Darrow's solutions may vary slightly; check local product information for details.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Darrow's solution (pharmacopeial). Martindale: The Complete Drug Reference [online]. Sweetman S (Ed). Pharmaceutical Press, London.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_6_12395=[""].join("\n");
var outline_f12_6_12395=null;
var title_f12_6_12396="T cell surface protein function";
var content_f12_6_12396=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F72603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F72603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Co-stimulatory molecules in T cell activation and regulation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       T cell molecule",
"      </td>",
"      <td class=\"subtitle1\">",
"       Ligand",
"      </td>",
"      <td class=\"subtitle1\">",
"       Functions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       CD2",
"      </td>",
"      <td>",
"       CD58 (LFA-3)",
"      </td>",
"      <td>",
"       Adhesion, activation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       CD4",
"      </td>",
"      <td>",
"       MHC class II",
"      </td>",
"      <td>",
"       Adhesion, activation (associates with Lck tyrosine kinase)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       CD5",
"      </td>",
"      <td>",
"       CD72",
"      </td>",
"      <td>",
"       Adhesion, activation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       CD8",
"      </td>",
"      <td>",
"       MHC class I",
"      </td>",
"      <td>",
"       Adhesion, activation (associates with Lck tyrosine kinase)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       CD11a/CD18 (LFA-1)",
"      </td>",
"      <td>",
"       CD54 (ICAM-1)",
"      </td>",
"      <td>",
"       Adhesion, activation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       CD27",
"      </td>",
"      <td>",
"       CD70",
"      </td>",
"      <td>",
"       Adhesion, activation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       CD28",
"      </td>",
"      <td>",
"       CD8O, CD86 (B7-1, B7-2)",
"      </td>",
"      <td>",
"       Adhesion, major co-stimulatory pathway",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       CD69",
"      </td>",
"      <td>",
"       ?",
"      </td>",
"      <td>",
"       C-type lectin, early T cell activation marker, triggers calcium-mediated activation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       CD134 (OX40)",
"      </td>",
"      <td>",
"       OX40 ligand",
"      </td>",
"      <td>",
"       Adhesion, activation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       CDw137 (4-1BB)",
"      </td>",
"      <td>",
"       4-1BB ligand",
"      </td>",
"      <td>",
"       Adhesion, activation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       CD154 (CD40L)",
"      </td>",
"      <td>",
"       CD40",
"      </td>",
"      <td>",
"       Expressed on activated T cells, important stimulator of APC function and B cell Ig class switching",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       CTLA-4",
"      </td>",
"      <td>",
"       CD80, CD86 (B7-1, B7-2)",
"      </td>",
"      <td>",
"       Down-regulates T cell activation",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ICAM: intercellular adhesion molecule; LFA: leukocyte function antigen; MHC: major histocompatibility complex; TCR: T cell receptor.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_6_12396=[""].join("\n");
var outline_f12_6_12396=null;
var title_f12_6_12397="ACC AHA therapy VT VF MI";
var content_f12_6_12397=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54328&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54328&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Ventricular tachycardia (VT)/ventricular fibrillation (VF) in acute myocardial infarction (MI)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general agreement for the following approaches to VT/VF in patients with acute MI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; VF or pulseless VT should be treated with an unsynchronized electric shock with an initial monophasic shock energy of 200 J*; if unsuccessful, a second shock of 200 to 300 J should be given, and, if necessary, a third shock of 360 J.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Sustained (&gt;30 seconds or causing hemodynamic collapse) polymorphic VT should be treated with an unsynchronized electric shock using an initial monophasic shock energy of 200 J*; if unsuccessful, a second shock of 200 to 300 J should be given, and, if necessary, a third shock of 360 J.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Episodes of sustained monomorphic VT associated with angina, pulmonary edema, or hypotension (blood pressure &lt;90 mmHg) should be treated with a synchronized electric shock of 100 J initial monophasic shock energy*. Increasing energies may be used if not initially successful. Brief anesthesia is preferred if hemodynamically tolerable.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &bull;&nbsp; Sustained monomorphic VT not associated with angina, pulmonary edema, or hypotension (blood pressure &lt;90 mmHg) should be treated with one of the following regimens:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Amiodarone: 150 mg infused over 10 minutes. If further therapy is necessary, repeat 150 mg infusion every 10 to 15 minutes as needed or a constant infusion of 1.0 mg/min for six hours followed by a maintenance infusion of 0.5 mg/min for 18 hours. The total cumulative dose, including additional doses during cardiac arrest, must not exceed 2.2 g over 24 hours.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Synchronized electrical cardioversion starting at 50 J monophasic energy. Brief anesthesia is necessary.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence or opinion is in favor of benefit for the following modalities in the treatment of VT/VF in patients with acute MI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; For VF or pulseless VT refractory to electric shock, amiodarone (300 mg or 5 mg/kg bolus) followed by a repeat unsynchronized electric shock.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Electrolyte and acid-base disturbances should be corrected to prevent recurrent episodes of VT/VF when an initial episode of VT/VF has been treated. The serum potassium should be greater than 4.0 meq/L (4.0 mmol/L) and the serum magnesium should be greater than 2.0 mg/dL (0.8 mmol/L).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &bull;&nbsp; For refractory polymorphic VT, in addition to potassium and magnesium balance:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Aggressive attempts to reduce myocardial ischemia, including therapies such as beta blockers, intra-aortic balloon pump, and emergency percutaneous coronary intervention or bypass surgery.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Temporary pacing at a higher rate, if the heart rate is less than 60 beats/min or the corrected QT interval is prolonged.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb - The evidence or opinion is less well established for the following modality in the treatment of VT/VF in patients with acute MI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Intravenous procainamide for VT or shock-refractory VF. The usual regimen is 20 to 30 mg/min loading infusion, up to 12 to 17 mg/kg, which may be followed by an infusion of 1 to 4 mg/min. The length of time required for administration limits the value of this approach.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or general agreement that the following modalities are not useful in the treatment of VT/VF in patients with acute MI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; The routine use of prophylactic lidocaine for suppression of isolated ventricular premature beats, couplets, runs of accelerated idioventricular rhythm, or nonsustained VT.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Prophylactic antiarrhythmic therapy when using fibrinolytic agents.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The initial shock energy required with biphasic defibrillators is approximately one-half that with monophasic defibrillators.",
"    </div>",
"    <div class=\"reference\">",
"     Data from from Antman, EM, Anbe, DT, Armstrong, PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. Available at: www.acc.org/qualityandscience/clinical/statements.htm (accessed August 24, 2006).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_6_12397=[""].join("\n");
var outline_f12_6_12397=null;
var title_f12_6_12398="Neutrophil count in measles";
var content_f12_6_12398=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F65459&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F65459&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    White cell count in measles",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 329px; height: 399px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mean absolute neutrophil and lymphocyte counts during measles in 16 uncomplicated cases. Normal levels indicated by the broken line. There is a mild leukocytosis for a few days before the onset of fever. This is followed by leukopenia during the week of cough, coryza, conjunctivitis, Koplik spots and rash.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_6_12398=[""].join("\n");
var outline_f12_6_12398=null;
var title_f12_6_12399="Irreducible middle phalanx neck fracture";
var content_f12_6_12399=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F78576&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F78576&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Irreducible middle phalanx neck fracture as a result of volar plate interposition",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGwAUQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5fNFGaM0AAPalzTaWgBc0maSigAPNGaSloAM0UUUAFFFFACUUtJQAUh6UtNY8UANNJSmkoADSUUUAFLSgZp4TOBjJPagBmM04ADk1aS0Y4LHHsKspaqFGFz9aAM4dKMitUW64+6KDbg/wgUAZWcjg1GTxitGS0B6HBxVOW3kTkjI9aAIaSiigBaKSjNAD160+ogaeDQA6lpoPpS/WgBaSiloAKKO1FABiiiigAopKWgAooooAKKSloASloo7UAFFFFABRRSUAFIxoJphNAATSGj60hoADRRRQAUUUA4xQBYgiLHitSGEBAMcmmWiDYvHJ6+9X4V3D2oAijixyamWPGOKsIg7jp0p6pjpQBX8r5ueKDHgngnNWNoIwRz2p2zkYoAotF0yMVA8WQRitN4s8momi6gdaAMS5sQxJX5W+lZskbxn5x+NdO8RBNU5oOCG+b3NAGFRV24tAATGDmqR4OCORQAUoNJ2ooAdmnqajzSigCSlpoIP1pc0AFLSUtABRRRQAUUlLQAlLSUtABSUtJQAtFJmg0AFGaTcKTdxxQA6msaTcaaaADNBpKKACiiigAooooAKTvS0D7w+tAG3b/cT2FaNuMJjsaz7Ybio7YrUhwF560ATKoxnoakUYGSPpTY1dx8ik+4FOVZOmxifpQA4Lk4GBSkDdzSrGwGGU/WpFyAMAUAQkEA/Wo2WrLDqKaykgUAUnQkEioJI8dRV91x05qB1HOByaAM2WPJPXNZ91bBgSvDVsyp8w9aryR/N1oA50gq2CMEUVo3lvvBZQN386zqAClBpKKAHU8GoxSg0APHNOqMHmnigBaKKKAGhqWo80bqAJCaKjzS7jQA7IoLUykoAUmjNNooAXNFJR3oAM0UUUAFFFH4UAFFJRQAUUUUAFKv3h9aSlT7659aAN+yGcHsa0sjA9O5qjbD5VznFXkxtA7UAdRYiFbWFlT5TVia4hD48nPv706xjSbT4ViIyvBxUs6xgYYgEd/egCERq6lgvTqMfyrO1Kz8kpLEP3bdfatdI9p2sSaW7QG1kQjkCgDm2z2FMbkAVIBx05pD6EYFAELjg56VAVAzmrJHfvUbqDn1oApyICemKryL3NXSCfftUDjBPHWgDPkj5JrJvYdjblHBremTK+9UbmPchU46UAY1FBG1iD1ooAKUUlHegB47U+owaeDmgB1FFFAEPakzQaKACiilANAAOtOVCfX8KsWtsWIZs7a0Et1U4AHHegDLW1lb+H+lP+xSY5IFa6xZFL5fagDEe2kUZ4P0qFlI4IxXQGL24qGWAHIZQRQBiUVcnsyMlOD6GqbAqcEc0AJml70lFABmiiigAooooAKdH/AKxfrTakthm4Qe9AHRQcAd6uL8y5qrCMCrKkhCeOaAOt8I5+zMXPB4qxcqruY245yCO9M8NoF0wZB/8Ar04Mxu2VSCBzz60AWFDq2/G8KPypWLNKDxtccirAgkYDnBcfnTbmML5TOB8pOQKAOYuAY7h14wDUJyRxVi7bfdSMORniomyeD+FAEB4pr9P9rFSHjqeM0zA5I9OtAEDHIx09vWoH9BxVhvmUACo3zgkYoAqSjr2qnOMqO1X3QHnFVJxkYoAw71NsmexqvV/UE+QH0NZ4oAWiiigAFOB9KSgUAP3H2opuaKAG0UUUAKBVi0i3SDPIqK3XfIBjNbNrGAnI70ALEnHPerflqMEYORUaLxwefSrO04Q4zxQBGFweOlP2456VIq9eMCnhAMcUAV9uQBTHQdutWypNMKryM9aAKDw9eaoXVsHBxjcO9bDIDwOlVpl4oA550ZCQw5ptal1AHXGMHtWY6FGww5oASiiigAooooAKltBm4T61FVqyX96nrQBuRdasgggDmoIh+VWrZVa4iX1YcUAdxpeYrFQPTNR2xVS2RlmbJNWI122gHTtVVSsUm49QaAOjSLYqZOWC5WsXVJdsqjPXrWvbyiaKBhxwQTWFrZAuMZGFB/OgDDmOZnI6U0kY69qVh1IOM9hTSc9aAGk5GOMDvUZHHHQVI3I6YqI/KOmR70ARkgjgnNRHp3xUx6ZA4NRtznnmgCu3XrzVacHg9DVqU88dPWqs3QgUAZl6uYm4rJFbN0PkYcnisYUALRRRQAUtJRQAtFFFACUUUUATWbbZ1461txEY5rAjO2RTnvW1Ewxk80AW0PFWlOIx6DrVJD0zitqwsJLiAsflHUE96AKoIBBPSn4HHNadrDZh23usjLyR2rQe1tb2IeWgU44K0Ac8Vyue+aYR6d6s3MDwSeW6nHr2qIL6HrQBXZOCccVBIowCevarbjBNQuMDk5FAFCRMg461n3cG9TgYI71rSLkZHWq0q85oAwWUqcGkq9dw7uQPmqieODQAUUUUAKgywq/aAeaAeKr2se45rTt7cBs5xQBdjPGCK09Eh87UUBHyrzVGGIDB610PhiP/AEt3xwABQB0F9MsFugbjHQVjBxI4YMeTjFT6rKZp5cfcXiqdvG0m0KOc0AddooJtCD/CeKwNWheTVHZvwrqNCi8u0kDfM1c/qx26i4zg4zQBlSwiJc96qdeD+lW72QZxmqhwF4NAA3CgcGmn260vXpimPzwODQBG+dv071Cw+XmpnOOtQsc/WgCKT24qpKe/QmrTn16VUmNAFC7OEOQRmsbvWvfOBExrIoAWikFLQAUUUUAGaKKKACiikoAUnvWtbsDGvXmsitCwcGMgnlaANNSMD1rsPDDLd20kchIIG0Ad64tWyB0B9a2/D1y9vqMJBwrnDCgDYmsYoGYbWVyfwqe3LWrRoqhgeSRWvqEKTQ+Ye3UVlsmE+Q47CgCXUbbzInfHGM1zYHbqRXZW8JfTnUsCwFcndQeVO6noeQaAKsgB781A4OOtWZAD+Heo2AP0oAqOOhxUDrkfXrVphnOMmoX6YOc0AUpUHT9azLqHa25frWxKoIPaqlwm4frQBk0U6RdrYojGXUUAaNpGFAyMGtW3AB/wqjAB0q9bgD1oAtxbmB4wB3rovDw2QyuOcd6w7KTy32sOD1zW9Bst7NguBu6UARSOXLsx6ntV2wj8qAyZG7sDUOn2TXHzOcKOeO9WLplChIuQvWgDo9CnEiupNZPiGLZdq+AM0/Q5ljmGSMCpvEiiS2WRcHBoA5Wc5k5qEnipJuZBx9KiGMnPSgA4zjPFRkgE09+pA49qic4GQcUAMkySMmopBzx1p7nOM81C59OKAGSHj2qnKe9WJG4wOapznoO1AGbqR+QAcc1n9qs3z5kCg5AqtQAUUUUALRRRQAUUUUAJRR3ooAM1ZsGAkI9RVanxNtkBFAGyh49K0LVissLZOA2ay434GBwa0YWK7W9DQB6PDODChPQr0Peq7pGWZY125+b6VHaHzbGNz0AFLvZZQ4PHofSgDSsYtlvMx/unmuT1UjzEIyccV2tjiS3mHIbH4YrjdWxBK0ZOSDn6UAZr/pUDdKmxvzz1pjDHXpQBARn1qJhxkGrD4IGBUDHPAoAryDn69aryoc1abgkYqCUdDmgDLu0zk4FQ2i7nPrV26XKnngUyGAxupxwRmgC7CvQGrsXC5qrEPbmrkS4FAFkY+U1qWym8iQLn5DjNZlvG88oiiUs3pXW6dZCyg2EDzSMn2oAtRFLS125BbFUf4GZfWp2AC5Y5yarkAk7SQV60AT2ZCyqI+ST81X9RVmsXVMcc4qnYw7E3HqxzWlIrNbOeMYoA4xyTI2etMwc561NcKY5TnuTUL/KOOpoARj7cjvUb8jJ6jtTyw6d6ic9TxQBG/HsKglIx1p1w+Rxx6YqnIw5BzxQAssnHBqhcyAKTnipnORx0NZeoN0UZxQBUdizZNJRRQAUUUCgBaBRRQAcUUCigBDRRRQAUUUUAalu25F9a01xsHtWLp7EnbWyh4I9fWgDt/DkouNO4/hpZm+favJB5qn4MkxHLGTjHark8O2SQg85zQBv6W/mWOduHAwfpXH+IYiuoFjwGFdPorMIyJCAD0HrWX4otiybwOQaAOawf/r0wnnBPWnqc4GajcZOD1oAjkHoKhPXgcVYf19KifFAEDDtUUgHIHPvUrY3Z71E2MnFAFbZvcLipp4yEHfFTWkO7LEd+DVqePMLcc0AUYV4rS02zkvZdiDA7mqEa/L6HoK7vQ7SNbaIrxxyfegB2lWEVrFsgXc4+/J6fSrqRMZCWxyfXrWraWUSldpHNTz6bI5/0bbnOSD6UAc89sVO7ZkA5qERs7EqMKTk1uTl4lKTxhVHGaaLeGZRsAA7kGgCnGhIAUcYqe4dUt/KxgsMH2qWGFoiSDuUnBx2FZd87+cxUHYTgUAYuogqoz1BxVBjnFXtUcNIqjPqaoMDj2NAETtznPSomPHTrT5D6jOO1QSEnAHFAEMh5zVWXIyRmrLt1B69Khk6E45oApSvxk8YrMuW3PzWncKSp7VjuSXJPWgBKKKKACiiigBaKBRQAdaKKKAENFFFABRRRQBa05sT47EVtQZYisKyUmQFeoNb9uu0Hd1NAHQeGJAupBAflYV0F6u1iccdK5TSJBHqUDZ4zgmu0uV3W4OOM0AV7SQqY+eAe1aWpxLcQEjkMKw2OxgAcCtPTboMmxuh45oA4y4Q29w0ZHQ8VE/J3Hiuh8Q2JwZVHzCsAcrzQBG45qBueealbg+tNbDKADyaAK5Uc5xntULDJK1O4x2NLapvmLY6UAXLWLbGFHWpJY9yE4waniTgdqmjgMjYPQdaAMSCGSRyqjIz1rrNJkZLdI5SVI/Wqttbqsh2gYzWxZWrXEwjRQB6+g9aAHC/itWBiaYuPTmtrTNaW4IMsLwSdA7HANRpa29lExWMO443HnNYeph5JvnyqdRjoKAOtuXikBE4yc5BqgQkbboyNvU4rM0y9Esfkysd6/wCrJPX2onmEBDEkZPK0AXbqcImVOAxzgVn6nf28USgLuc9vWqeoXgjjZsBnbpntWMSXbe5yfWgAlkaZy7d/0qFjg98VIevBNMfB+lAEL8D8aiYY5NSvhW5H/wBeo2PWgCCRe4xVWX71XHzg9qqSlSMigCm4yCO3vWRcxmOU+/NbjjIzWXqCDAYDnvQBSooooAKKKKAFopKWgAoo6UUAJRRRQAUUUUAaOnqAgPcnmteLpzjFZNhnyga1IDxQBcjby5I2Axhga71gGslbPUA15/n92a7excTaPE3JAXFAGfPkzKoOPen27+W+M4INMmQK6kc5NNOS5HAz+lAG9JtuEX1YbTXF3MRgupomGADxmuusyPJU7gSp5rH8UWxWUTAHB60AYJ4GKhkqdyMcc+lRP93pmgCB3HQ1PYjk4AINQHGOQDVrTcbOg68UAaKcjmtCyj/dknue9Uk6ema0bI4h2jnmgB4KrKVC9RXR6TGYLYvjJJx+FYAUCb1rooCBZx4HGOlADneMyOrSbQegxURtxIpR1DL6io22hwT+FTRSfO/y8Y/WgDNl0loWaSEAgHIGelVdRcxqXKnIHeuiIUJ5gLN/eUd653xG/mkeQCPWgDBeR5myeT6UwkhuVxU8D7UYFcOOvvUNw+5hgYNADS3rUbHvjjtQc0wtxgdqAGueefzp2m2t3ql+tjpNpc6hfN0t7WIyP+IHQe5wKq3UXnptLunup6/WvbPhT8cbTwhYxaVq3hezhshgG70aIRu2P4pIyfmPqQ2evFADPCP7PPiDVI1u/Ft9b6BYAb3hQia42jk5P3E475bHcV4lqw09NVvRo3n/ANm+c32czvukaMHCljgckAEjAwTX3ponjHw7490K9j8Mappt/NLbuhtblSdpKkYlhOG2ZOCOMjODXyPe/Eeayup7a6+HXw4iuIJGiljbQOUdThlP7zsQRQB5q7YBFZ96cxmvTz8VsHj4e/DY/wDcB/8AtlRT/Fzyh/yTv4bH2/sL/wC2UAeSUVa1a8/tHVby++zW1p9pmeb7Pax7IYtzE7EX+FRnAHYAVVoAKKKKAAUtFFABRRRQAlFFFABRRRQBoacfk/HFakBAH1NZWnk7OPWtSDt3oAtg/IRiuv0YltEOOCvIrjwRtAB5rrdFH/EpO4npQArrlgc8HrTUjRZPmOTn8qsSFVTCjPcUiwO8m6NTuPr0oAnsyFJ25IPUU7XommstpXB28Zp8ds6h2B2sOasXKlreNHbdL1NAHBMMDHccZqFsr0/Gr2pxCK+dOAOuKoyEhTuFAELng4H5VJp8mJiuODURwTxTY28qdTzjNAHQQsDz1qxbzeW5z0NVIMEr79Kc54PfFAGlbyhpWIbOK6mybdajHPGK84t7xoZiG6da6rRNdiXCuRsPrQBr4KOW2gnPANSBS5G0Yz1ANWswTRiSAhhjgjtVeKTMgQjnPUcUASwwBnOJGQjsaW40tJ2z8uQM5pDfxRSFSPmHUmntqdmi5yzMegoA5jW9GlhzJEN3c4Fc27ngMMMOOa7y41V5HK+QQp6GsLUtLWSNphw/XAoAwQMZ9TUTdT61fFiRGGY57n2qGS3VASCc0AUs/MSRzUTHOeKmx81RsTyMDigCurmG5juIHkguIzujmiYo6H1DDkVFf3d1e3M91fXMt1czPvkmmO53PqT3PuetTOCM1TmIGeKAKkjbcnOT6Vn3L7n6nirVzIRnnjFZ55NABRRRQAUdqKKAFopKKAFopM0UAFFFFABRRRQBfsAQnQ8960o8HqeazrPhB9OlaEW7oBz6UAXFO4hQOScCu1sIwlssI5IHNcjpK+ZqUCNjGc13Vpbgsd+R6YoAktkWPYgwO2TzUqusMRLKS6Z3cdatxRQqAdvHXJqeXyXdsgncO3SgDLluw8a4T5WwPQ003IkO1VxgcCrktmpiwEIHQVj37G2RiTh8bFFAHK3splvJmbk7sCqr5AxjrUrqVuHB6k1DLk5B/CgCAg5PGKgmZgRz0qZs55JwO1JBH5suSOAaANeybfCpI5xUs/3CcngdKSIYUcY9qiuXwjUAUEIDNnkE05QCcqcY7VChAH1qaPJ+93oAswXFxAC0E7p9DXWeF3vL1hLLITGOM+prkIo2kkSNeSxxXpeg2f2a1jjGMjrQBcuLBZoixAB7mqSWcQcjALDvW1c/LBgng1m2mHcr78UASWcUaHDrktxgik1JVWAqqjJ7Yq5DGFbceSKy9Qk/entg80AY96sQywGCBjHvXPXsseGCDB7mtHV7nYzhTweK5+aQuST0oAhY5NRHlvQ05zgDFRMD15zQAPjPtVa4XIzirIYdz0qvcEFSe1AGHdnDMOetVasXv3x781XoAKKKKACiiigAooooAMUUUUAFFFFABRRSoMutAGlbKNo457Gr0Y5BwfrVG35HTHar0eaALVqxjnjlBxtIJ9a7+0v0kjQhvQ15+vStrRFkKHYTyf0oA7Se6ji5+8xHAFVWlv7oARKVXpwOlTWtorbJJOmOpq+ZFVQFZgB3FAGDdadrNuDJbTuwHJRuaxrq+u3OJ4DvHBI7V3UF40RG47iOx71l65ZxPGLqEbS5wy+9AHCO4ZiehqF/Q59q1NRsyB5kYGe49ay26AtQBVkzuAHf0rVsodiAH61BZ24Zy5rTVMKPSgBOMY5qnfEiJq0WTI4ODWZqQ/dfU4zQBRjJwcjipWDMysvSo0GPpUytheOaANrwvaG4v/NblEH616RZIFj561y/hSyEFmn95vmOa7CMKsW9sgLQBV1OXau1ee1RafGTNwMk/pUF44kkPXg5rU0dPk3kgd6AJbgDk9lGK5nVrjylY5HHrW/qM5RHHHPeuA8QXZeQRjv1FAGRcyGaZ2J4qtKCD7dqkbjPSoZeaAInOOvIpoYcntQSDx0qPOD9KAEPUGoZuEbJGKlZ89TzVe4YBCPWgDGvvviq1TXTbn561DQAUUUUAFFFFABRRRQAUUUUAFFFFABTo/vim06PiRfrQBqQdBxxVyNulU4SCBjoKtoM/jQBZB44/Kuk8N7TDuYcA4OO1c2jcjuMVv8AhI7pJ0H3Sc0AdiGJgwR+7HOahwyAlGJHpSQglCqnAbjntUn+r2lOO2aAGRTMzHOCRwKnlKyabcqQdwGcGoYUDvKEwHHc9zT55vLt5UYj7uGNAHNzgumWGB25rBuIs3JXnB5relkV2IPOOnvWcqB5ix6dKAJLaEKgA4FWgoA6Uqp8oFSHgZ4oAgYEIR0FZ98oaIgjgc1pyJmql0vBGO1AGNGAcA1d023N1qEUSjKg5NVlwMgjGK6bwfaEhrhl5Y4WgDsdMgCovTaOMVfum2QEHPrimWaBIxxwBk1XvpiykHjPSgCsv71zjpW9aDyrXJArFsIgcc8k9K3LkmK1VTwSM0AYGu3ASNjnHevPbiUyzux55wK6rxTclICvXNciBhM4GTQAxm5x096ifoSTmpXGBx+VQNkr2z60AROBtqKVhxjHIqRsZzkVWfk0AMeQAfNVC9uBjAJA9KnmOM8gmsi5ctIc9BQAxjk5pKKKACiiigAooooAKKKKACiiigAooooAKF4YfWiigDUgcFeOCKtoT2FUrYrj3xzVxGGMUAWoyB9a6PwYN1xPXMxsOmOveum8Cn/S7j8KAOpS3Jvo13EKO3rUcmPtDIW2qTtH1q/Kiozuc5AwKqIiTXS7175BoAuWkOYpjnO0da5y+naRysWdnQk9zXWtHtsphjbkdPauNu22K4C9f0oAoPIsSlmIZycLT7Vd3zMBk9apKBNdDH3U6VqwoAOmBQBIi5wO1OKcnJ5NPAA4oPP1FAELDgcVWnJ8tu3FXmwVxnn0qrOo2kDjigDAA3MFHc4r0XQbUQ28SjoBniuI0iD7RqagjKoc16XpsPHTigC+4xGAMYPX6Vi38oeUKp46ZrbvGWC2Ynk4wK5WednlAwBk/jQBv6ZGDJGo69a0NbbYqqeBio9GjO5T3wBzUPiSYrKwzkAdqAOC8SyiSXHbNYpHy46j+VX9YIeU45yaoMwAFAEbnamMdqruTgdhUshPrULEjOOc0ARSYA96rS8detWJM4yMZqpMcdTyaAKd0wQEnnFZLEsST1NXr58Lt5Gao0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFKvLCgC/b5GTVxASucVUgHercZOc44AoAsRkbeR2rqfAq4aZmHBbg1yoPy5rs/BCYt1z/E1AHXXbKLTnqao2p3Or5wo4q/eqTDhQCBVSxAbAx0btQBp3hBtnz3XFcNr0ghUgdDXeXyn7OymvPPEhLTLGO5oAraXHtXJ5Lc1rovTFU7SMKigDOK0FHHHFACdO1LgAUueMnpShc9qAI2wO3NQXGNnHerW3rxxVW6G4BR16UASeELbdJPKw5LYFd9Yx/KgB5Fc/wCH7L7PAFHXqa6TcIbcuB8x4FAGbrk+5tnIVaxRsaSMLksDUmpztJJuzkZxUGmxmXUIRgkZyaAO90hMIp9s1zviaU+Y47mustx5dufpXC+IJQ91IM4I7UAcde/6/AORVJ8bsd6nvGbzmB4GetVmP4mgBkjZPFQv09/anO3GcVFuG3BFAEcvTr0qpMasSkZOKoXcu2Njx0oAzbt98mOwqGgnJJPeigBKWiigAooooAKKKKACiiigAooooAKKKKACnRffFNqSAfMfpQBfhUBRirK4GOe1V4uEFToMc0ATZAXGetd14PQCyiyOeua4TI8s5Feg+Ex/oMWR2oA6hifKdX6YqlYuIplwMhj1qxMx2yDsF61SsiWkQHgZ4oA2tQIZGPTjNefamm+9DMOhrvb0gDB7iuO1SIC4BxyTQBHEo2579qsJx+NQwZxjFWUBJ4FAAV4I4welHQYPensMn0HvSyKFx+lAEWDziixg+1X8akcKcmnPwuQK2vC1mSjzFTuY/pQBqW0GxsDim6ncFEATG1eKuXAMCZA5I5rEvJFkbLHAFAGZKFbjrzkjvWt4cti92ZSCEHQVluFDlkyxPT3rpvDaskWZDyO1AHQOQti+R2rzXUnEk7keteg61J5GnsQcfLXnVww2u/saAOZvx/pLDOKquSce3enzPvkZnzkn9KhY8c5I7UARzEVCxp05OOOKjbIXPoKAIJjgYyMVlag33Vz9avztuHpWNO++QmgBlFFFABRRRQAUUUUAFFFFABRRQATwKACip0tyRk5/CigCCirc0HPT8aqspU4NACVNB3qGpoOlAF6EHGT9KnTHvmoIehH6elWIwNvvQA8gGPNejeFxts4hjhhxXnGTjFeleG+bOE9goxQBuyf6iY+2CKo2LKZ8ZKqCKvyLi3uD7DArGspP9OIPAoA6a7hDumOgHWuW1+PbOpxxnqK7SaFvKjk7YrnNfg3kMBzjNAGJDxyeal5wB27UkSngdKsqMn/doAgYEAYPB60vLHGcinMAcEA4NKy7QTj2HtQA2OL7TOkIB56+1d7pVmIIAB8oA61ieGdOYHz3HJ4WulvnWC2CL948GgDH1uYCQqpyMdq56T54m3E5PJrV1NwRyvI71i7yYnDsFz09aAJ7NVM6Z7etdPow/fqCM5bJPtXJ6Yo84sSSR3Ndd4bfJduqgGgCv40utsYiXqTXB6vKY7FtuAz8V0viq5866zjn0rhdbm824CA5C9aAM7IA55qN24ANSNgdaryEdCaAI5DzioJGABBOKkkxjkc1WnPynNAFS5fEbc9R1rLq5fP2B61ToAKKKKACiiigAooooAKKKAMkAUAAGTgVct4O5HHc0W0Hr+NXo0AHFAAiDbRUwT6/hRQBWkXORVKeLoDjPrWnIOvp2qrMuepxigDMIwSPSrFt2z0zTZlzgjGTxT4PkOxl5NAFxTkk8/jUwz271DHnGGqdc8cjFAEjZ2dfpXpXhkg2UBA7CvNCAEA7CvSfDAP2GHHTA4oA37ggWUoxzmsG0LNqaADjNb18dtgQDyTWXZRbLqNmPPWgDugu+wUHqK5/VoQVz+tdRbIGssdflzWLqUX7rI6A0AciV2sQRzmpAB+dTXaAPkcetRhD1BGKAGSD0yKsadaNdzhR91etRwwSTybI89eTXVafax2MCr/EeSe9AGnaxpa26jo3YVQv58x5K9Dj8anLF23bj7VWny0RwRwaAOf1V2AznjOB7msmWN+Aeh9a2NYQFIyXBKnOPU1nOyvLsYkt6ehoAW2JicgsPu84rp9AkVdMmZSNwGTiuTkhKIWXqPeuh0lxHotw+Mcc+tAHM69dZ8yQnBGeK5DeXZmbqa2dTlaVHJ+6M5FYvHHpQBFMxGDUDsGBzippjxx2qrJk8elAEbNhc44qpPLjr1qdzxg9apXPTJFAGfMxaQk0yg8k0UAFFFFABRRRQAUUUUAABJ4q5aw85P4023gPBI5rQiXb2HFAAigYqaNfmyc4oVMn3qVeDigBceg4oqReB2ooAqP19ahdMls4qw3Q9s1EwOPSgCjPGOnAGRVh4spkdQKbKCSMDvV5EJTJHagCjG2UHJJFWAcionjMc3tUo5x6UASuMIPavR/CxBsojnPAzXnL5CEe1eg+C/3lnCCe1AHVXEebXJPGeKzljy6sD0OK2r6PbbRoAM9aoRx9BtwM0AdjpY3Wqgc5TFZ2ooBE645U1oaGfljGcduag1JeZTjIBoA5O9i3E8c1Q2FiFUfMTit64jDKTWXDmO9XdjG7qaAN+y08RQKMjHU1LIDu3YJwO1SqWAXacA1at4AVJznPT60AZ8KyMATxznmo5Y8REscZbAFdEliAgJQkioptPhljCklGBzigDidRg3DGOQc49azGiZcn+I8Y9K7DVdIm3hoW3DHOOprCeBl3+ZwR1yOvtQBmBcyIM5T+I1qXEnlaW6LxuBqtNGY13MAqgbiKrT3BfTpQeCwyPpQBy9znyZSTkEVk54HGa1LgfuSD0FZTfWgCOQ/KaqOx5GOKsS/dx+tVpfYUAQOOSKo3bAKe5q25OOtZ94QowB1oAqUUUUAFFFFABRRRQAVZt4DwSOtJbw5YFgf8K0UTgDHAoAEUflU0aDHNKqfSpUUcDFAABtxkGpUU55pMszgE8L0qwoGOOaAG7M9sUVLjHrRQBnEYY45qI5zk81MxwajkOTQBAwOeK0FB8sYz0qi/BXitOLDR47UAUbpOM45FRKeAKvvGWyMVRA2sy+hoAnbmLJFeheAEeS0jOOBXnr8RHAr1T4fx+XpsPHJFAHTX6YiXDZIFZ8K5bPr+laWon+HpxziqcRxIAPpQB0WnELEm3j1p1yAwkOd2RVS1YiNQT+FXhgrwM5FAGDIhK47Z6Vi3S4nz6c8VvXIMcpXmsW/wkvTtQBqwyGaNAG4AFXFnEYBDHjnArDsy2Awzgdqvx2tzcMOdintQBoLrskaD5MHvk09PEaMo85FPNV/7JEeC7Z/Gq17pcDKfk59VNAFyTVba4m/cymJz2qtdOsqFZUBA53DvXLXlsbe6IywX+/2p7XFxAuGfzIz0I7CgC1dRggkkYbg81h3ciy3bKflXbtAHSnXc5nj2RnbIf4s1mSSNFL868qO/egDJvpcO0Y9cGqLccZz6VLOSZpDzyahYjPcelAELH19agl54zgetTNnPr61BIc554oArPWbeNlhjpWjIRz0rMucbhigCGiiigAoopVBPQUAJVm2g3N81OhgxjPXrmryR4IPAoARUwOBzViNehNKFGOe9SomCR6UAKiAY9KcOO2eacMelSpGO9ABGox0qVRgc9KAoAGeaGOML1J4AoAN6rwWorWtNAmnhEjZBbtRQBzDZAxUbA9akcA5P6UwnCkDigCFyRxtzWpbY8teMGs1sM6k+vNbFug4wRxQAjrkDg1nXK7Zg2ODWyUzx096o38XyA4ztNAFSQZUZyBnFeweDlWLTYW7Ba8h2mRo0A5ZgK9l0GJYNLjQ8/KB9KANG5AZt5OT1zVaNt58wcEcU8yDyWIydvH1pbfDBdoG3GTQBdhkyAPStaCRcKCOehxWJAT5g44z0FaKuyMr56mgCHUlKy5wMetYM6mW62kcV0OqEsgK8g84rMsLfzrpiR8uc5oA0tM09VjDygY7CrcrEHauAB/KlZ8qFA+UDgio9xK8Luz09QaAIZe3zk7j27VWuCwPQhvapndw4YAZ9PeoJZ2Yk9HoAyrsiRiJRgt0rJnV7FiWUtbHqPSti5Q7yxBBY4Ue9OSE3EDwylTxwDzQBxmqbVXz4DiP+VY1zeFk2o24nqT2roZo/Llkt5cFScGuXu4RBdPEOgOQaAIWxjnvVdh2OcjnNTt069ajk6elAFZwdpxVaUYHPOauOD0z0qvJz9KAKkijGazLlRyV5Ga1ZARnvis+5wCcYoApUU4LuzgYNWIYeQevv6UARJCTyeBVuO3AX0J9KmijA+lWFT2oAijjwmKsqvIGO1OSP5emamUcAZANADFGByOTUiggggU9I89RUiR4HOMUANjTnJGamAx1GTQpz93kn0rQsdHuLt8uGiT3oAz0WSWQJApZz2FdXoXh7y9s90Mv6HtV/S9PtrH5VjG/HU9asy3eXMa9f5UAaMaQqoGRRWS8u046+9FAHm17bPa3BjPK9QarsBjOK6i9thd27qR+8UZU1zBBBw2cigCIqPMArXt48KNpwKx2yWA6tn862rYttUYzQBZAyAR19KZNFuHTrU6AYx3FKy8HNAGTpkLPqsSE8K2a9es8LaqOg29a8z0u1KaiJyMDPevQLe43RITgL6UAaEWOVY5DfdA71Or7VwV68YFQW7ZA2gY521ZCtsBxnI59jQA+IBX3AHaOKvw/NEew7VSiDeUCePardtLtwp4XPTFADpcm3wD8w4osIiLR5AMv3pkrBWOenX8K1tHRXsiVPyse9AFaMAKu4bcDn60bPmCrknGTx0qWf5eGTJ3daa5cf6kZZuvtQBTkG0dBnNZd7DuywYk9RituVSCA2GOOtULhQ8ZU8HtQBkrI3ylzlV6A+tNtWLThwuH+tLOnkgggk5ptuhEgxymc89qAMLWsf2ngAEDmud8QRBZ4nHG4V0WrYl1CQoOF6msHxGBst+eaAMdsZ45qJxj+fNSd+aZJkjvQBBnGTxzVd/THSrMg44qvJyOlAFZxt5PeoY7fzZN2PlqyEMkgUA1eSEKgUUAYdzblZhjofapY05wBxVu+UDFRRrg8ZAoAdFEMdcVMie1ORcgZ6VKuF+vpQA1EwQPXvUiIDnPY08LkA9M96cEwOlAARzz0PetDSdKa+bfI2yAdT61Xs4GuLiOIdSeT7V28VrHFAsYAHHFAGfHa2NmP3aDA/iYdamgvGaQCNMKO5pDaOzHzDkZ4yOlSxIIcIBnPA96AJAJGJfqx7ilkwgEQxvbq1KjLncCQEGB7mncKBJKcy+lAEAi2cM24+ooqbzI1AyVJ60UAc/ARllf0yCKwtctBDKkwGBL29a6q0ihjP71shuMVzviu58/UBDGAI4RgYoA5/aBImeBmtyDG0EDj1FZsUPmsCT0rVt0+UZ4oAsoMcAZzUhUtgfxE4oiHrTnHIbPAOaANDyCsWAOg64rZ01S8alRnAHFRw7ZLRWUAggfjV7T50Q4bkjqKANezsnO0lwvcVrR6dmEgt82c1TsrxCoXaCD+lbcNwCnKrjHQUAVTYuNo4bI5NNMBQEFCWXitVJUaMAKTimTtuQ5HHr3oAx7iB2CttwAuK29CixpWDgEZ4rIu8tCx5C55rodECizQYGD2oAguFO5ARwo5qo7AFtowxFa1yPnct9KzJAIyWYfQ0AVQMct0IqCWEP9wk85q4fniYdW7VZgtCWTjGetAHP39oXjXeSGXnI71kTP8AZYXklYB8cD0rrdZuI7JGA+aQdBXn+vzTTEysACeo9KAMx3YuzsMsxzya5/W5TJebRwqirdzfxohRAzOeM1ksWd2LHJJoAbgYzTJBn8qe+MErxUTueQO/pQBXc8CoX546Y71Mc46DNQOP4QOtAFmyj+Uuec9KutGCtFqm2MKBnAqyyccDigDF1CPBXBHXtUKDAwver2pxjYMjBHWqcY4FAD0UAAGpkA49aRRyMjrUirzwBQA4A8Yp+D9fam4/PsK0LPTZ7lA5BQGgCXQT5cjzcZHArprUrM2Xck5BAPas610h4QAinnmpmSaA5CZA54oA6n7CXVSRuXuR3pt3pkiqGjTgDoKz9C10wsIpDuXPRu1dnb3Ed0m+Eg8crQBxTxhGIUfKOgNU3U85zuJ4z6V1WracD++t17/MKw2iSF2ab5yegFAGP5bZOAW9xRV+QNu+XYo7CigDCnUojBexySfSuZ1kY1CRifv8j6V0J1O3ugxwyhumRWRqUKzfNE4Yg4oAhsomKDjk1oIAe+Krwo0YUFTg9KuKuQCOKAJEUnGKeQTnHWlj9M9Kc3UY60AWtJvvJjeGTtyK0NNm8yYkYHPINYccZLl+m0VoaDNtdywLMOntQB29i8UUbSS/Kvqepq4Nawo+zwAj1asSzSa7wzjIHGD0rdt7aNI1yAx7+1AC/wBo3LggrtHqtRvfzRkBi2OxNa0RVQFjReBk1YaOG4i2SxqM9cDpQBhi5eQbSQQxGRXXaaoSBen4VzMemFNRWPaSnUMK6q2gaNVUfd9aAG3gwGYelYs6nIyxx6Gty/G0gAZ45rKZQWPGQentQA60TbOpbBz2Fa7bUQvjkDpVDTowH+fkjvV+9Oy0fHp1oA4zVX8+V3bpnNcbq8plDoCMHpXT6zJ5ULe9chcAvlumPSgDkp1MUzK2TUX3SMYx1rS1mDBEnORWeATz0zQBG5JHGMVAwJzU8ihT1qJvlP1oAgf6fSoUXfOB71PIRk56e1Os03SEigDUijwox0xU+0lAOlJEvyD2qXGB0oAydSQCA+xrPTnHatjUFBhYYGfWsiIdsfSgCVRg5JqTI2gkc01e+elX9HsW1DUEjHMancxoA1NF0lFVLi7OCeQldRbrGp+RMr71Rlw0mFI2L8oxUkblXRevqaANlGQ7T5eSOmDQvksNk0e056iqUdyySKuMjv7VNKySMpbcGJyAPSgCtqGkJNuktyEcdGHf2qHR9Tlt7jyZTtkQ8j1rWWbaRlgVPG32rP1yxyouIsCReh9qAOrSYXG0owAIy3vWRqFsPn8sKB3PrWZot+SPKZvmHPNXr+6VCHyORnaDQBmPD8x+QN75opZbhJm3qQBjp6UUAf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Some phalangeal fractures are irreducible, which is usually due to soft tissue interposition, most commonly the volar plate in juxta-articular fractures as shown here. Irreducible fractures require operative intervention.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_6_12399=[""].join("\n");
var outline_f12_6_12399=null;
